e10vk
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal year ended
January 3,
2010
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period
from to .
|
Commission file number: 000-30361
Illumina, Inc.
(Exact name of Registrant as
Specified in Its Charter)
|
|
|
Delaware
|
|
33-0804655
|
(State or other Jurisdiction
of
|
|
(I.R.S. Employer
|
Incorporation or
Organization)
|
|
Identification No.)
|
9885 Towne Centre Drive,
San Diego, California
|
|
92121
(zip code)
|
(Address of Principal Executive
Offices)
|
|
|
Registrants telephone number, including area code:
(858) 202-4500
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
Title of Each Class
|
|
Name of Exchange on Which Registered
|
|
Common Stock, $0.01 par value (including associated
Preferred Stock Purchase Rights)
|
|
The NASDAQ Global Select Market
|
Securities registered pursuant to Section 12(g) of the
Act:
None
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes þ No o
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o No þ
Indicate by check mark whether the Registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the Registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such
files). Yes o No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
is not contained herein, and will not be contained, to the best
of Registrants knowledge, in definitive proxy or
information statements incorporated by reference in
Part III of this
Form 10-K
or any amendment to this
Form 10-K. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
|
|
|
|
Large
accelerated
filer þ
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller reporting
company o
|
(Do not check if a smaller
reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange
Act). Yes o No þ
As of February 5, 2010, there were 120,298,934 shares
(excluding 24,068,450 shares held in treasury) of the
Registrants Common Stock outstanding. The aggregate market
value of the Common Stock held by non-affiliates of the
Registrant as of June 28, 2009 (the last business day of
the Registrants most recently completed second fiscal
quarter), based on the closing price for the Common Stock on The
NASDAQ Global Select Market on that date, was $4,649,494,956.
This amount excludes an aggregate of 2,197,137 shares of
Common Stock held by officers and directors and each person
known by the Registrant to own 10% or more of the outstanding
Common Stock. Exclusion of shares held by any person should not
be construed to indicate that such person possesses the power,
directly or indirectly, to direct or cause the direction of the
management or policies of the Registrant, or that the Registrant
is controlled by or under common control with such person.
DOCUMENTS
INCORPORATED BY REFERENCE
Portions of the Registrants definitive proxy statement for
the annual meeting of stockholders expected to be held on
May 12, 2010 are incorporated by reference into
Items 10 through 14 of Part III of this Report.
ILLUMINA,
INC.
FORM 10-K
FOR THE FISCAL YEAR ENDED JANUARY 3, 2010
TABLE OF CONTENTS
1
Special
Note Regarding Forward-Looking Statements
This annual report on
Form 10-K
contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended. These statements discuss our current
expectations concerning future results or events, including our
future financial performance. We make these forward-looking
statements in reliance on the safe harbor protections provided
under the Private Securities Litigation Reform Act of 1995.
These statements include, among others:
|
|
|
|
|
statements concerning our expectations as to our future
financial performance, results of operations, or other
operational results or metrics;
|
|
|
|
statements concerning the benefits that we expect will result
from our business activities and certain transactions we have
completed, such as increased revenue, decreased expenses, and
avoided expenses and expenditures; and
|
|
|
|
statements of our expectations, beliefs, future plans and
strategies, anticipated developments (including new products),
and other matters that are not historical facts.
|
These statements may be made expressly in this document or may
be incorporated by reference to other documents we have filed or
will file with the Securities and Exchange Commission, or SEC.
You can identify many of these statements by looking for words
such as anticipates, believes,
can, continue, could,
estimates, expects, intends,
may, plans, potential,
predicts, should, or will or
the negative of these terms or other comparable terminology and
similar references to future periods. These forward-looking
statements are subject to numerous assumptions, risks, and
uncertainties that may cause actual results or events to be
materially different from any future results or events expressed
or implied by us in those statements. Many of the factors that
will determine or effect these results or events are beyond our
ability to control or project. Specific factors that could cause
actual results or events to differ from those in the
forward-looking statements include:
|
|
|
|
|
our ability to develop and commercialize further our
Solexa®,
BeadArraytm,
and
VeraCode®
technologies and to deploy new sequencing, genotyping, and gene
expression products and applications for our technology
platforms;
|
|
|
|
our ability to manufacture robust instrumentation, consumables,
and reagents;
|
|
|
|
reductions in the funding levels to our primary customers,
including as the result of timing and amount of funding provided
by the American Recovery and Reinvestment Act of 2009; and
|
|
|
|
other factors detailed in our filings with the SEC, including
the risks, uncertainties, and assumptions described in
Item 1A Risk Factors below, or in information
disclosed in public conference calls, the date and time of which
are released beforehand.
|
Our forward-looking statements speak only as of the date of this
annual report. We undertake no obligation, and do not intend, to
publicly update or revise forward-looking statements, to review
or confirm analysts expectations, or to provide interim
reports or updates on the progress of any current financial
quarter, whether as a result of new information, future events,
or otherwise. All subsequent written and oral forward-looking
statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by the cautionary
statements contained in this annual report. Given these
uncertainties, we caution investors not to unduly rely on our
forward-looking statements.
Available
Information
Our annual report on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K,
and all amendments to those reports are available free of charge
on our website, www.illumina.com. The information on our
website is not incorporated by reference into this report. Such
reports are made available as soon as
2
reasonably practicable after filing with, or furnishing to, the
SEC. The SEC also maintains an Internet site at www.sec.gov
that contains reports, proxy and information statements, and
other information regarding issuers that electronically file
with the SEC. Copies of our annual report on
Form 10-K
will be made available, free of charge, upon written request.
Illumina®,
Array of
Arraystm,
BeadArraytm,
BeadXpress®,
CSPro®,
DASL®,
Genetic
Energytm,
GoldenGate®,
GoldenGate
Indexingtm,
GenomeStudio®,
illuminaDxtm,
HiSeqtm,
Infinium®,
IntelliHyb®,
iSelect®,
Making Sense Out of
Life®,
Oligator®,
Sentrix®,
Solexa®,
and
VeraCode®
are our trademarks. This report also contains brand names,
trademarks, or service marks of companies other than Illumina,
and these brand names, trademarks, and service marks are the
property of their respective holders.
Unless the context requires otherwise, references in this annual
report on
Form 10-K
to Illumina, the Company,
we, us, and our refer to
Illumina, Inc. and its subsidiaries.
3
PART I
Overview
We are a leading developer, manufacturer, and marketer of
integrated systems for the analysis of genetic variation and
biological function. We were incorporated in California in April
1998 and reincorporated in Delaware in July 2000. Our principal
executive offices are located at 9885 Towne Centre Drive,
San Diego, California 92121. Our telephone number is
(858) 202-4500.
Using our proprietary technologies, we provide a comprehensive
line of products and services that currently serve the
sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our
customers include leading genomic research centers,
pharmaceutical companies, academic institutions, clinical
research organizations, and biotechnology companies.
We develop and commercialize sequencing technologies used to
perform a range of analyses, including de novo sequencing, whole
genome re-sequencing, gene expression analysis, and small RNA
analysis. Our product and service offerings also include
leading-edge solutions for single-nucleotide polymorphism (SNP)
genotyping, copy number variation (CNV), DNA methylation
studies, gene expression profiling, and low-multiplex analysis
of DNA, RNA, and protein. We believe we are the only company
with genome-scale technology for sequencing, genotyping, and
gene expression the three cornerstones of modern
genetic analysis.
Our tools provide researchers around the world with the
performance, throughput, cost effectiveness, and flexibility
necessary to determine and analyze the billions of bits of
genetic information needed to extract valuable medical
information from advances in genomics and proteomics. We believe
this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug
discovery and clinical research, allow diseases to be detected
earlier, and permit better choices of drugs for individual
patients.
In 2007 we acquired Solexa, Inc. As a result of that
transaction, we acquired the sequencing technology utilized in
our HiSeq 2000 and Genome Analyzer instrument platforms. These
products perform DNA sequencing based on a proprietary
reversible terminator
sequencing-by-synthesis
(SBS) chemistry.
During the first quarter of 2008, we reorganized our operating
structure into two newly-created business segments, the Life
Sciences Business Unit and the Diagnostics Business Unit. During
2009, the Diagnostics Business Unit had limited business
activity and, accordingly, operating results are reported on an
aggregate basis as one operating segment. In the future, at each
reporting period end, we will reassess our reportable operating
segments, particularly as we enter the market for molecular
diagnostics.
Industry
Background
DNA,
RNA, and Protein
The genetic content that controls an organisms living
cells is encoded in deoxyribonucleic acid, or DNA. The human
body, for instance, is composed of billions of cells, each
containing DNA, which encodes the basic instructions for
cellular function. The complete set of an organisms DNA is
called its genome. The human genome is organized into 23 pairs
of chromosomes that are further divided into over 30,000 smaller
regions called genes. Each gene is comprised of a string of
nucleotide bases labeled A, C, G, and T, representing adenine,
cytosine, guanine, and thymine, respectively. Human DNA has
approximately 3 billion nucleotide bases and their precise
order is known as the DNA sequence. When a gene is
expressed, a partial copy of its DNA
sequence called messenger RNA or mRNA is
used as a template to direct the synthesis of a protein.
Proteins, in turn, direct all cellular function.
4
Genetic
Variation and Biological Function
Every person inherits two copies of each gene one
from each parent. The two copies of each gene may be identical,
or they may be different. These differences are referred to as
genetic variation. Examples of the physical consequences of
genetic variation include differences in eye and hair color.
Genetic variation can also have important medical consequences.
Genetic variation affects disease susceptibility, including
predisposition to cancer, diabetes, cardiovascular disease, and
Alzheimers disease. In addition, genetic variation may
cause people to respond differently to the same drug treatment.
Some people may respond well, others may not respond at all, and
still others may experience adverse side effects. A common form
of genetic variation is a SNP. A SNP is a variation in a single
position of a nucleotide base in a DNA sequence. It is estimated
that the human genome contains over 30 million SNPs.
While in some cases a single SNP will be responsible for
medically important effects, it is now believed that
combinations of SNPs may contribute to the development of most
common diseases. Since there are millions of SNPs, it is
important to investigate many representative, well-chosen SNPs
simultaneously in order to discover medically valuable
information.
Another contributor to disease is the over- or under-expression
of genes within an organisms cells. A very complex network
of genes interacts to maintain health in complex organisms. The
challenge for scientists is to delineate the associated
genes expression patterns and their relationship to
disease. Historically, this problem was addressed by
investigating effects on a
gene-by-gene
basis. This is time consuming, and difficulties exist when
several pathways cannot be observed or controlled at
the same time. With the advent of microarray technology,
thousands of genes can now be tested at the same time.
There are multiple methods of studying genetic variation and
biological function, including sequencing, SNP genotyping, and
gene expression profiling, each of which is uniquely addressed
in our breadth of products and services. Our broad portfolio of
current products and services supports a range of applications,
from highest multiplexing (for whole-genome discovery and
profiling) to mid-and low-multiplexing options (for
high-throughput targeted screening). Furthermore, our products
and services support both the upstream discovery process and the
downstream test development process in order to understand
genetic variation at the DNA, RNA, and protein levels.
Sequencing
DNA sequencing is the process of determining the order of
nucleotide bases (A, C, G, or T) in a DNA sample, which can
be further divided into de novo sequencing, re-sequencing, and
tag sequencing. In de novo sequencing, the goal is to determine
the sequence of a representative sample from a species never
before sequenced. Understanding the similarities and differences
in DNA sequence between many species can help our understanding
of the function of the protein structures encoded in the DNA.
In re-sequencing, the sequence of nucleotide bases is compared
to a standard or reference sequence from a given species to
identify changes that reflect genetic variation. Re-sequencing
studies can be performed on a genome-wide basis, which is
referred to as whole-genome re-sequencing, or on targeted areas
of the genome (for example, regions identified by genome-wide
association studies), which is known as targeted re-sequencing.
This is an extremely comprehensive form of genetic analysis, in
which every base is characterized for possible mutations. We
believe that these underlying discoveries will likely feed the
development of new array products for broader testing and
biomarker validation.
In tag sequencing, short sequences, often representative of a
larger molecule or genomic location, are detected and counted.
In these applications, the number of times that each tag is seen
provides quantification of an underlying biological process. As
an example, in digital gene expression, one or more tag
sequences may be analyzed for each expressed gene, and the
number of copies of these tags that are detected in an
experiment is a measure of how actively that gene is being
expressed in the tissue sample being analyzed. Similarly, a tag
sequencing approach known as ChIP sequencing is used to
determine the locations and extent of protein and DNA
interactions throughout the genome.
5
SNP
Genotyping
SNP genotyping is the process of determining which nucleotide
base (A, C, G, or T) is present at a particular site in the
genome within any organism. The most common use of SNP
genotyping is for genome-wide association studies (GWAS) to look
for an association between DNA sequence variants and a specific
phenotype of interest. This is commonly done by studying the DNA
of individuals that are affected by a common disease or that
exhibit a specific trait against the DNA of control individuals
who do not have this disease or trait. The use of SNP genotyping
to obtain meaningful statistics on the effect of an individual
SNP or a collection of SNPs requires the analysis of millions of
SNP genotypes and the testing of large populations for each
disease. For example, a single large study could involve
genotyping more than 1,000,000 SNPs per sample in more than
1,000 samples, thus requiring one billion assays. Using
previously available technologies, this scale of SNP genotyping
was both impractical and prohibitively expensive.
Large-scale SNP genotyping can be used in a variety of ways,
including studies designed to understand the genetic
contributions to disease (disease association studies), genomics
based drug development, clinical trial analysis (responders and
non-responders, and adverse event profiles), disease
predisposition testing, and disease diagnosis. SNP genotyping
can also be used outside of healthcare, for example in the
development of plants and animals with commercially desirable
characteristics. These markets will require billions of SNP
genotyping assays annually.
Gene
Expression Profiling
Gene expression profiling is the process of determining which
genes are active in a specific cell or group of cells and is
accomplished by measuring mRNA, the intermediary messenger
between genes and proteins. Variation in gene expression can
cause disease, or act as an important indicator of disease or
predisposition to disease. By comparing gene expression patterns
between cells from different environments, such as normal tissue
compared to diseased tissue or in the presence or absence of a
drug, specific genes or groups of genes that play a role in
these processes can be identified. Studies of this type, often
used in drug discovery, require monitoring thousands, and
preferably tens of thousands, of mRNAs in large numbers of
samples. Once a smaller set of genes of interest has been
identified, researchers can then examine how these genes are
expressed or suppressed across numerous samples, for example,
within a clinical trial.
As gene expression patterns are correlated to specific diseases,
gene expression profiling is becoming an increasingly important
diagnostic tool. Diagnostic use of expression profiling tools is
anticipated to grow rapidly with the combination of the
sequencing of various genomes and the availability of more
cost-effective technologies.
Molecular
Diagnostics
Molecular diagnostics is the process of examining nucleic acids,
including DNA and RNA, and protein biomarkers to detect or
identify infectious diseases, genetic diseases and disorders,
human cancers, and to help understand
subject-to-subject,
gene-based variation in the efficacy or safety of drug
substances (pharmacogenics). As knowledge of the genome and its
function continues to expand, new medical and diagnostic
applications are being developed. Molecular diagnostic tests can
be used as diagnostic tools as well as in genetic disease
susceptibility testing. Molecular diagnostic tests can also be
used to identify a disease, monitor its progression and response
to treatment, or predict individual predisposition to a disease
and individual response to treatment. By identifying small,
individual genetic differences or
variants that lie at the root of differing drug
responses, molecular diagnostic tests can be used to select
appropriate medication and dosage.
Our
Principal Markets
From our inception, we have believed that the analysis of
genetic variation and function will play an increasingly
important role in molecular biology and that by empowering
genetic analysis, our tools will further disease research, drug
development, and the development of molecular tests. Our
customers include leading genomic research centers, academic
institutions, clinical research organizations, and
pharmaceutical
6
and biotechnology companies. In addition, fundamental
developments in recent years have created significant new
opportunities for us in the emerging market of molecular
diagnostics.
Life
Sciences Research Market
The life sciences research market consists of laboratories
generally associated with universities, medical research
centers, government institutions such as the United States
National Institutes of Health, and other research institutions
as well as biotechnology and pharmaceutical companies.
Researchers at these institutions are using our products and
services in a broad spectrum of scientific activities, such as:
next-generation sequencing,
mid-to-high-complexity
genotyping and gene expression (for whole-genome discovery and
profiling), and low complexity genotyping and gene expression
(for high-throughput targeted screening). Next-generation
sequencing is the most rapidly growing of these three areas. It
is fueled by private and public funding, new global initiatives
to broadly characterize genetic variation, and the migration of
legacy genetic applications to sequencing based technologies.
Applied
Markets
We provide products and services to enable or improve activities
in particular markets, which we refer to as applied markets. A
current focus of our products for these markets is in the area
of agricultural research, including microarrays that contain
SNPs for custom and focused genotyping of seeds and crops (such
as maize) and livestock (such as cattle, horses, pigs, and
sheep). The applied markets may also include opportunities for
our products and services in the fields of forensic analysis,
veterinary diagnostics, cytogenics, retail pet genomics, and
consumer genotyping and sequencing. In July 2009, we launched a
service program to provide high-quality personal genome
sequencing for consumers. In connection with our personal
sequencing service, we collaborate with a number of partners,
including 23andMe, Inc.; deCODE genetics ehf; Knome, Inc.;
National Center for Genome Resources; Navigenics, Inc.; and
Pathway Genomics, to encourage secondary data analysis of a
personal genome, such as calculation of disease risk, ancestry,
and information on traits of interest. Although we do not
perform personal genotyping directly as a service, several
companies use our technology and products to provide personal
genotyping services.
Molecular
Diagnostics Market
The primary growth drivers in the molecular diagnostics market
are the continued discovery of genetic markers with proven
clinical utility, the increasing adoption of genetic based
diagnostic tests, and the expansion of reimbursement programs to
include a greater number of approved diagnostic tests. We
believe that molecular diagnostic tests will create a
fundamental shift in both the practice of medicine and the
economics of the pharmaceutical industry by creating an
increased emphasis on preventative and predictive molecular
medicine. Physicians will be able to use these tests for the
early detection of disease and to treat patients on a
personalized basis, allowing them to select the most effective
therapy with the fewest side effects. We believe our BeadXpress
instrument platform, using our VeraCode technology, is ideally
suited to provide a cost-effective, high-throughput, mid- to
low-multiplex solution to the molecular diagnostic market.
During the third quarter of 2009, we submitted our BeadXpress
instrument platform for review by the U.S. Food and Drug
Administration (FDA). Assuming FDA approval of this instrument
platform, we plan to develop clinical diagnostic testing panels
for use on the BeadXpress instrument platform, including
possible panels for multi-drug resistant organisms, herpes, and
respiratory viruses, and we expect to continue research into the
potential development of cancer diagnostic panels, initially
focusing on ovarian cancer and gastric cancer. In addition,
during the fourth quarter of 2009 we made a pre-IDE
(investigational device exemption) submission with the FDA for a
cytogenetics test intended to be used as an aid in the postnatal
diagnosis of chromosomal abnormalities known to be associated
with developmental delay and mental retardation. The pre-IDE
package included our iScan instrument platform together with
associated microarrays, reagents, and software. Following
completion of the IDE process, we intend to seek FDA clearance
for the iScan instrument platform and related reagents.
7
Our
Principal Technologies
Sequencing
Technology
Our DNA sequencing technology is based on the use of our
proprietary SBS biochemistry. In SBS, single stranded DNA is
extended from a priming site, one base at a time, using
reversible terminator nucleotides. These are DNA bases that can
be added to a growing second strand, but which initially cannot
be further extended. This means that at each cycle of the
chemistry, only one base can be added. Each base that is added
includes a fluorescent label that is specific to the particular
base (A, C, G, or T). Thus, following incorporation, the
fluorescence can be imaged, its color determined, and the base
itself can be inferred. Once this is done, an additional step
removes both the fluorescence and the blocking group that had
prevented further extension of the second strand. This allows
another base to be added, and the cycle can then be repeated.
Our technology is capable of generating over 100 billion
bases of DNA sequence from a single experiment with a single
sample preparation. The reversible terminator bases that we use
are novel synthetic molecules that we manufacture. They are not
well incorporated by naturally occurring polymerases, so we have
also developed proprietary polymerase enzymes for this purpose.
Both the nucleotides and enzymes are the subject of significant
intellectual property owned by us.
In our DNA sequencing systems, we apply the SBS biochemistry on
microscopic islands of DNA, referred to as DNA clusters. Each
cluster starts as a single DNA molecule fragment, typically a
few hundred bases long, attached to the inside surface of a flow
cell. We then use a proprietary amplification biochemistry to
create copies of each starting molecule. As the copies are made,
they are covalently linked to the surface, so they cannot
diffuse away. After a number of cycles of amplification, each
cluster might have approximately 1,000 copies of the original
starting molecule, but still be only about a micron
(one-millionth of a meter) in diameter. By making so many
copies, the fluorescent signal from each cluster is
significantly increased. Because the clusters are so small,
hundreds of millions of clusters can be independently formed
inside a single flow cell. This large number of clusters can
then be sequenced simultaneously by alternate cycles of SBS
biochemistry and fluorescent imaging. Sequence reads are aligned
against a reference genome and genetic differences are called
using specially developed data analysis software.
BeadArray
Technology
Our BeadArray technology combines microscopic beads and a
substrate in a simple, proprietary manufacturing process to
produce arrays that can perform many assays simultaneously,
enabling large-scale analysis of genetic variation and
biological function in a unique high-throughput, cost effective,
and flexible manner. We achieve high-throughput with a high
density of test sites per array, and we are able to format
arrays in various configurations in the format of standard
microscope slides. We seek to maximize cost effectiveness by
reducing consumption of expensive reagents and valuable samples
and through the low manufacturing costs associated with our
technologies. Our ability to vary the size, shape, and format of
the well patterns and to create specific bead pools, or sensors,
for different applications provides the flexibility to address
multiple markets and market segments. We believe that these
features have enabled our BeadArray technology to become a
leading platform for the high-growth market of SNP genotyping
and have allowed us to be a key player in the gene expression
market.
Our proprietary BeadArray technology consists of 2-micron silica
beads that self-assemble into microwells etched into an array
substrate. We have deployed our BeadArray technology in two
different array formats, the Array Matrix and the BeadChip. Our
first bead based product was the Array Matrix, which
incorporates fiber optic bundles comprised of approximately
50,000 individual fibers, with 96 of these bundles placed into
an aluminum plate to form an Array Matrix. In late 2009, we
announced that during 2010 we would no longer sell Array Matrix
products and would instead deploy our BeadArray technology only
on BeadChips. BeadChips are microscope slide-size silicon wafers
with varying numbers of sample sites per slide. BeadChips are
chemically etched to create tens of millions of wells for each
sample site.
In a separate process, we create sensors by affixing hundreds of
thousands of copies of a specific type of oligonucleotide
molecule to each of the billions of microscopic beads in a
batch. We make different batches of
8
beads, with the beads in a given batch coated with one
particular type of molecule. The particular molecules on a bead
define that beads function as a sensor.
To form an array, a pool of coated beads is brought into contact
with the array surface where they are randomly drawn into the
wells, one bead per well. The beads in the wells comprise our
individual arrays. Because the beads assemble randomly into the
wells, we perform a final procedure called decoding
in order to determine which bead type occupies which well in the
array. We employ several proprietary methods for decoding, which
is a process that requires only a few steps to identify all the
beads in the array. One beneficial by-product of the decoding
process is a functional validation of each bead in the array.
This quality control test characterizes the performance of each
bead and can identify and eliminate use of any empty wells. We
ensure that each bead type on the array is sufficiently
represented by including multiple copies of each bead type.
Multiple bead type copies improve the reliability and accuracy
of the resulting data by allowing statistical processing of the
results of identical beads.
An experiment is performed by preparing a sample, such as DNA,
and introducing it to the array. The molecules in the sample
bind to their matching molecules on the coated beads. The
molecules in either the sample or on the bead are labeled with
fluorescent dye either before or after the binding, which can be
detected by shining a laser on the BeadChip. This allows the
detection of the molecules resulting in a quantitative analysis
of the sample.
VeraCode
Technology
Our proprietary VeraCode technology platform leverages the power
of digital holographic codes to provide a robust detection
method for multiplex assays requiring high precision, accuracy,
and speed. VeraCode enables low-cost multiplexing from 1 to
384-plex in a single well. At the heart of the VeraCode
technology are cylindrical glass beads measuring 240 microns in
length by 28 microns in diameter. Each VeraCode bead type is
inscribed with a unique digital holographic code to designate
and track the specific analyte or genotype of interest
throughout the multiplex reaction. When excited by a laser, each
VeraCode bead emits a unique code image, allowing for quick and
specific detection by Illuminas BeadXpress Reader System.
Depending on desired multiplex levels, assays are created by
pooling microbeads with code diversities from one to several
hundred. Unlike traditional microarrays, the VeraCode microbeads
are used in solution, which takes advantage of solution-phase
kinetics for more rapid hybridization times, dramatically
reducing the time to achieve results. This technology enables us
to serve a number of markets including research, agriculture,
forensics, pharmaceuticals, and molecular diagnostics.
Our
Products
Using our proprietary technologies, our products give our
customers the ability to analyze the genome at any level of
complexity from whole genome sequencing to low multiplex assays.
This enables us to serve a number of markets, including
research, agriculture, forensics, pharmaceuticals, and molecular
diagnostics. The majority of our product sales consist of
instruments and consumables based on these various technologies.
For the fiscal years ended January 3, 2010,
December 28, 2008, and December 30, 2007, instrument
sales comprised 34%, 32%, and 33%, respectively, of total
revenues, and consumable sales represented 59%, 58%, and 53%,
respectively, of total revenues.
9
Our major products, which we expect to be available for shipment
during the first quarter of 2010, include the following:
Instrumentation
Platforms
|
|
|
|
|
|
|
|
|
|
Product
|
|
|
Product Description
|
|
|
Applications
|
|
|
Launch Date
|
HiSeq 2000
|
|
|
Instrument for high-throughput (up to 200 Gb per run and up to
25 GB per day) sequencing using our SBS sequencing technology
|
|
|
DNA sequencing, gene regulation analysis, sequencing-based
transcriptome analysis, SNP discovery and structural variation
analysis, cytogenetic analysis, DNA-protein interaction analysis
(ChIP-seq), sequencing-based methylation analysis, and small RNA
discovery and analysis
|
|
|
Q1 2010
|
Genome Analyzer IIx
|
|
|
Instrument for medium to high-throughput (up to 95 Gb per run)
sequencing using our SBS sequencing technology
|
|
|
DNA sequencing, gene regulation analysis, sequencing-based
transcriptome analysis, SNP discovery and structural variation
analysis, cytogenetic analysis, DNA-protein interaction analysis
(ChIP-seq), sequencing-based methylation analysis, and small RNA
discovery and analysis
|
|
|
Q2 2009
|
Genome Analyzer IIe
|
|
|
Instrument for low to medium throughput (up to 40 Gb per run)
sequencing using our SBS sequencing technology
|
|
|
DNA sequencing, gene regulation analysis, sequencing-based
transcriptome analysis, SNP discovery and structural variation
analysis, cytogenetic analysis, DNA-protein interaction analysis
(ChIP-seq), sequencing-based methylation analysis, and small RNA
discovery and analysis
|
|
|
Q1 2010
|
iScan System
|
|
|
High-resolution imaging instrument to rapidly scan our BeadArray
based assays
|
|
|
SNP genotyping and CNV analysis, custom genotyping, cytogenetic
analysis, focused genotyping, linkage analysis, whole-genome
genotyping and copy number analysis, gene regulation and
epigenetic analysis, array-based methylation analysis, gene
expression analysis, array-based transcriptome analysis, FFPE
sample analysis, and whole-genome gene expression analysis
|
|
|
Q1 2008
|
BeadXpress Reader
|
|
|
Low- to mid-multiplex, high-throughput instrument for readout of
assays (e.g., biomarker validation and development of molecular
diagnostics) deployed on VeraCode bead technology
|
|
|
Custom low- to mid-plex genotyping, custom low- to mid-plex
methylation analysis, SNP screening, and protein screening
|
|
|
Q1 2007
|
|
|
|
|
|
|
|
|
|
|
10
Consumables
|
|
|
|
|
|
|
|
|
|
Product
|
|
|
Product Description
|
|
|
Applications
|
|
|
Launch Date
|
InfiniumHD Whole-Genome BeadChips
|
|
|
Multi-sample DNA Analysis microarrays that interrogate up to 1.2
million markers per sample, depending on the BeadChip. Product
line includes the following BeadChips with human and
agriculturally relevant genome panels: HumanOmniExpress,
HumanOmni1-Quad, Human1M-Duo, and BovineHD
|
|
|
Array based whole-genome genotyping
|
|
|
Q1 2008 through Q1 2010
|
iSelect Custom Genotyping BeadChips
|
|
|
Customer designable SNP genotyping arrays for 3,000 to 200,000
markers for use with any species
|
|
|
Array based custom genotyping
|
|
|
Q2 2006 through Q1 2010
|
GoldenGate Assay Method
|
|
|
High throughput assay and genotyping system
|
|
|
High throughput, array based genotyping
|
|
|
Q3 2009
|
GoldenGate Universal-32 Sample BeadChip
|
|
|
32 sample GoldenGate genotyping arrays
|
|
|
Array based genotyping
|
|
|
Q4 2008
|
Paired-End Genomic DNA Sample Prep Kit
|
|
|
Streamlined library preparation kit to generate 200
500 kb insert paired-end reads
|
|
|
Whole-genome sequencing, targeted sequencing, gene expression
discovery and profiling, and epigenomics analysis
|
|
|
Q2 2008
|
VeraCode GoldenGate
|
|
|
Flexible low plex GoldenGate genotyping arrays compatible with
the BeadXpress System
|
|
|
High throughput, array based genotyping
|
|
|
FY 2007
|
Standard Sequencing Kit
|
|
|
Reagents used for SBS chemistry on our sequencing platforms
|
|
|
Whole-genome sequencing, targeted sequencing, gene expression
discovery and profiling, and epigenomics analysis
|
|
|
Q1 2007
|
Infinium Assay Kit
|
|
|
Reagents used to perform Infinium assays on the iScan platform
|
|
|
Array-based genotyping
|
|
|
Q1 2008 through Q1 2010
|
|
|
|
|
|
|
|
|
|
|
Our
Services
Sequencing
We have been offering sequencing services since 2007. Our
services range from small sets of samples requiring as little as
one run to finish, to large-scale projects, like whole-genome
sequencing, necessitating multiple instruments running in
parallel for extended periods of time. The breadth of
applications offered
11
includes novel custom products as well as all released products.
These applications include but are not limited to human whole
exome and custom targeted re-sequencing, de novo sequencing,
small RNA discovery and profiling, gene expression using random
primed RNA sampling technology, ChIP SEQ, and methylome
interrogation.
Genotyping
We have been offering genotyping services since 2002. Our
genotyping services offer all of our genotyping products,
including standard and custom GoldenGate, standard Infinium and
Infinium HD, as well as iSelect Infinium. Our projects range in
size from a few hundred samples to over 10,000 samples. Our
customer base includes academic institutions, and biotech and
pharmaceutical companies.
Intellectual
Property
We have an extensive intellectual property portfolio, including,
as of February 1, 2010, ownership of, or exclusive licenses
to, 159 issued U.S. patents and 171 pending
U.S. patent applications, including eight allowed
applications that have not yet issued as patents. Our issued
patents include those directed to various aspects of our arrays,
assays, oligo synthesis, sequencing technology, instruments, and
chemical detection technologies, and have terms that expire
between 2010 and 2027. We continue to file new patent
applications to protect the full range of our technologies. We
have filed or have been granted counterparts for many of these
patents and applications in foreign countries.
We also rely upon trade secrets, know-how, copyright, and
trademark protection, as well as continuing technological
innovation and licensing opportunities to develop and maintain
our competitive position. Our success will depend in part on our
ability to obtain patent protection for our products and
processes, to preserve our trade secrets, to enforce our
patents, copyrights and trademarks, to operate without
infringing the proprietary rights of third parties, and to
acquire licenses related to enabling technology or products.
We are party to various exclusive and non-exclusive license
agreements and other arrangements with third parties that grant
us rights to use key aspects of our array and sequencing
technologies, assay methods, chemical detection methods, reagent
kits, and scanning equipment. We have exclusive licenses from
Tufts University to patents that are directed to our BeadArray
technology. These patents were filed by Dr. David Walt, who
is a member of our board of directors, the Chairman of our
Scientific Advisory Board, and one of our founders. Our
exclusive licenses expire with the termination of the underlying
patents, which will occur between 2010 and 2020. We have
additional nonexclusive license agreements with various third
parties for other components of our products. In most cases, the
agreements remain in effect over the term of the underlying
patents, may be terminated at our request without further
obligation, and require that we pay customary royalties while
the agreement is in effect.
Research
and Development
We have made substantial investments in research and development
since our inception. We have assembled a team of skilled
engineers and scientists who are specialists in biology,
chemistry, informatics, instrumentation, optical systems,
software, manufacturing, and other related areas required to
complete the development of our products. Our research and
development efforts have focused primarily on the tasks required
to optimize our sequencing, BeadArray, VeraCode, and oligo
synthesis technologies and to support commercialization of the
products and services derived from these technologies.
Our research and development expenses for 2009, 2008, and 2007
were $140.6 million, $100.0 million, and
$73.9 million, respectively. We expect research and
development expense to increase during 2010 as we continue to
expand our research and product development efforts.
Marketing
and Distribution
Our current products address the genetic analysis portion of the
life sciences market, in particular, experiments involving
sequencing, SNP genotyping, and gene expression profiling. These
experiments may be
12
involved in many areas of biologic research, including basic
human disease research, pharmaceutical drug discovery and
development, pharmacogenomics, toxicogenomics, and agricultural
research. Our potential customers include pharmaceutical,
biotechnology, agrichemical, diagnostics, and consumer products
companies, as well as academic or private research centers. The
genetic analysis market is relatively new and emerging and its
size and speed of development will ultimately be driven by,
among other items:
|
|
|
|
|
the ability of the research community to extract medically
valuable information from genomics and to apply that knowledge
to multiple areas of disease-related research and treatment;
|
|
|
|
the availability of sufficiently low cost, high-throughput
research tools to enable the large amount of experimentation
required to study genetic variation and biological
function; and
|
|
|
|
the availability of government and private industry funding to
perform the research required to extract medically relevant
information from genomic analysis.
|
We market and distribute our products directly to customers in
North America, Europe, and the Asia-Pacific region. In each of
these areas, we have dedicated sales, service, and application
support personnel responsible for expanding and managing their
respective customer bases. In addition, in certain markets
within Europe, the Asia-Pacific region, the Middle East, and
South Africa we sell our products and provide services to
customers through distributors that specialize in life science
products. We expect to continue to increase our sales and
distribution resources during 2010 and beyond as we launch a
number of new products and expand the number of customers that
can use our products.
Manufacturing
We manufacture sequencing and array instrument platforms,
reagent kits, scanning equipment, and oligos. Our manufacturing
capacity for consumables and instruments has grown during 2009
to support our increased customer demand. We are also focused on
continuing to enhance the quality and manufacturing yield of our
BeadChips and flow cells. To continue to increase throughput and
improve the quality and manufacturing yield as we increase the
complexity of our products, we are exploring ways to continue
increasing the level of automation in the manufacturing process.
We adhere to access and safety standards required by federal,
state, and local health ordinances, such as standards for the
use, handling, and disposal of hazardous substances.
Raw
Materials
Our manufacturing operations require a wide variety of raw
materials, electronic and mechanical components, chemical and
biochemical materials, and other supplies. We have multiple
commercial sources for many of our components and supplies;
however, there are some raw materials we obtain from single
source suppliers. To mitigate potential risks arising from
single source suppliers, we believe that we can redesign our
products for alternative components or use alternative reagents.
In addition, while we generally attempt to keep our inventory at
minimal levels, we purchase incremental inventory as
circumstances warrant to protect our supply chain.
Competition
Although we expect that our products and services will provide
significant advantages over products and services currently
available from other sources, we expect to encounter intense
competition from other companies that offer products and
services for the sequencing, SNP genotyping, gene expression,
and molecular diagnostics markets. These include companies such
as Affymetrix, Inc.; Agilent Technologies, Inc.; Beckman
Coulter, Inc.; Complete Genomics, Inc.; General Electric
Company; Helicos BioSciences Corporation; Life Technologies
Corporation; Luminex Corporation; Pacific Biosciences, Inc.;
Roche Diagnostics Corp.; Sequenom, Inc.; and Qiagen N.V. Some of
these companies have or will have substantially greater
financial, technical, research, and other resources and larger,
more established marketing, sales, distribution, and service
organizations than we do. In addition, they may have greater
name recognition than we do in the markets we address and in
some cases a larger installed base of systems. Each of these
markets is very competitive and we expect new competitors to
emerge and the intensity of competition to increase. In
13
order to effectively compete with these companies, we will need
to demonstrate that our products have superior throughput, cost,
and accuracy advantages over competing products.
Segment
and Geographic Information
During the first quarter of 2008, we reorganized our operating
structure into two newly created business segments, Life
Sciences and Diagnostics. Our Life Sciences Business Unit
includes all products and services that are primarily related to
the research market, namely the product lines based on our
sequencing, BeadArray, and VeraCode technologies, and our
Diagnostics Business Unit focuses on the emerging opportunity in
molecular diagnostics. During 2009, we had limited activity
related to the Diagnostics Business Unit and operating results
were reported on an aggregate basis to our chief operating
decision maker, the chief executive officer. Accordingly, we
operated in one reportable segment during 2009.
We currently sell our products to a number of customers outside
the United States, including customers in other areas of North
America, Europe, and the Asia-Pacific region. Shipments to
customers outside the United States totaled $319.1 million,
or 48% of our total revenue, during 2009, compared to
$293.2 million, or 51%, and $159.1 million, or 43%, in
2008 and 2007, respectively. Sales to customers outside of the
United States were generally denominated in U.S. dollars.
In 2008, we reorganized our international structure to establish
more efficient channels among product development, product
manufacturing, and sales. The reorganization increased our
foreign subsidiaries anticipated dependence on the
U.S. entity for management decisions, financial support,
production assets, and inventory thereby making the foreign
subsidiaries more of a direct and integral component of the
U.S. entitys operations. As a result, we reassessed
the primary economic environment of our foreign subsidiaries and
determined the subsidiaries are more U.S. dollar based,
resulting in a U.S. dollar functional currency
determination. We expect that sales to international customers
will continue to be an important and growing source of revenue.
See Note 13 of the Notes to Consolidated Financial
Statements for further information concerning our foreign and
domestic operations.
Backlog
Our backlog was $227.6 million and $113.0 million at
January 3, 2010 and December 28, 2008, respectively.
Generally, our backlog consists of orders believed to be firm as
of the balance sheet date; however, we may allow customers to
make product substitutions as we launch new products. The timing
of shipments depends on several factors including, agreed upon
shipping schedules, which may span multiple quarters, and
whether the product is catalog or custom. We reasonably expect
an estimated 90% of the backlog as of January 3, 2010 to be
shipped within the fiscal year ending January 2, 2011.
Although we generally recognize revenue at the time of shipment
and transfer of title to a customer, we may be required to defer
the recognition of revenue even after shipment depending on the
specific arrangement with a customer and the applicable
accounting treatment. A material portion of our backlog at
January 3, 2010 is associated with a large order we
received from one customer for which we anticipate using
operating lease accounting that will require us to recognize
revenue over a period of three years with the majority of that
revenue recognized in 2011 and 2012.
Seasonality
Historically, customer purchasing patterns have not shown
significant seasonal variation, although demand for our products
is usually lowest in the first quarter of the calendar year and
highest in the third quarter of the calendar year as a result,
in part, of U.S. academic customers spending unused budget
allocations before the end of the U.S. governments
fiscal year.
Environmental
Matters
We are committed to the protection of our employees and the
environment. Our operations require the use of hazardous
materials that subject us to a variety of federal, state, and
local environmental and safety laws and regulations. We believe
we are in material compliance, in all material respects, with
current applicable laws and regulations; however, we could be
held liable for damages and fines should contamination
14
of the environment or individual exposures to hazardous
substances occur. In addition, we cannot predict how changes in
these laws and regulations, or the development of new laws and
regulations, will affect our business operations or the cost of
compliance.
Government
Regulation
Our products are not currently subject to FDA clearance or
approval if they are not intended to be used for the diagnosis
of disease. However, as we expand our product line to encompass
products that are intended to be used for the diagnosis of
disease, such as molecular diagnostic products, regulation by
governmental authorities in the United States and other
countries will be a significant factor in the development,
testing, production, and marketing of such products. Products
that we develop in the molecular diagnostic markets, depending
on their intended use, will be regulated as medical devices by
the FDA and comparable agencies of other countries and may
require either receiving clearance following a pre-market
notification process, also known as a 510(k) clearance, or
premarket approval (PMA), from the FDA prior to marketing.
Obtaining the requisite regulatory approvals can be expensive
and may involve considerable delay.
The shorter 510(k) clearance process, which generally takes from
three to six months after submission, but can take significantly
longer, may be utilized if it is demonstrated that the new
product is substantially equivalent to a similar
product that has already been cleared by the FDA. The longer PMA
process is much more costly, uncertain, and generally takes from
nine months to two years after filing. Because we cannot assure
you that any molecular diagnostic products that we develop will
be subject to the shorter 510(k) clearance process, or will
ultimately be approved at all, the regulatory approval process
for such products may be significantly delayed and may be
significantly more expensive than anticipated. If we fail to
obtain, or experience significant delays in obtaining,
regulatory approvals for molecular diagnostic products that we
develop, we may not be able to launch or successfully
commercialize such products in a timely manner, or at all.
Changes to the current regulatory framework, including the
imposition of additional or new regulations, could arise at any
time during the development or marketing of our products, which
may negatively affect our ability to obtain or maintain FDA or
comparable regulatory approval of our products, if required.
In addition, the regulatory approval or clearance process
required to manufacture, market, and sell our existing and
future products that are intended for, and marketed and labeled
as, Research Use Only, or RUO, is uncertain if such
products are used or could be used, even without our consent,
for the diagnosis of disease. If the FDA or other regulatory
authorities assert that any of our RUO products are subject to
regulatory clearance or approval, our business, financial
condition, or results of operations could be adversely affected.
Employees
As of January 3, 2010, we had a total of
1,781 employees. None of our employees are represented by a
labor union. We consider our employee relations to be positive.
Our success will depend in large part upon our ability to
attract and retain employees. In addition, we employ a number of
temporary and contract employees. We face competition in this
regard from other companies, research and academic institutions,
government entities, and other organizations.
Our business is subject to various risks, including those
described below. In addition to the other information included
in this
Form 10-K,
the following issues could adversely affect our operating
results or our stock price.
We
face intense competition, which could render our products
obsolete, result in significant price reductions, or
substantially limit the volume of products that we
sell.
We compete with life sciences companies that design,
manufacture, and market products for analysis of genetic
variation and biological function and other applications using a
wide-range of competing technologies. We anticipate that we will
continue to face increased competition as existing companies
develop new or
15
improved products and as new companies enter the market with new
technologies. One or more of our competitors may render our
technology obsolete or uneconomical. Some of our competitors
have greater financial and personnel resources, broader product
lines, a more established customer base, and more experience in
research and development than we do. Furthermore, life sciences
and pharmaceutical companies, which are our potential customers
and strategic partners, could also develop competing products.
We believe that customers in our markets display a significant
amount of loyalty to their initial supplier of a particular
product; therefore, it may be difficult to generate sales to
potential customers who have purchased products from
competitors. To the extent we are unable to be the first to
develop or supply new products, our competitive position may
suffer.
The market for molecular diagnostics products is currently
limited and highly competitive, with several large companies
already having significant market share, intellectual property
portfolios, and regulatory expertise. Established diagnostic
companies also have an installed base of instruments in several
markets, including clinical and reference laboratories, which
could deter acceptance of our products. In addition, some of
these companies have formed alliances with genomics companies
that provide them access to genetic information that may be
incorporated into their diagnostic tests.
Our
success depends upon the continued emergence and growth of
markets for analysis of genetic variation and biological
function.
We design our products primarily for applications in the life
sciences, agricultural, and pharmaceutical industries. The
usefulness of our technologies depends in part upon the
availability of genetic data and its usefulness in identifying
or treating disease. We are focusing on markets for analysis of
genetic variation and biological function, namely sequencing,
genotyping, and gene expression profiling. These markets are new
and emerging, and they may not develop as quickly as we
anticipate, or reach their full potential. Other methods of
analysis of genetic variation and biological function may emerge
and displace the methods we are developing. Also, researchers
may not seek or be able to convert raw genetic data into
medically valuable information through the analysis of genetic
variation and biological function. For instance, demand for our
microarray products may be adversely affected if researchers
fail to find meaningful correlations between genetic variation,
such as SNPs, and disease susceptibility through genome wide
association studies. In addition, factors affecting research and
development spending generally, such as changes in the
regulatory environment affecting life sciences and
pharmaceutical companies, and changes in government programs
that provide funding to companies and research institutions,
could harm our business. If useful genetic data is not available
or if our target markets do not develop in a timely manner,
demand for our products may grow at a slower rate than we
expect, and we may not be able to sustain profitability.
If the
quality of our products does not meet our customers
expectations, then our sales and operating earnings, and
ultimately our reputation, could be negatively
impacted.
In the course of conducting our business, we must adequately
address quality issues associated with our products and
services, including defects in our engineering, design, and
manufacturing processes, as well as defects in third-party
components included in our products. Because our instruments and
reagents are highly complex, the occurrence of defects may
increase as we continue to introduce new products and services.
Although we have established internal procedures to minimize
risks that may arise from product quality issues, there can be
no assurance that we will be able to eliminate or mitigate
occurrences of these issues and associated liabilities. In
addition, identifying the root cause of quality issues,
particularly those affecting reagents, may be difficult, which
increases the time needed to address quality issues as they
arise and increases the risk that similar problems could recur.
Finding solutions to quality issues can be expensive and we may
incur significant costs or lost revenue in connection with, for
example, shipment holds, product recalls, and warranty or other
service obligations. In addition, quality issues can impair our
relationships with new or existing customers and adversely
affect our brand image, and our reputation as a producer of high
quality products could suffer, which could adversely affect our
business as well as our financial results.
16
If we
do not successfully manage the development and launch of new
products or services, including product transitions, our
financial results could be adversely affected.
We face risks associated with launching new products and
pre-announcing products and services when the products or
services have not been fully developed or tested. If our
products and services are not able to deliver the performance or
results expected by our target markets or are not delivered on a
timely basis, our reputation and credibility may suffer. If we
encounter development challenges or discover errors in our
products late in our development cycle it may cause us to delay
our product launch date. In addition, we may experience
difficulty in managing or forecasting customer reactions,
purchasing decisions, or transition requirements or programs
(such as trade-in programs) with respect to newly launched
products (or products in development) relative to our existing
products, which could adversely affect sales of our existing
products. The expenses or losses associated with unsuccessful
product development or launch activities or lack of market
acceptance of our new products could adversely affect our
business, financial condition, or results of operations.
If we
are unable to increase our manufacturing capacity and develop
and maintain operation of our manufacturing capability, we may
not be able to launch or support our products in a timely
manner, or at all.
We continue to increase our capacity to meet the anticipated
demand for our products. Although we have significantly
increased our manufacturing capacity and we believe we have
plans in place sufficient to ensure we have adequate capacity to
meet our business plan for 2010, there are uncertainties
inherent in expanding our manufacturing capabilities and we may
not be able to sufficiently increase our capacity in a timely
manner. For example, manufacturing and product quality issues
may arise as we increase production rates at our manufacturing
facilities and launch new products. Also, we may not manufacture
the right product mix to meet customer demand, especially as we
introduce new products. As a result, we may experience
difficulties in meeting customer, collaborator, and internal
demand, in which case we could lose customers or be required to
delay new product introductions, and demand for our products
could decline. Additionally, in the past, we have experienced
variations in manufacturing conditions and quality control
issues that have temporarily reduced or suspended production of
certain products. Due to the intricate nature of manufacturing
products that contain DNA, we may encounter similar or
previously unknown manufacturing difficulties in the future that
could significantly reduce production yields, impact our ability
to launch or sell these products (or to produce them
economically), prevent us from achieving expected performance
levels, or cause us to set prices that hinder wide adoption by
customers.
Additionally, we currently manufacture in a limited number of
locations. Our manufacturing facilities are located in
San Diego and Hayward, California; Singapore; and Little
Chesterford, United Kingdom. These areas are subject to natural
disasters such as earthquakes, wildfires, or floods. If a
natural disaster were to damage one of our facilities
significantly or if other events were to cause our operations to
fail, we may be unable to manufacture our products, provide our
services or develop new products.
Also, many of our manufacturing processes are automated and are
controlled by our custom-designed Laboratory Information
Management System (LIMS). Additionally, the decoding process in
our array manufacturing requires significant network and storage
infrastructure. If either our LIMS system or our networks or
storage infrastructure were to fail for an extended period of
time, it may adversely impact our ability to manufacture our
products on a timely basis and could prevent us from achieving
our expected shipments in any given period.
Our
acquisitions expose us to risks that could adversely affect our
business, and we may not achieve the anticipated benefits of
acquisitions of businesses or technologies.
As part of our strategy to develop and identify new products,
services, and technologies, we have made, and may continue to
make, acquisitions of technologies, products, or businesses.
Acquisitions involve
17
numerous risks and operational, financial, and managerial
challenges, including the following, any of which could
adversely affect our business, financial condition, or results
of operations:
|
|
|
|
|
difficulties in integrating new operations, technologies,
products, and personnel;
|
|
|
|
lack of synergies or the inability to realize expected synergies
and cost-savings;
|
|
|
|
difficulties in managing geographically dispersed operations;
|
|
|
|
underperformance of any acquired technology, product, or
business relative to our expectations and the price we paid;
|
|
|
|
negative near-term impacts on financial results after an
acquisition, including acquisition-related earnings charges;
|
|
|
|
the potential loss of key employees, customers, and strategic
partners of acquired companies;
|
|
|
|
claims by terminated employees and shareholders of acquired
companies or other third parties related to the transaction;
|
|
|
|
the issuance of dilutive securities, assumption or incurrence of
additional debt obligations or expenses, or use of substantial
portions of our cash;
|
|
|
|
diversion of managements attention and company resources
from existing operations of the business;
|
|
|
|
inconsistencies in standards, controls, procedures, and policies;
|
|
|
|
the impairment of intangible assets as a result of technological
advancements, or
worse-than-expected
performance of acquired companies; and
|
|
|
|
assumption of, or exposure to, unknown contingent liabilities or
liabilities that are difficult to identify or accurately
quantify.
|
In addition, the successful integration of acquired businesses
requires significant efforts and expense across all operational
areas, including sales and marketing, research and development,
manufacturing, finance, legal, and information technologies. We
cannot assure you that any of the acquisitions we make will be
successful or will be, or will remain, profitable. Our failure
to successfully address the above risks may prevent us from
achieving the anticipated benefits from any acquisition in a
reasonable time frame, or at all.
The
timing and extent of funding provided by the American Recovery
and Reinvestment Act of 2009 (the Recovery Act) could adversely
affect our business, financial condition, or results of
operations.
The Recovery Act was enacted in February 2009 to provide
stimulus to the U.S. economy in the wake of the economic
downturn. As part of the Recovery Act legislation, over
$10 billion in funding was provided to the National
Institute of Health through September 2010 to support the
advancement of scientific research. A portion of the stimulus
funding may support the analysis of genetic variation and
biological function and have a significant positive impact on
our business. In the short-term, however, our customers may
delay or reduce their purchases of our products as they wait to
learn whether, and to what extent, they will receive stimulus
funding. If our customers are unable to obtain stimulus money
they may reduce their research and development budgets resulting
in a decrease in demand for our products. In addition, it is
unclear what will happen to demand for our products after the
stimulus funds from the Recovery Act have been allocated and
spent. A decline in demand will reduce our revenues, which would
adversely affect our business, financial condition, or results
of operations.
Unfavorable
global economic conditions could adversely affect our business,
financial condition, or results of operations.
Our results of operations could be adversely affected by general
conditions in the global economy and in the global financial
markets. The recent global financial crisis caused extreme
volatility and disruptions in the capital and credit markets. A
severe or prolonged economic downturn, such as the recent global
financial
18
crisis, could result in a variety of risks to our business,
including, in particular, reductions or delays in planned
improvements to healthcare systems, research and development
funding, and purchases of our products and services, or
cost-containment efforts by governments and private
organizations that could adversely affect our business,
financial condition, or results of operations. In addition, the
liquidity of our investment portfolio could be impaired such as
when more than $50 million of auction rate securities that
we held for investment became illiquid in February 2008 because
their scheduled auctions failed. Furthermore, as is the case for
almost any other business, we face the following risks from a
severe or prolonged economic downturn:
|
|
|
|
|
severely limited access to financing over an extended period of
time, which may limit our ability to fund our growth strategy,
could result in a need to delay capital expenditures,
acquisitions, or research and development projects;
|
|
|
|
losses from our investment portfolio or to a counterpartys
inability to fulfill its payment obligations;
|
|
|
|
inability to refinance existing debt at competitive rates,
reasonable terms, or sufficient amounts; and
|
|
|
|
increased volatility or adverse movements in foreign currency
exchange rates.
|
In addition, certain of our customers may face challenges
gaining timely access to sufficient credit, which could result
in an impairment of their ability to make timely payments to us.
If that were to occur, our allowance for doubtful accounts and
our days sales outstanding could increase. Additionally, these
economic conditions may cause our smaller suppliers to be unable
to supply in a timely manner sufficient quantities of customized
components, which would impair our ability to manufacture on
schedule and at commercially reasonable costs. Suppliers may
also extend lead times, limit supplies, or increase prices due
to capacity constraints or other factors.
Our
continued growth is dependent on continuously developing and
commercializing new products.
Our target markets are characterized by rapid technological
change, evolving industry standards, changes in customer needs,
existing and emerging competition, strong price competition, and
frequent new product introductions. Accordingly, our continued
growth depends on continuously developing and commercializing
new products and services, including improving our existing
products and services, in order to address evolving market
requirements on a timely basis. If we fail to innovate or
adequately invest in new technologies, our products and services
will become dated and we could lose our competitive position in
the markets that we serve as customers purchase new products
offered by our competitors. We believe that successfully
introducing new products and technologies in our target markets
on a timely basis provides a significant competitive advantage
because customers make an investment of time in selecting and
learning to use a new product and may be reluctant to switch
once that selection is made.
To the extent that we fail to introduce new and innovative
products, or such products are not accepted in the market or
suffer significant delays in development, we may lose market
share to our competitors, which will be difficult or impossible
to regain. An inability, for technological or other reasons, to
successfully develop and introduce new products could reduce our
growth rate or otherwise have an adverse effect on our business.
In the past, we have experienced, and are likely to experience
in the future, delays in the development and introduction of new
products. We cannot assure you that we will keep pace with the
rapid rate of change in our markets or that our new products
will adequately meet the requirements of the marketplace,
achieve market acceptance, or compete successfully with
competing technologies. Some of the factors affecting market
acceptance of new products and services include:
|
|
|
|
|
availability, quality, and price relative to competing products
and services;
|
|
|
|
the functionality of new and existing products and services;
|
|
|
|
the timing of introduction of the new product or service
relative to competing products and services;
|
|
|
|
scientists and customers opinions of the utility of
the new product or service;
|
|
|
|
citation of the new product or service in published research;
|
19
|
|
|
|
|
regulatory trends and approvals; and
|
|
|
|
general trends in life sciences research and applied markets.
|
We
depend on third-party manufacturers and suppliers for components
and materials used in our products, and if shipments from these
manufacturers or suppliers are delayed or interrupted, or if the
quality of the components or materials supplied do not meet our
requirements, we may not be able to launch, manufacture, or ship
our products in a timely manner, or at all.
The nature of our products requires customized components and
materials that currently are available from a limited number of
sources, and, in the case of some components and materials, from
only a single source. If deliveries from these vendors are
delayed or interrupted for any reason, or if we are otherwise
unable to secure a sufficient supply, we may not be able to
obtain these components or materials timely or in sufficient
quantities or qualities, or at all, in order to meet demand for
our products. We may need to enter into contractual
relationships with manufacturers for commercial-scale production
of some of our products, or develop these capabilities
internally, and we cannot assure you that we will be able to do
this on a timely basis, in sufficient quantities, or on
commercially reasonable terms. Accordingly, we may not be able
to establish or maintain reliable, high-volume manufacturing at
commercially reasonable costs. In addition, the manufacture or
shipment of our products may be delayed or interrupted if the
quality of the components or materials supplied by our vendors
does not meet our requirements. Any delay or interruption to our
manufacturing process or in shipping our products could result
in lost revenue, which would adversely affect our business,
financial condition, or results of operations.
An
inability to manage our growth or the expansion of our
operations could adversely affect our business, financial
condition, or results of operations.
Our business has grown rapidly, with total revenues increasing
from $73.5 million for the year ended January 1, 2006
to $666.3 million for the year ended January 3, 2010
and with the number of employees increasing from 375 to 1,781
during the same period. We expect to continue to experience
rapid and substantial growth in order to achieve our operating
plans. The rapid expansion of our business and addition of new
personnel may place a strain on our management and operational
systems. Our ability to effectively manage our operations and
growth requires us to continue to expend funds to enhance our
operational, financial, and management controls, reporting
systems, and procedures and to attract and retain sufficient
numbers of talented employees on a global basis. If we are
unable to scale up and implement improvements to our
manufacturing process and control systems in an efficient or
timely manner, or if we encounter deficiencies in existing
systems and controls, then we will not be able to make available
the products required to successfully commercialize our
technology. Our future operating results will depend on the
ability of our management to continue to implement and improve
our research, product development, manufacturing, sales and
marketing, and customer support programs, enhance our
operational and financial control systems, expand, train, and
manage our employee base, integrate acquired businesses, and
effectively address new issues related to our growth as they
arise. There can be no assurance that we will be able to manage
our recent or any future expansion or acquisition successfully,
and any inability to do so could adversely affect our business,
financial condition, or results of operations.
If we
lose our key personnel or are unable to attract and retain
additional personnel, we may be unable to achieve our
goals.
We are highly dependent on our management and scientific
personnel, including Jay Flatley, our president and chief
executive officer. The loss of their services could adversely
impact our ability to achieve our business objectives. In
addition, we will need to hire additional qualified personnel
with expertise in molecular biology, chemistry, biological
information processing, sales, marketing, and technical support.
We compete for qualified management and scientific personnel
with other life science companies, universities, and research
institutions, particularly those focusing on genomics.
Competition for these individuals, particularly in the
San Diego and San Francisco area, is intense, and the
turnover rate can be high. Failure to attract and retain
management and scientific personnel would prevent us from
pursuing collaborations or developing our
20
products or technologies. Additionally, integration of acquired
companies and businesses can be disruptive, causing key
employees of the acquired business to leave. Further, we use
stock options and restricted stock to provide incentives for our
key personnel to remain with us and to align their interests
with those of the Company by building long-term stockholder
value. If our stock price decreases, the value of these equity
awards decreases and therefore reduces a key employees
incentive to stay.
Doing
business internationally creates operational and financial risks
for our business.
Conducting and launching operations on an international scale
requires close coordination of activities across multiple
jurisdictions and time zones and consumes significant management
resources. If we fail to coordinate and manage these activities
effectively, including the risks noted below, our business,
financial condition, or results of operations could be adversely
affected. We are focused on expanding our international
operations in key markets. We have sales offices located
internationally throughout Europe and the Asia-Pacific region,
as well as manufacturing facilities in the United Kingdom and
Singapore. During 2009, the majority of our sales to
international customers and purchases of raw materials from
international suppliers were denominated in U.S. dollars.
Shipments to customers outside the United States comprised 48%,
51%, and 43% of our total revenue for the years ended
January 3, 2010, December 28, 2008, and
December 30, 2007, respectively. We intend to continue to
expand our international presence by selling to customers
located outside of the United States and we expect the total
amount of
non-U.S. sales
to continue to grow.
International sales entail a variety of risks, including:
|
|
|
|
|
longer payment cycles and difficulties in collecting accounts
receivable outside of the United States;
|
|
|
|
currency exchange fluctuations;
|
|
|
|
challenges in staffing and managing foreign operations;
|
|
|
|
tariffs and other trade barriers;
|
|
|
|
unexpected changes in legislative or regulatory requirements of
foreign countries into which we sell our products;
|
|
|
|
difficulties in obtaining export licenses or in overcoming other
trade barriers and restrictions resulting in delivery
delays; and
|
|
|
|
significant taxes or other burdens of complying with a variety
of foreign laws.
|
Changes in the value of the relevant currencies may affect the
cost of certain items required in our operations. Changes in
currency exchange rates may also affect the relative prices at
which we are able sell products in the same market. Our revenues
from international customers may be negatively impacted as
increases in the U.S. dollar relative to our international
customers local currency could make our products more expensive,
impacting our ability to compete. Our costs of materials from
international suppliers may increase if in order to continue
doing business with us they raise their prices as the value of
the U.S. dollar decreases relative to their local currency.
Foreign policies and actions regarding currency valuation could
result in actions by the United States and other countries to
offset the effects of such fluctuations. The recent global
financial downturn has led to a high level of volatility in
foreign currency exchange rates and that level of volatility may
continue, which could adversely affect our business, financial
condition, or results of operations.
We are
subject to risks related to taxation in multiple jurisdictions
and the possible loss of the tax deduction on our outstanding
convertible notes.
We are subject to income taxes in both the United States and
numerous foreign jurisdictions. Significant judgments based on
interpretations of existing tax laws or regulations are required
in determining the provision for income taxes. Our effective
income tax rate could be adversely affected by various factors,
including, but not limited to, changes in the mix of earnings in
tax jurisdictions with different statutory tax rates, changes in
the valuation of deferred tax assets and liabilities, changes in
existing tax laws or tax rates,
21
changes in the level of non-deductible expenses (including
share-based compensation), changes in our future levels of
research and development spending, mergers and acquisitions, or
the result of examinations by various tax authorities.
In addition, we could lose some or all of the tax deduction for
interest expense associated with our $400 million aggregate
principal amount of convertible notes due in 2014 if these notes
are not subject to the special Treasury Regulations governing
contingent payment debt instruments, the notes are converted, or
we invest in non-taxable investments.
Any
inability to effectively protect our proprietary technologies
could harm our competitive position.
Our success depends to a large extent on our ability to develop
proprietary products and technologies and to obtain patents and
maintain adequate protection of our intellectual property in the
United States and other countries. If we do not protect our
intellectual property adequately, competitors may be able to use
our technologies and thereby erode our competitive advantage.
The laws of some foreign countries do not protect proprietary
rights to the same extent as the laws of the United States, and
many companies have encountered significant challenges in
establishing and enforcing their proprietary rights outside of
the United States. These challenges can be caused by the absence
of rules and methods for the establishment and enforcement of
intellectual property rights outside of the United States.
The patent positions of companies developing tools for the life
sciences, agricultural, and pharmaceutical industries, including
our patent position, generally are uncertain and involve complex
legal and factual questions. We will be able to protect our
proprietary rights from unauthorized use by third parties only
to the extent that our proprietary technologies are covered by
valid and enforceable patents or are effectively maintained as
trade secrets. In addition, patent applications in the United
States may be maintained in secrecy until patents issue, and
publication of discoveries in the scientific or patent
literature tend to lag behind actual discoveries by several
months. We intend to apply for patents covering our technologies
and products as we deem appropriate. However, our patent
applications may be challenged and may not result in issued
patents or may be invalidated or narrowed in scope after they
are issued. Questions as to inventorship or ownership may also
arise. Any finding that our patents or applications are
unenforceable could harm our ability to prevent others from
practicing the related technology, and a finding that others
have inventorship or ownership rights to our patents and
applications could require us to obtain certain rights to
practice related technologies, which may not be available on
favorable terms, if at all. Furthermore, as issued patents
expire, we may lose some competitive advantage as others develop
competing products, and, as a result, we may lose revenue.
In addition, our existing patents and any future patents we
obtain may not be sufficiently broad to prevent others from
practicing our technologies or from developing competing
products. There is also the risk that others may independently
develop similar or alternative technologies or design around our
patented technologies. Also, our patents may fail to provide us
with any competitive advantage. We may need to initiate lawsuits
to protect or enforce our patents, or litigate against third
party claims, which would be expensive, and, if we lose, may
cause us to lose some of our intellectual property rights and
reduce our ability to compete in the marketplace. Furthermore,
these lawsuits may divert the attention of our management and
technical personnel.
We also rely upon trade secrets and proprietary know-how
protection for our confidential and proprietary information, and
we have taken security measures to protect this information.
These measures, however, may not provide adequate protection for
our trade secrets, know-how, or other confidential information.
Among other things, we seek to protect our trade secrets and
confidential information by entering into confidentiality
agreements with employees, collaborators, and consultants. There
can be no assurance that any confidentiality agreements that we
have with our employees, collaborators, and consultants will
provide meaningful protection for our trade secrets and
confidential information or will provide adequate remedies in
the event of unauthorized use or disclosure of such information.
Accordingly, there also can be no assurance that our trade
secrets will not otherwise become known or be independently
developed by competitors.
22
Litigation,
other proceedings, or third party claims of intellectual
property infringement could require us to spend significant time
and money and could prevent us from selling our products or
services.
Our success depends, in part, on our non-infringement of the
patents or proprietary rights of third parties. Third parties
have asserted and may in the future assert that we are employing
their proprietary technology without authorization. As we enter
new markets, we expect that competitors will likely claim that
our products infringe their intellectual property rights as part
of a business strategy to impede our successful entry into those
markets. In addition, third parties may have obtained and may in
the future obtain patents allowing them to claim that the use of
our technologies infringes these patents. We could incur
substantial costs and divert the attention of our management and
technical personnel in defending ourselves against any of these
claims. Any adverse ruling or perception of an adverse ruling in
defending ourselves against these claims could have an adverse
impact on our stock price, which may be disproportionate to the
actual import of the ruling itself. Furthermore, parties making
claims against us may be able to obtain injunctive or other
relief, which effectively could block our ability to develop
further, commercialize, or sell products, and could result in
the award of substantial damages against us. In the event of a
successful infringement claim against us, we may be required to
pay damages and obtain one or more licenses from third parties,
or be prohibited from selling certain products. In addition, we
may be unable to obtain these licenses at a reasonable cost, if
at all. We could therefore incur substantial costs related to
royalty payments for licenses obtained from third parties, which
could negatively affect our gross margins. In addition, we could
encounter delays in product introductions while we attempt to
develop alternative methods or products. Defense of any lawsuit
or failure to obtain any of these licenses on favorable terms
could prevent us from commercializing products, and the
prohibition of sale of any of our products could adversely
affect our ability to grow or maintain profitability.
Our
products, if used for the diagnosis of disease, could be subject
to government regulation, and the regulatory approval and
maintenance process for such products may be expensive,
time-consuming, and uncertain both in timing and in
outcome.
Our products are not currently subject to FDA clearance or
approval if they are not intended to be used for the diagnosis
of disease. However, as we expand our product line to encompass
products that are intended to be used for the diagnosis of
disease, certain of our products are likely to become subject to
regulation by the FDA, or comparable agencies of other
countries, including requirements for regulatory approval of
such products before they can be marketed. Such regulatory
approval processes or clearances may be expensive,
time-consuming, and uncertain, and our failure to obtain or
comply with such approvals and clearances could have an adverse
effect on our business, financial condition, or operating
results. In addition, changes to the current regulatory
framework, including the imposition of additional or new
regulations, could arise at any time during the development or
marketing of our products, which may negatively affect our
ability to obtain or maintain FDA or comparable regulatory
approval of our products, if required.
Molecular diagnostic products, in particular, depending on their
intended use, may be regulated as medical devices by the FDA and
comparable agencies of other countries and may require either
receiving clearance from the FDA following a pre-market
notification process or premarket approval from the FDA, in each
case prior to marketing. Obtaining the requisite regulatory
approvals can be expensive and may involve considerable delay.
If we fail to obtain, or experience significant delays in
obtaining, regulatory approvals for molecular diagnostic
products that we develop, we may not be able to launch or
successfully commercialize such products in a timely manner, or
at all.
In addition, the regulatory approval or clearance process
required to manufacture, market, and sell our existing and
future products that are intended for, and marketed and labeled
as, Research Use Only, or RUO, is uncertain if such
products are used or could be used, even without our consent,
for the diagnosis of disease. If the FDA or other regulatory
authorities assert that any of our RUO products are subject to
regulatory clearance or approval, our business, financial
condition, or results of operations could be adversely affected.
23
Our
operating results may vary significantly from period to period,
and we may not be able to sustain operating
profitability.
Our revenue is subject to fluctuations due to the timing of
sales of high-value products and services, the effects of new
product launches and related promotions, the impact of seasonal
spending patterns, the timing and size of research projects our
customers perform, the timing of our customers funding,
changes in overall spending levels in the life sciences
industry, and other unpredictable factors that may affect
customer ordering patterns. Given the difficulty in predicting
the timing and magnitude of sales for our products and services,
we may experience
quarter-to-quarter
fluctuations in revenue resulting in the potential for a
sequential decline in quarterly revenue. While we anticipate
future growth, there is some uncertainty as to the timing of
revenue recognition on a quarterly basis. This is because a
substantial portion of our quarterly revenue is typically
recognized in the last month of a quarter and because the
pattern for revenue generation during that month is normally not
linear, with a concentration of orders in the final week of the
quarter. In light of that, our revenue cut-off and recognition
procedures, together with our manufacturing and shipping
operations, may experience increased pressure and demand during
the time period shortly before the end of a fiscal quarter.
A large portion of our expenses is relatively fixed, including
expenses for facilities, equipment, and personnel. In addition,
we expect operating expenses to continue to increase
significantly in absolute dollars, and we expect that our
research and development and selling and marketing expenses will
increase at a higher rate in the future as a result of the
development and launch of new products. Accordingly, our ability
to sustain profitability will depend, in part, on the rate of
growth, if any, of our revenue and on the level of our expenses,
and if revenue does not grow as anticipated, we may not be able
to maintain annual or quarterly profitability. Any significant
delays in the commercial launch of our products, unfavorable
sales trends in our existing product lines, or impacts from the
other factors mentioned above, could adversely affect our future
revenue growth or cause a sequential decline in quarterly
revenue. In addition, non-cash stock-based compensation expense
and expenses related to prior and future acquisitions are also
likely to continue to adversely affect our future profitability.
Due to the possibility of significant fluctuations in our
revenue and expenses, particularly from quarter to quarter, we
believe that quarterly comparisons of our operating results are
not a good indication of our future performance. If our
operating results fluctuate or do not meet the expectations of
stock market analysts and investors, our stock price could
decline.
From time to time, we receive large orders that have a
significant effect on our operating results in the period in
which the order is recognized as revenue. The timing of such
orders is difficult to predict, and the timing of revenue
recognition from such orders may affect period to period changes
in net sales. As a result, our operating results could vary
materially from quarter to quarter based on the receipt of such
orders and their ultimate recognition as revenue.
Changes
in accounting standards and subjective assumptions, estimates,
and judgments by management related to complex accounting
matters could significantly affect our financial results or
financial condition.
Generally accepted accounting principles and related accounting
pronouncements, implementation guidelines, and interpretations
with regard to a wide range of matters that are relevant to our
business, such as revenue recognition, asset impairment and fair
value determinations, inventories, business combinations and
intangible asset valuations, and litigation, are highly complex
and involve many subjective assumptions, estimates, and
judgments. Changes in these rules or their interpretation or
changes in underlying assumptions, estimates, or judgments could
significantly change our reported or expected financial
performance or financial condition. In addition, the timing of
large orders can have a significant effect on our business and
operating results from quarter to quarter.
Ethical,
legal, and social concerns related to the use of genetic
information could reduce demand for our products or
services.
Genetic testing has raised ethical, legal, and social issues
regarding privacy and the appropriate uses of the resulting
information. Governmental authorities could, for social or other
purposes, call for limits on or
24
regulation of the use of genetic testing or prohibit testing for
genetic predisposition to certain conditions, particularly for
those that have no known cure. Similarly, such concerns may lead
individuals to refuse to use genetics tests even if permissible.
These and other ethical, legal, and social concerns about
genetic testing may limit market acceptance of our technology
for certain applications or reduce the potential markets for our
technology, either of which could have an adverse effect on our
business, financial condition, or results of operations.
|
|
Item 1B.
|
Unresolved
Staff Comments.
|
None.
The following chart indicates the facilities we lease as of
January 3, 2010, the location and size of each facility,
and their designated use. We believe our facilities are adequate
for our current and near-term needs, and that we will be able to
locate additional facilities as needed.
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate
|
|
|
|
|
Lease
|
|
Location
|
|
Square Feet
|
|
|
Operation
|
|
Expiration Dates
|
|
|
San Diego, CA
|
|
|
272,000
|
|
|
R&D, Manufacturing, Storage,
|
|
|
2012 2023
|
|
|
|
|
|
|
|
Distribution and Administrative
|
|
|
|
|
Hayward, CA
|
|
|
105,000
|
|
|
R&D, Manufacturing and Administrative
|
|
|
2010 2014
|
|
Little Chesterford, United Kingdom
|
|
|
49,000
|
|
|
R&D, Manufacturing and Administrative
|
|
|
2010 2024
|
|
Singapore
|
|
|
36,000
|
|
|
Manufacturing and Administrative
|
|
|
2010 2013
|
|
Eindhoven, the Netherlands
|
|
|
11,500
|
|
|
Distribution and Administrative
|
|
|
2011
|
|
Tokyo, Japan
|
|
|
6,500
|
|
|
Sales and Administrative
|
|
|
2014
|
|
Melbourne, Australia
|
|
|
4,000
|
|
|
Sales and Administrative
|
|
|
2013
|
|
China
|
|
|
3,000
|
|
|
Sales and Administrative
|
|
|
2010 2012
|
|
|
|
Item 3.
|
Legal
Proceedings.
|
From time to time, we are party to litigation and other legal
proceedings in the ordinary course, and incidental to the
conduct, of our business. While the results of any litigation or
other legal proceedings are uncertain, management does not
believe the ultimate resolution of any pending legal matters is
likely to have a material adverse effect on our financial
position or results of operations.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders.
|
No matters were submitted to a vote of security holders during
the fourth quarter of fiscal 2009.
25
PART II
|
|
Item 5.
|
Market
for Registrants Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities.
|
Market
Information
Our common stock has been quoted on The NASDAQ Global Select
Market under the symbol ILMN since July 28,
2000. Prior to that time, there was no public market for our
common stock. The following table sets forth, for the periods
indicated, the quarterly high and low sales prices per share of
our common stock as reported on The NASDAQ Global Select Market.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
2008
|
|
|
High
|
|
Low
|
|
High
|
|
Low
|
|
First Quarter
|
|
$
|
38.87
|
|
|
$
|
23.43
|
|
|
$
|
38.30
|
|
|
$
|
27.89
|
|
Second Quarter
|
|
|
39.53
|
|
|
|
34.27
|
|
|
|
43.50
|
|
|
|
34.90
|
|
Third Quarter
|
|
|
41.23
|
|
|
|
31.10
|
|
|
|
47.88
|
|
|
|
36.97
|
|
Fourth Quarter
|
|
|
43.74
|
|
|
|
26.50
|
|
|
|
42.32
|
|
|
|
18.82
|
|
Stock
Performance Graph
The graph below compares the cumulative total stockholder
returns on our common stock for the last five fiscal years with
the cumulative total stockholder returns on the NASDAQ Composite
Index and the NASDAQ Biotechnology Index for the same period.
The graph assumes that $100 was invested on December 31,
2004 in our common stock and in each index and that all
dividends were reinvested. No cash dividends have been declared
on our common stock. Stockholder returns over the indicated
period should not be considered indicative of future stockholder
returns.
Holders
As of February 5, 2010 we had 400 record holders of our
common stock.
Dividends
We have never paid cash dividends and have no present intention
to pay cash dividends in the foreseeable future. In addition,
the indenture for our convertible senior notes due 2014, which
are convertible into cash
26
and, in certain circumstances, shares of our common stock,
requires us to increase the conversion rate applicable to the
notes if we pay any cash dividends.
Purchases
of Equity Securities by the Issuer
In July 2009, our board of directors authorized a
$75 million stock repurchase program and concurrently
terminated a $120 million stock repurchase program
authorized by our board of directors in October 2008, under
which we had purchased stock totaling $70.8 million in
2008. In November 2009, upon the completion of the repurchase
plan authorized in July 2009, our board of directors authorized
an additional $100 million stock repurchase program, which
was completed in December 2009. The following table summarizes
shares repurchased pursuant to these programs during the quarter
ended January 3, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number of
|
|
|
Approximate Dollar
|
|
|
|
|
|
|
|
|
|
Shares Purchased as
|
|
|
Value of Shares
|
|
|
|
Total Number of
|
|
|
|
|
|
Part of Publicly
|
|
|
that May Yet Be
|
|
|
|
Shares
|
|
|
Average Price
|
|
|
Announced
|
|
|
Purchased Under
|
|
Period
|
|
Purchased(1)
|
|
|
Paid per Share(1)
|
|
|
Programs(1)
|
|
|
the Programs(1)
|
|
|
September 28 October 25, 2009
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
75,000,000
|
|
October 26 November 22, 2009
|
|
|
1,289,331
|
|
|
|
30.87
|
|
|
|
1,289,331
|
|
|
|
35,197,269
|
|
November 23, 2009 January 3, 2010
|
|
|
4,766,696
|
|
|
|
28.36
|
|
|
|
4,766,696
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
6,056,027
|
|
|
$
|
28.90
|
|
|
|
6,056,027
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
All shares purchased during the quarter ended January 3, 2010
were in connection with our stock repurchase programs authorized
by our board of directors in July 2009 and November 2009. All
stock repurchases were made in open-market transactions or under
a 10b5-1 trading program. |
Sales of
Unregistered Securities
None during the fourth quarter of fiscal 2009.
|
|
Item 6.
|
Selected
Financial Data.
|
The following table sets forth selected historical consolidated
financial data for each of our last five fiscal years during the
period ended January 3, 2010.
Statement
of Operations Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended_
|
|
|
January 3,
|
|
December 28,
|
|
December 30,
|
|
December 31
|
|
January 1,
|
|
|
2010
|
|
2008
|
|
2007
|
|
2006
|
|
2006
|
|
|
(53 weeks)
|
|
(52 weeks)(1)
|
|
(52 weeks)(1)
|
|
(52 weeks)
|
|
(52 weeks)
|
|
|
(In thousands, except per share data)
|
|
Total revenue
|
|
$
|
666,324
|
|
|
$
|
573,225
|
|
|
$
|
366,799
|
|
|
$
|
184,586
|
|
|
$
|
73,501
|
|
Income (loss) from operations(2),(3),(4)
|
|
|
125,597
|
|
|
|
80,457
|
|
|
|
(301,201
|
)
|
|
|
37,812
|
|
|
|
(21,447
|
)
|
Net income (loss)
|
|
|
72,281
|
|
|
|
39,416
|
|
|
|
(287,305
|
)
|
|
|
39,968
|
|
|
|
(20,874
|
)
|
Net income (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
0.59
|
|
|
|
0.34
|
|
|
|
(2.65
|
)
|
|
|
0.45
|
|
|
|
(0.26
|
)
|
Diluted
|
|
|
0.53
|
|
|
|
0.30
|
|
|
|
(2.65
|
)
|
|
|
0.41
|
|
|
|
(0.26
|
)
|
Shares used in calculating net income (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
123,154
|
|
|
|
116,855
|
|
|
|
108,308
|
|
|
|
89,002
|
|
|
|
80,294
|
|
Diluted
|
|
|
137,096
|
|
|
|
133,607
|
|
|
|
108,308
|
|
|
|
97,508
|
|
|
|
80,294
|
|
27
Balance
Sheet Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
December 28,
|
|
December 30,
|
|
December 31,
|
|
January 1,
|
|
|
2010
|
|
2008(1)
|
|
2007(1)
|
|
2006
|
|
2006
|
|
|
(In thousands)
|
|
Cash, cash equivalents and short-term investments(4),(5),(6),(7)
|
|
$
|
693,527
|
|
|
$
|
640,075
|
|
|
$
|
386,082
|
|
|
$
|
130,804
|
|
|
$
|
50,822
|
|
Working capital
|
|
|
540,354
|
|
|
|
483,113
|
|
|
|
397,040
|
|
|
|
159,950
|
|
|
|
57,992
|
|
Total assets
|
|
|
1,429,937
|
|
|
|
1,327,171
|
|
|
|
929,981
|
|
|
|
300,584
|
|
|
|
100,610
|
|
Long-term debt, current portion(7)
|
|
|
290,202
|
|
|
|
276,889
|
|
|
|
16
|
|
|
|
|
|
|
|
|
|
Long-term debt, less current portion(7)
|
|
|
|
|
|
|
|
|
|
|
258,007
|
|
|
|
|
|
|
|
54
|
|
Total stockholders equity(2),(3),(4),(5),(6)
|
|
|
864,248
|
|
|
|
798,667
|
|
|
|
353,927
|
|
|
|
247,342
|
|
|
|
72,497
|
|
In addition to the following notes, see Item 7,
Managements Discussion and Analysis of Financial
Condition and Results of Operations and Item 8,
Financial Statements and Supplementary Data for
further information regarding our consolidated results of
operations and financial position for periods reported therein
and for known factors that will impact comparability of future
results.
|
|
|
(1) |
|
Adjusted for required retroactive adoption of authoritative
accounting guidance for convertible debt instruments that may be
settled in cash upon conversion effective December 29,
2008. See Note 7 of Notes to Consolidated Financial
Statements for further information. |
|
(2) |
|
The consolidated financial statements include results of
operations of acquired companies commencing on their respective
acquisition dates. We completed acquisitions of Avantome, Inc.,
Solexa, Inc., and Cyvera Corporation in August 2008, January
2007 and April 2005, respectively. As part of the accounting for
these acquisitions, we recorded charges to write-off acquired
in-process research and development, or IPR&D, of
$11.3 million, $24.7 million, $303.4 million and
$15.8 million during the fiscal years ended January 3,
2010, December 28, 2008, December 30, 2007 and
January 1, 2006, respectively. See Note 1 of Notes to
Consolidated Financial Statements for further information. |
|
(3) |
|
On January 2, 2006 we adopted authoritative guidance
related to share-based payments using the modified prospective
transition method. Because we elected to use the modified
prospective transition method, results for prior periods have
not been restated to include share-based compensation expense.
See Note 1 and Note 9 of Notes to Consolidated
Financial Statements for further information. |
|
(4) |
|
For the year ended December 30, 2007, we recorded a
$54.0 million charge for the settlement of our litigation
with Affymetrix. In January 2008, we paid $90.0 million
related to the Affymetrix settlement. See Note 4 of Notes
to Consolidated Financial Statements. |
|
(5) |
|
In August 2008, a total of 8,050,000 shares were sold to
the public at a public offering price of $43.75 per share,
raising net proceeds to us of $342.7 million. See
Note 9 of Notes to Consolidated Financial Statements. |
|
(6) |
|
For the years ended January 3, 2010, December 28, 2008
and December 30, 2007, we repurchased 6.1 million,
3.1 million and 14.8 million shares, respectively, of
common stock for $175.1 million, $70.8 million and
$251.6 million, respectively. See Note 9 of Notes to
Consolidated Financial Statements. |
|
(7) |
|
In February 2007, we issued $400.0 million principal amount
of 0.625% Convertible Senior Notes due 2014. During the
third quarter of 2008, the conditions to convertibility were
satisfied resulting in a change in the classification of the
principal amount of the notes from long-term to current. See
Note 7 of Notes to Consolidated Financial Statements for
further information. |
|
|
Item 7.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations.
|
Certain statements set forth below constitute forward-looking
statements. See Special Note Regarding Forward-Looking
Statements for additional factors relating to such
statements, and see Risk Factors in
28
Item 1A of this report for a discussion of certain risk
factors applicable to our business, financial condition and
results of operations.
Business
Overview
We are a leading developer, manufacturer, and marketer of
integrated systems for the analysis of genetic variation and
biological function. Using our proprietary technologies, we
provide a comprehensive line of products and services that
currently serve the sequencing, genotyping, and gene expression
markets, and we expect to enter the market for molecular
diagnostics. Our customers include leading genomic research
centers, pharmaceutical companies, academic institutions,
clinical research organizations, and biotechnology companies.
We develop and commercialize sequencing technologies used to
perform a range of analyses, including de novo sequencing, whole
genome re-sequencing, gene expression analysis, and small RNA
analysis. Our product and service offerings also include
leading-edge solutions for single-nucleotide polymorphism (SNP)
genotyping, copy number variation (CNV), DNA methylation
studies, gene expression profiling, and low-multiplex analysis
of DNA, RNA, and protein. We believe we are the only company
with genome-scale technology for sequencing, genotyping, and
gene expression the three cornerstones of modern
genetic analysis.
Our tools provide researchers around the world with the
performance, throughput, cost effectiveness, and flexibility
necessary to determine and analyze the billions of bits of
genetic information needed to extract valuable medical
information from advances in genomics and proteomics. We believe
this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug
discovery and clinical research, allow diseases to be detected
earlier, and permit better choices of drugs for individual
patients.
During the first quarter of 2008, we reorganized our operating
structure into a newly created Life Sciences Business Unit,
which includes all products and services that are primarily
related to the research market, namely those based on our
sequencing, BeadArray and Veracode technologies. We also created
a Diagnostics Business Unit to focus on the emerging opportunity
in molecular diagnostics. For the year ended January 3,
2010, we had limited activity related to the Diagnostics
Business Unit and operating results were reported on an
aggregate basis to the chief operating decision maker, the chief
executive officer. Accordingly, we operated in one segment for
the year ended January 3, 2010. We will begin reporting in
two segments once revenues, operating profit or loss, or assets
of the Diagnostics Business Unit exceed 10% of the consolidated
amounts.
Our analysis presented below is organized to provide the
information we believe will be useful for understanding the
relevant trends going forward. However, this discussion should
be read in conjunction with our consolidated financial
statements and the notes thereto in Item 15 of this report.
Business
Trends and Outlook
Our financial results have been, and will continue to be,
impacted by several significant trends, which are described
below:
Next
Generation Sequencing
Strong demand for next generation sequencing applications
continues to drive both sequencing instrument and consumable
sales. In 2009 we made advances to our sequencing technology,
including enhanced chemistry, algorithms, and hardware which
substantially improved accuracy, read length, data density, and
ease of use. The combination of these advances increased the
output and decreased the cost of sequencing and expanded the
number of applications that researchers can perform on our
sequencing systems. In early 2010 we expect to begin customer
shipments of our recently announced HiSeq 2000 next generation
sequencing instrument, which we believe will allow customers to
sequence whole human genomes for less than $10,000 in reagent
costs. We anticipate our revenue for 2010 will have higher
growth in the second half of the year
29
compared to the first half due to the timing of the
manufacturing
scale-up of
the HiSeq 2000 and other significant product launches scheduled
for later in the year. We believe that as the cost of next
generation sequencing continues to decline, the number of
samples available for sequencing will significantly increase.
Genome
Wide Association Studies (GWAS)
We experienced a slowdown in the sales of our microarray
products during 2009 that was largely attributable to
researchers reducing or suspending the initiation of new studies
as they waited for rare variant content emerging from the 1000
Genomes Project, an international research effort launched in
2008 to establish the most detailed catalog of human genetic
variation. Despite advances in sequencing technology, we believe
microarrays remain a cheaper, faster and materially more
accurate technology for use when genetic content is known. The
information content of specific microarrays is fixed and
reproducible; as such, specific microarrays provide repeatable,
standardized assays for certain subsets of bases within the
overall genome. During 2010, as part of our previously announced
GWAS roadmap, we plan to launch arrays that will feature
millions of more markers per BeadChip and new rare variant
content from the 1000 Genomes Project. As these arrays become
available, we believe activity in the microarray market will
increase relative to 2009.
American
Recovery and Reinvestment Act of 2009 (the Recovery
Act)
The Recovery Act was enacted in February 2009 to provide
stimulus to the U.S. economy in the wake of the economic
downturn. As part of the Recovery Act legislation, over
$10 billion in funding was provided to the National
Institute of Health (NIH) through September 2010 to support the
advancement of scientific research. In the second and third
quarters of 2009 we experienced negative unintended consequences
of the Recovery Act as customers delayed orders while they
waited to receive stimulus funds. During the fourth quarter of
2009, we believe we saw an increase in the distribution of
Recovery Act funds and received an estimated $16 million in
orders directly related to Recovery Act grants. We believe a
significant portion of Recovery Act awards may be distributed in
2010, which may create a pipeline of opportunity in the upcoming
year.
Life
Science Research Funding Across Regional Markets
We have developed a broad sales and distribution network with a
sales presence in more than 40 countries. Our financial results
will continue to be impacted by significant regional trends in
life science research funding as described below:
|
|
|
|
|
United States. A significant increase to the
NIH budget in addition to Recovery Act stimulus funds has made
for a strong funding environment in the United States that we
expect to continue into 2010.
|
|
|
|
Asia-Pacific. Strong funding in China was
partially offset by a funding decrease in Japan due to a change
in government that resulted in the suspension of supplemental
life science research funding during the second and third
quarters of 2009. During the fourth quarter of 2009, we saw an
increase in activity in the Japanese market as funds began to be
released, which we expect to continue into 2010.
|
|
|
|
Europe. Central and southern European markets
had a strong year driven by the establishment and expansion of
genome centers. However, there was a decrease in funding in
northern European countries, primarily due to reduced
institutional funding in areas like the United Kingdom and the
financial crisis in Iceland. We saw some positive signs during
the fourth quarter of 2009 in Northern Europe, and, although we
expect funding to stabilize, we do not expect a material
increase in activity in this region in 2010.
|
Cost
of Revenue
Our cost of revenue as a percentage of revenue declined during
2009 due to cost efficiencies in our manufacturing process and
an improved mix of sequencing consumables driven by growth in
the installed base of our sequencing systems. We expect changes
in our product mix to continue to affect our cost of revenue as
a percentage of revenue, particularly in the latter half of the
year. We anticipate cost of revenue as a
30
percentage of revenue to be lower in the first half of the year
and then increase as the mix shifts to newer products and the
effects of our trade-in promotions associated with the launch of
the HiSeq 2000 are realized. Additionally, we expect price
competition to continue in our market causing added variability
in our cost of revenue as a percentage of revenue on a quarterly
and annual basis.
Operating
Expense
We expect to incur additional operating costs to support the
expected growth in our business. As a result of revenues growing
faster in the second half of 2010, we expect operating expenses
as a percentage of revenue to be higher in the first half of the
year compared with the second half. We believe a substantial
investment in research and development is essential to remaining
competitive and expanding into additional markets. Accordingly,
we expect our research and development expenses to increase in
absolute dollars as we expand our product base. Selling, general
and administrative expenses are also expected to increase in
absolute dollars as we continue to expand our staff and add
sales and marketing infrastructure.
While these trends are important to understanding and evaluating
our financial results, the other transactions, events and trends
discussed in Risk Factors in Item 1A of this
report may also materially impact our business operations and
financial results.
31
Results
of Operations
To enhance comparability, the following table sets forth audited
consolidated statement of operations data for the years ended
January 3, 2010, December 28, 2008 and
December 30, 2007 stated as a percentage of total
revenue.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue
|
|
|
94
|
%
|
|
|
93
|
%
|
|
|
89
|
%
|
Service and other revenue
|
|
|
6
|
|
|
|
7
|
|
|
|
11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
100
|
|
|
|
100
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue (excluding impairment of manufacturing
equipment and amortization of intangible assets)
|
|
|
29
|
|
|
|
34
|
|
|
|
33
|
|
Cost of service and other revenue
|
|
|
2
|
|
|
|
2
|
|
|
|
3
|
|
Research and development
|
|
|
21
|
|
|
|
17
|
|
|
|
20
|
|
Selling, general and administrative
|
|
|
26
|
|
|
|
26
|
|
|
|
27
|
|
Impairment of manufacturing equipment
|
|
|
|
|
|
|
1
|
|
|
|
|
|
Amortization of intangible assets
|
|
|
1
|
|
|
|
2
|
|
|
|
1
|
|
Acquired in-process research and development
|
|
|
2
|
|
|
|
4
|
|
|
|
83
|
|
Litigation settlements
|
|
|
|
|
|
|
|
|
|
|
15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
81
|
|
|
|
86
|
|
|
|
182
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations
|
|
|
19
|
|
|
|
14
|
|
|
|
(82
|
)
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
2
|
|
|
|
2
|
|
|
|
4
|
|
Interest expense
|
|
|
(4
|
)
|
|
|
(4
|
)
|
|
|
(5
|
)
|
Other income (expense), net
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other expense, net
|
|
|
(2
|
)
|
|
|
(1
|
)
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
|
17
|
|
|
|
13
|
|
|
|
(83
|
)
|
Provision (benefit) for income taxes
|
|
|
6
|
|
|
|
6
|
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
11
|
%
|
|
|
7
|
%
|
|
|
(79
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comparison
of Years Ended January 3, 2010 and December 28,
2008
Our fiscal year is the 52 or 53 weeks ending the Sunday
closest to December 31, with quarters of 13 or
14 weeks ending the Sunday closest to March 31,
June 30, and September 30. The year ended
January 3, 2010 was 53 weeks and the year end
December 28, 2008 was 52 weeks.
32
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
|
|
Percentage
|
|
|
|
2010
|
|
|
2008
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Product revenue
|
|
$
|
627,240
|
|
|
$
|
532,390
|
|
|
$
|
94,850
|
|
|
|
18
|
%
|
Service and other revenue
|
|
|
39,084
|
|
|
|
40,835
|
|
|
|
(1,751
|
)
|
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
666,324
|
|
|
$
|
573,225
|
|
|
$
|
93,099
|
|
|
|
16
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue consists primarily of revenue from the sale of
consumables and instruments.
Consumable revenue increased $57.6 million, or 17%, to
$391.3 million for the year ended January 3, 2010
compared to $333.7 million for the year ended
December 28, 2008. Microarray consumable revenue, which
constituted more than half of our consumable revenue, declined
$11.4 million, or 4%, primarily attributable to lower sales
of whole-genome genotyping arrays partially offset by growth in
focused content arrays. The decline was driven by customers
delaying the start of new GWAS in anticipation of new and rare
variant content from the 1000 Genome Project, order delays
directly related to stimulus funding under the Recovery Act and
the impact of reduced foundation funding at a few key customers.
Sales volume for our Infinium BeadChip product lines, which
constitute a majority of our microarray consumable sales, was
relatively flat on a sample basis during 2009 compared to 2008.
The average selling price per sample, however, declined due to a
change in product mix attributable to growth in the sales of our
focused content arrays coupled with lower sales of whole-genome
genotyping arrays and an increase in the average number of
samples per BeadChip.
Revenue from sequencing consumables increased
$68.9 million, or 144%, driven by growth in the installed
base of our Genome Analyzer systems and the progression of
customer labs ramping to production scale. The increase was
partially offset by a loss of sales related to a quality issue
affecting our paired-end cluster kits that arose in September
2009 when some of our larger sequencing customers began
experiencing higher than average error rates on the second read
of their paired-end analysis. During the fourth quarter, we
began shipping reformulated paired-end cluster kits at full
capacity and cleared the related shipping backlog.
Revenue from the sale of instruments increased
$40.0 million, or 22%, to $225.7 million for the year
ended January 3, 2010 compared to $185.7 million for
the year ended December 28, 2008 primarily due to a
$56.4 million, or 43%, increase in sales of our sequencing
systems. During 2009 as compared to 2008 both units sold and
average selling prices increased for our Genome Analyzer
systems, which constitute a majority of sequencing instrument
revenue. The increase in units sold was driven by increased
demand for next generation sequencing and our
sequencing-by-synthesis
technology. The increase in average selling prices was
attributable to the product transition from the Genome Analyzer
I to the Genome Analyzer II in the second quarter of 2008
and technological improvements leading to the launch of the
Genome Analyzer IIx in the second quarter of 2009. The increase
in sequencing instrument revenue was partially offset by a
$16.4 million, or 30%, decrease in the sales of our
microarray systems, which declined primarily due to customers
delaying the start of new GWAS in anticipation of new and rare
variant content from the 1000 Genomes Project, order delays
directly related to stimulus funding under the Recovery Act and
the impact of reduced foundation funding at a few key customers.
Cost of
Product and Service and Other Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
|
|
Percentage
|
|
|
|
2010
|
|
|
2008
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Cost of product revenue
|
|
$
|
190,714
|
|
|
$
|
192,868
|
|
|
$
|
(2,154
|
)
|
|
|
(1
|
)%
|
Cost of service and other revenue
|
|
|
15,055
|
|
|
|
12,756
|
|
|
|
2,299
|
|
|
|
18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenue
|
|
$
|
205,769
|
|
|
$
|
205,624
|
|
|
$
|
145
|
|
|
|
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33
Total cost of revenue, which excludes the impairment of
manufacturing equipment and the amortization of intangible
assets, remained flat despite higher sales, primarily due to a
decrease in manufacturing costs and improved efficiencies.
Cost of product revenue as a percentage of related revenue was
30% for the year ended January 3, 2010, compared to 36% for
the year ended December 28, 2008. The decrease was
primarily due to lower costs for our sequencing consumables and
instrumentation. The cost of sequencing consumables decreased as
a percentage of related revenue due to improved overhead
absorption from increased volumes and the benefit of decreased
costs associated with the reformulation of our sequencing kits
launched at the end of the third quarter of 2008. The cost of
sequencing instruments decreased as a percentage of related
revenue due to production efficiencies and reduced material
costs coupled with higher average selling prices.
Operating
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
|
|
Percentage
|
|
|
|
2010
|
|
|
2008
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Research and development
|
|
$
|
140,616
|
|
|
$
|
99,963
|
|
|
$
|
40,653
|
|
|
|
41
|
%
|
Selling, general and administrative
|
|
|
176,337
|
|
|
|
148,014
|
|
|
|
28,323
|
|
|
|
19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
$
|
316,953
|
|
|
$
|
247,977
|
|
|
$
|
68,976
|
|
|
|
28
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The increase in research and development was driven primarily by
a $22.9 million increase in personnel-related expenses,
including salaries, non-cash stock-based compensation and
benefits, a $10.4 million increase to non-personnel related
expenses and an increase in outside services of
$3.2 million attributable to consulting fees. These
increases are primarily related to the growth in our efforts to
optimize and commercialize our sequencing and BeadArray
technologies.
The increase in selling, general and administrative expenses was
driven by an increase of $26.6 million in personnel-related
expenses associated with the growth of our business, including
salaries, non-cash stock-based compensation and benefits.
Acquired
In-Process Research and Development (IPR&D)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
January 3,
|
|
December 28,
|
|
|
|
Percentage
|
|
|
2010
|
|
2008
|
|
Change
|
|
Change
|
|
|
(In thousands)
|
|
|
|
|
|
Acquired in-process research and development
|
|
$
|
11,325
|
|
|
$
|
24,660
|
|
|
$
|
(13,335
|
)
|
|
|
(54
|
)%
|
During the year ended December 28, 2008, we recorded
acquired IPR&D charges of $24.7 million as a result of
the Avantome, Inc. acquisition in August 2008. During the year
ended January 3, 2010, we recorded additional IPR&D
charges of $11.3 million related to milestone payments made
to Avantome Inc.s former shareholders.
Other
Income (Expense), Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
|
|
Percentage
|
|
|
|
2010
|
|
|
2008
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Interest income
|
|
$
|
11,029
|
|
|
$
|
12,519
|
|
|
$
|
(1,490
|
)
|
|
|
(12
|
)%
|
Interest expense
|
|
|
(23,718
|
)
|
|
|
(22,210
|
)
|
|
|
(1,508
|
)
|
|
|
7
|
|
Other income, net
|
|
|
1,217
|
|
|
|
1,921
|
|
|
|
(704
|
)
|
|
|
(37
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other expense, net
|
|
$
|
(11,472
|
)
|
|
$
|
(7,770
|
)
|
|
$
|
(3,702
|
)
|
|
|
48
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34
Interest income decreased despite an increase in our average
cash and investment balance due to an overall decline in
interest rates during 2009. Interest expense increased due to
the amortization of the discount on our convertible senior
notes. Other income, net decreased due to a decrease of
$1.5 million in gains on net foreign currency transactions,
which was partially offset by a gain of $0.8 million on the
conversion of a portion of our debt during the first quarter of
2009.
Provision
for Income Taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
January 3,
|
|
December 28,
|
|
|
|
Percentage
|
|
|
2010
|
|
2008
|
|
Change
|
|
Change
|
|
|
(In thousands)
|
|
|
|
|
|
Provision for income taxes
|
|
$
|
41,844
|
|
|
$
|
33,271
|
|
|
$
|
8,573
|
|
|
|
26
|
%
|
The increase in the provision for income taxes was attributable
to the increase in the consolidated income before income taxes.
The effective tax rate decreased from 45.8% in 2008 to 36.7% in
2009 predominately because the amount of nondeductible acquired
IPR&D recognized for financial reporting purposes was lower
by $13.3 million. Additionally, the percentage of
consolidated income before income taxes earned in foreign
jurisdictions, which primarily have lower statutory tax rates
than the U.S. statutory tax rate, increased from 36% in
2008 to 43% in 2009.
Comparison
of Years Ended December 28, 2008 and December 30,
2007
Our fiscal year is 52 or 53 weeks ending the Sunday closest
to December 31, with quarters of 13 or 14 weeks ending
the Sunday closest to March 31, June 30, and
September 30. The years ended December 28, 2008 and
December 30, 2007 were both 52 weeks.
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
|
|
Percentage
|
|
|
|
2008
|
|
|
2007
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Product revenue
|
|
$
|
532,390
|
|
|
$
|
326,699
|
|
|
$
|
205,691
|
|
|
|
63
|
%
|
Service and other revenue
|
|
|
40,835
|
|
|
|
40,100
|
|
|
|
735
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
573,225
|
|
|
$
|
366,799
|
|
|
$
|
206,426
|
|
|
|
56
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue consists primarily of revenue from the sale of
consumables and instruments.
Revenue from the sale of consumables increased
$140.2 million, or 72%, to $333.7 million for the year
ended December 28, 2008 compared to $193.5 million for
the year ended December 30, 2007. Growth in consumable
revenue was primarily attributable to strong demand for our
Infinium and sequencing products, which led to increased sales
of $104.8 million and $35.4 million, respectively. The
increase in revenue associated with our Infinium products was
attributable to the strong demand for our Infinium High-Density
BeadChips, particularly the Human610-Quad, which we began
shipping during the first quarter of 2008. Of the overall
increase in Infinium BeadChip sales, approximately 79% was due
to new product introductions with higher average selling prices,
while the remaining 21% can be attributed to increased volume.
The increase in sequencing consumables was primarily
attributable to the growth of our installed base of instruments
and the progression of customer labs ramping to production scale.
Revenue from the sale of instruments increased
$64.8 million, or 54%, to $185.7 million for the year
ended December 28, 2008 compared to $120.9 million for
the year ended December 30, 2007. The increase was
primarily attributable to a $63.0 million increase in sales
of our Genome Analyzer driven by both an increase in sales
volume and average selling prices. Additionally, during the
second quarter of 2008, we launched the iScan System, our
next-generation BeadChip scanner to replace the BeadArray
Reader. Any increase in revenue resulting from shipments of this
new system was offset by a reduction in sales of our BeadArray
Reader as we stopped manufacturing this product upon the launch
of our iScan System.
35
Cost of
Product and Service and Other Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
|
|
Percentage
|
|
|
|
2008
|
|
|
2007
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Cost of product revenue
|
|
$
|
192,868
|
|
|
$
|
119,991
|
|
|
$
|
72,877
|
|
|
|
61
|
%
|
Cost of service and other revenue
|
|
|
12,756
|
|
|
|
12,445
|
|
|
|
311
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of product and service and other revenue
|
|
$
|
205,624
|
|
|
$
|
132,436
|
|
|
$
|
73,188
|
|
|
|
55
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenue, which excludes the impairment of
manufacturing equipment and the amortization of intangible
assets, increased primarily due to higher instrument and
consumable sales.
Cost of product revenue as a percentage of related revenue was
36% for the year ended December 28, 2008 compared to 37%
for the year ended December 30, 2007. The decrease was
primarily due to favorable product mix driven by increased sales
of our new High-Density Infinium Beadchips, with higher average
selling prices as compared to the Infinium Beadchips sold in the
prior year. This was partially offset by increased provisions
for inventory obsolescence of $7.2 million for the year
ended December 28, 2008 compared to $1.9 million for
the year ended December 30, 2007. The increase in the
inventory reserve was primarily associated with product
transitions. During the year, we recorded reserves for product
obsolescence associated with the launch of our new Infinium
Beadchips and the launch of a new sequencing kit. Instrument
cost of sales as a percentage of related revenue increased
slightly over the prior year due to lower average selling prices
mainly associated with promotional campaigns as we launched our
next generation Beadarray Reader, the iScan in the first half of
2008.
Operating
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
|
|
Percentage
|
|
|
|
2008
|
|
|
2007
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Research and development
|
|
$
|
99,963
|
|
|
$
|
73,943
|
|
|
$
|
26,020
|
|
|
|
35
|
%
|
Selling, general and administrative
|
|
|
148,014
|
|
|
|
101,256
|
|
|
|
46,758
|
|
|
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
$
|
247,977
|
|
|
$
|
175,199
|
|
|
$
|
72,778
|
|
|
|
42
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The increase in research and development was driven by a
$17.4 million increase in personnel-related expenses
associated with increased headcount, including salaries,
non-cash stock-based compensation and benefits, an
$11.6 million increase to non-personnel related expenses
associated with the growth of our business and a
$1.5 million increase to accrued compensation expense
associated with contingent consideration for the Avantome
acquisition completed on August 1, 2008. These increases
were partially offset by a decrease in outside services of
$4.5 million primarily related to a decrease in consulting
fees.
The increase in selling, general and administrative expenses was
driven primarily by an increase of $42.8 million in
personnel-related expenses, including salaries, non-cash
stock-based compensation and benefits and a $4.0 million
increase to non-personnel related expenses. These increases were
primarily associated with the growth of our business.
Acquired
In-Process Research and Development (IPR&D)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
December 28,
|
|
December 30,
|
|
|
|
Percentage
|
|
|
2008
|
|
2007
|
|
Change
|
|
Change
|
|
|
(In thousands)
|
|
|
|
|
|
Acquired in-process research and development
|
|
$
|
24,660
|
|
|
$
|
303,400
|
|
|
$
|
(278,740
|
)
|
|
|
(92
|
)%
|
36
As a result of the Avantome, Inc. acquisition in August 2008 and
the Solexa Inc. acquisition in January 2007, we recorded
acquired IPR&D charges of $24.7 million and
$303.4 million, respectively.
Litigation
Settlements
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
December 28,
|
|
December 30,
|
|
|
|
Percentage
|
|
|
2008
|
|
2007
|
|
Change
|
|
Change
|
|
|
(In thousands)
|
|
|
|
|
|
Litigation settlements
|
|
$
|
|
|
|
$
|
54,536
|
|
|
$
|
(54,536
|
)
|
|
|
(100
|
)%
|
During the year ended December 30, 2007, we recorded a
charge of $54.5 million associated with two settlement
agreements. The total charge is comprised primarily of
$54.0 million related to a $90.0 million settlement
with Affymetrix entered into on January 9, 2008 for certain
patent litigation between the parties. See Note 4 of Notes
to Consolidated Financial Statements for further information
regarding the Affymetrix settlement.
Other
Income (Expense), Net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
|
|
Percentage
|
|
|
|
2008
|
|
|
2007
|
|
|
Change
|
|
|
Change
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
Interest income
|
|
$
|
12,519
|
|
|
$
|
16,025
|
|
|
$
|
(3,506
|
)
|
|
|
(22
|
)%
|
Interest expense
|
|
|
(22,210
|
)
|
|
|
(18,297
|
)
|
|
|
(3,913
|
)
|
|
|
21
|
|
Other income (expense), net
|
|
|
1,921
|
|
|
|
(47
|
)
|
|
|
1,968
|
|
|
|
(4,187
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other expense, net
|
|
$
|
(7,770
|
)
|
|
$
|
(2,319
|
)
|
|
$
|
(5,451
|
)
|
|
|
(235
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income decreased due to a change in our cash and
investment portfolio to a mix of shorter duration maturities and
an increased number of agency-rated investments coupled with the
overall decline in interest rates due to market conditions.
Interest expense increased due to the amortization of the
discount on our convertible senior notes and an additional month
and a half of interest expense recorded in the year ended
December 28, 2008 compared to the year ended
December 30, 2007. Other income (expense), net increased
primarily due to $1.9 million in net foreign currency
transaction gains for the year ended December 28, 2008
compared to immaterial losses recorded in the year ended
December 30, 2007.
Provision
(benefit) for Income Taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
|
|
|
December 28,
|
|
December 30,
|
|
|
|
Percentage
|
|
|
2008
|
|
2007
|
|
Change
|
|
Change
|
|
|
(In thousands)
|
|
|
|
|
|
Provision (benefit) for income taxes
|
|
$
|
33,271
|
|
|
$
|
(16,215
|
)
|
|
$
|
49,486
|
|
|
|
(305
|
)%
|
The provision (benefit) for income taxes in 2008 was different
than in 2007 primarily because the amount of nondeductible
acquired IPR&D recognized for financial reporting purposes
was lower by $278.7 million. In addition, for the year
ended December 30, 2007, the provision for income taxes was
reduced by $17.1 million as a result of the release of the
valuation allowance against a significant portion of our
U.S. deferred tax assets.
37
Liquidity
and Capital Resources
Cash
flow summary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
|
(In thousands)
|
|
|
Net cash provided by operating activities
|
|
$
|
174,496
|
|
|
$
|
87,882
|
|
|
$
|
56,294
|
|
Net cash used in investing activities
|
|
|
(255,718
|
)
|
|
|
(277,249
|
)
|
|
|
(67,686
|
)
|
Net cash (used in) provided by financing activities
|
|
|
(98,862
|
)
|
|
|
337,672
|
|
|
|
148,292
|
|
Effect of foreign currency translation
|
|
|
(2,307
|
)
|
|
|
3,778
|
|
|
|
(345
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
$
|
(182,391
|
)
|
|
$
|
152,083
|
|
|
$
|
136,555
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
Activities
Cash provided by operating activities for the year ended
January 3, 2010 consists of net income of
$72.3 million plus net non-cash adjustments of
$113.5 million and an $11.3 million increase in net
operating assets. The primary non-cash expenses added back to
net income included share based compensation of
$60.8 million and depreciation and amortization expense
related to property and equipment, intangibles and the debt
discount on our convertible notes totaling $51.5 million.
The main drivers in the change in net operating assets included
increases in accounts receivable, inventory, accounts payable
and accrued liabilities. These increases were primarily related
to the growth of our business.
Investing
Activities
Cash used in investing activities totaled $255.7 million
for the year ended January 3, 2010. We purchased and sold
available-for-sale
securities totaling $694.5 million and $515.2 million,
respectively. We incurred $51.8 million in capital
expenditures primarily associated with the expansion of our
facilities and infrastructure at our San Diego, Hayward and
UK locations. Additionally, in January 2009, we executed a
strategic alliance with Oxford Nanopore Technologies, which
consisted of a commercialization agreement and an
$18.0 million equity investment. We also agreed to make an
additional equity investment upon the achievement of a specific
technical milestone.
In August 2008, we completed our acquisition of Avantome, Inc.
As consideration for the acquisition, we paid $25.8 million
in cash, including transaction costs, at the closing of the
acquisition, and have subsequently paid $15.0 million as of
February 1, 2010 based on the achievement of, or amendments
relating to, certain milestones. We may pay up to an additional
$20.0 million in contingent cash consideration to
Avantomes former shareholders based on the achievement of
certain remaining milestones.
In January 2008, as part of our Affymetrix settlement, we
recorded a $36.0 million intangible asset for licensed
technology obtained in the settlement. See Note 4 of Notes
to Consolidated Financial Statements for further information
regarding intangible assets.
In January of 2007, we completed our acquisition of Solexa, Inc.
in a
stock-for-stock
merger transaction. The Company issued approximately
26.2 million shares of its common stock as consideration
for this merger. The acquisition resulted in net cash acquired
of $72.1 million.
Financing
Activities
Cash used in financing activities totaled $98.9 million for
the year ended January 3, 2010. During the year we
repurchased approximately 6.1 million shares of our common
stock for $175.1 million, which was partially offset by
$39.4 million in proceeds received from the exercise of
stock options and the sale of shares under our Employee Stock
Purchase Plan and $39.3 million of incremental tax benefits
related to stock options exercised.
38
In August 2008, we issued a total of 8.1 million shares at
a public offering price of $43.75 per share, raising net
proceeds to the Company of $342.7 million, after deducting
underwriting discounts and commissions and offering expenses.
During the year ended December 28, 2008, we also
repurchased approximately 3.1 million shares of our common
stock for $70.8 million.
In February 2007, we issued $400.0 million principal amount
of 0.625% convertible senior notes due 2014. The net proceeds
from the offering, after deducting the initial purchasers
discount and offering expenses, were approximately
$390.3 million. We used $201.6 million of the net
proceeds to purchase approximately 11.6 million shares of
our common stock in privately negotiated transactions
concurrently with the offering. We used $46.6 million of
the net proceeds of this offering to pay the net cost of
convertible note hedge and warrant transactions, which are
designed to reduce the potential dilution upon conversion of the
notes. See Note 7 of Notes to Consolidated Financial
Statements for further information regarding our convertible
senior notes.
Liquidity
We manage our business to maximize operating cash flows as the
primary source of our liquidity. Our ability to generate cash
from operations provides us with the financial flexibility we
need to meet operating, investing and financing needs.
Historically, we have issued debt and equity securities to
finance our requirements to the extent that cash provided by
operating activities was not sufficient to fund our needs. We
may require additional funding in the future and our failure to
raise capital on acceptable terms, when needed, could have a
material adverse effect on our business.
At January 3, 2010, we had approximately
$693.5 million in cash and short-term investments.
Short-term investments include marketable securities and auction
rate securities totaling $494.0 million and
$54.9 million, respectively. Our marketable securities
consist of debt securities in government sponsored entities,
corporate debt securities and U.S treasury notes. We do not hold
securities backed by mortgages. Our auction rate securities were
issued primarily by municipalities and universities. The markets
for auction rate securities effectively ceased when the vast
majority of auctions failed in February 2008, preventing
investors from selling their auction rate securities. As of
January 3, 2010, the securities continued to fail auction
and remained illiquid. In November 2008, we signed a settlement
agreement allowing us to sell our auction rate securities at par
value to UBS AG (UBS) at our discretion during the period of
June 30, 2010 through July 2, 2012. Because we intend
to exercise this right when it becomes available, we have
classified our auction rate securities as short-term on the
balance sheet. See Note 3 of Notes to Consolidated
Financial Statements for further information regarding our
auction rate securities.
Our outstanding convertible senior notes were convertible into
cash and, if applicable, shares of our common stock for the
period from April 1, 2008 through December 31, 2008
and became convertible again beginning April 1, 2009
through December 31, 2009. On December 29, 2008, a
noteholder converted notes in an aggregate principal amount of
$10.0 million. On February 4, 2009, the settlement
date, we paid the noteholder the conversion value of the notes
in cash, up to the principal amount of the notes. The excess of
the conversion value over the principal amount, totaling
$2.9 million, was paid in shares of common stock. This
equity dilution upon conversion of the notes was offset by the
reacquisition of the shares under the convertible note hedge
transactions entered into in connection with the offering of the
notes. See Note 7 of Notes to Consolidated Financial
Statements for further discussion of the terms of the
convertible senior notes.
Our primary short-term needs for capital, which are subject to
change, include expenditures related to:
|
|
|
|
|
potential strategic acquisitions and investments;
|
|
|
|
support of our commercialization efforts related to our current
and future products, including expansion of our direct sales
force and field support resources both in the United States and
abroad;
|
|
|
|
the continued advancement of research and development efforts;
|
|
|
|
the acquisition of equipment and other fixed assets for use in
our current and future manufacturing and research and
development facilities;
|
39
|
|
|
|
|
improvements in our manufacturing capacity and
efficiency; and
|
|
|
|
the expansion needs of our facilities, including costs of
leasing additional facilities.
|
We expect that our product revenue and the resulting operating
income, as well as the status of each of our new product
development programs, will significantly impact our cash
management decisions.
We anticipate that our current cash and cash equivalents and
income from operations will be sufficient to fund our operating
needs in 2010, barring unforeseen circumstances. Operating needs
include the planned costs to operate our business, including
amounts required to fund working capital and capital
expenditures. At the present time, we have no material
commitments for capital expenditures. Our future capital
requirements and the adequacy of our available funds will depend
on many factors, including:
|
|
|
|
|
our ability to successfully commercialize and further develop
our technologies and create innovative products in our markets;
|
|
|
|
scientific progress in our research and development programs and
the magnitude of those programs;
|
|
|
|
competing technological and market developments; and
|
|
|
|
the need to enter into collaborations with other companies or
acquire other companies or technologies to enhance or complement
our product and service offerings.
|
Off-Balance
Sheet Arrangements
We do not participate in any transactions that generate
relationships with unconsolidated entities or financial
partnerships, such as entities often referred to as structured
finance or special purpose entities, which would have been
established for the purpose of facilitating off-balance sheet
arrangements or other contractually narrow or limited purposes.
During the fiscal year ended January 3, 2010, we were not
involved in any off balance sheet arrangements
within the meaning of the rules of the Securities and Exchange
Commission.
Contractual
Obligations
Contractual obligations represent future cash commitments and
liabilities under agreements with third parties, and exclude
orders for goods and services entered into in the normal course
of business that are not enforceable or legally binding. The
following table represents our contractual obligations as of
January 3, 2010, aggregated by type (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period(1)
|
|
|
|
|
|
|
Less Than
|
|
|
|
|
|
|
|
|
More Than
|
|
Contractual Obligation
|
|
Total
|
|
|
1 Year
|
|
|
1 3 Years
|
|
|
3 5 Years
|
|
|
5 Years
|
|
|
Debt obligations(2)
|
|
$
|
400,968
|
|
|
$
|
2,437
|
|
|
$
|
4,875
|
|
|
$
|
393,656
|
|
|
$
|
|
|
Operating leases
|
|
|
148,415
|
|
|
|
11,668
|
|
|
|
24,870
|
|
|
|
22,310
|
|
|
|
89,567
|
|
Contingent consideration(3)
|
|
|
10,000
|
|
|
|
10,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts due under executive deferred compensation plan
|
|
|
4,007
|
|
|
|
4,007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
563,390
|
|
|
$
|
28,112
|
|
|
$
|
29,745
|
|
|
$
|
415,966
|
|
|
$
|
89,567
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Excludes $11.8 million of uncertain tax benefits. We have
not included this amount in the table because we cannot make a
reasonably reliable estimate regarding the timing of settlements
with taxing authorities, if any. See Note 11 of Notes to
the Consolidated Financial Statements for further discussion of
our uncertain tax positions. |
|
(2) |
|
Debt obligations include the principal amount of our convertible
senior notes and interest payments totaling 0.625% per annum.
Although these notes mature in 2014, we classify the notes as
current liabilities because the conditions to convertibility
were satisfied during the last three fiscal quarters of |
40
|
|
|
|
|
2009 and may be satisfied during certain quarters in 2010. See
Note 7 of Notes to Consolidated Financial Statements for
further discussion of the terms of the convertible senior notes. |
|
(3) |
|
The $10.0 million included within contingent consideration
is the amount owed to the former shareholders of Avantome, Inc.
for the achievement of a certain date-specific milestones. The
table excludes $20.0 million in additional contingent cash
consideration we may be required to pay based on the achievement
of certain additional milestones that do not have a fixed
funding date and are subject to certain conditions that may or
may not occur. |
Critical
Accounting Policies and Estimates
The preparation of financial statements in accordance with
U.S. generally accepted accounting principles requires
management to make estimates and assumptions that affect the
amounts reported in our consolidated financial statements and
accompanying notes. Management bases its estimates on historical
experience, market and other conditions and various other
assumptions it believes to be reasonable. Although these
estimates are based on managements best knowledge of
current events and actions that may impact us in the future, the
estimation process is by its nature uncertain given that
estimates depend on events over which we may not have control.
If market and other conditions change from those that we
anticipate, our consolidated financial statements may be
materially affected. In addition, if our assumptions change, we
may need to revise our estimates, or take other corrective
actions, either of which may also have a material effect on our
consolidated financial statements.
We believe that the following critical accounting policies and
estimates have a higher degree of inherent uncertainty and
require our most significant judgments. In addition, had we used
estimates different from any of these, our consolidated
financial statements could have been materially different from
those presented. Members of our senior management have discussed
the development and selection of our critical accounting
policies and estimates, and our disclosure regarding them, with
the audit committee of our board of directors. Our accounting
policies are more fully described in Note 1 of the
Consolidated Financial Statements.
Revenue
Recognition
Our revenue is generated primarily from the sale of products and
services. Product revenue primarily consists of sales of arrays,
reagents, flow cells and instrumentation. Service and other
revenue consists of revenue received for performing genotyping
and sequencing services, extended warranty sales and amounts
earned under research agreements with government grants, which
are recognized in the period during which the related costs are
incurred. The timing of revenue recognition and the amount of
revenue actually recognized in each case depends upon a variety
of factors, including the specific terms of each arrangement and
the nature of our deliverables and obligations. Determination of
the appropriate amount of revenue recognized involves
significant judgments and estimates and actual results may
differ from our estimates.
We recognize revenue when persuasive evidence of an arrangement
exists, delivery has occurred or services have been rendered,
the sellers price to the buyer is fixed or determinable
and collectibility is reasonably assured. In instances where
final acceptance of the product or system is required, revenue
is deferred until all the acceptance criteria have been met. All
revenue is recorded net of any discounts.
Revenue for product sales is recognized generally upon shipment
and transfer of title to the customer, provided no significant
obligations remain and collection of the receivable is
reasonably assured. Revenue for genotyping and sequencing
services is recognized when earned, which is generally at the
time the genotyping or sequencing analysis data is delivered to
the customer or agreed-to milestones are reached.
In order to assess whether the price is fixed or determinable,
we ensure there are no refund rights. If payment terms are based
on future performance, we defer revenue recognition until the
price becomes fixed or determinable. We assess collectibility
based on a number of factors, including past transaction history
with the customer and the creditworthiness of the customer. If
we determine that collection of a payment is not reasonably
assured, revenue recognition is deferred until the time
collection becomes reasonably assured, which is generally upon
receipt of payment.
41
Sales of instrumentation generally include a standard one-year
warranty. We also sell separately priced maintenance (extended
warranty) contracts, which are generally for one year, starting
upon the expiration of the initial warranty. Revenue for
extended warranty sales is recognized ratably over the term of
the extended warranty period. Reserves are provided for
estimated product warranty expenses at the time the associated
revenue is recognized. If we were to experience an increase in
warranty claims or if costs of servicing its products under
warranty were greater than its estimates, gross margins could be
adversely affected.
We regularly enter into contracts where revenue is derived from
multiple deliverables including any mix of products
and/or
services. These products
and/or
services are generally delivered within a short time frame,
approximately three to six months, of the contract execution
date. Revenue recognition for contracts with multiple
deliverables is based on the individual units of accounting
determined to exist in the contract. A delivered item is
considered a separate unit of accounting when the delivered item
has value to the customer on a stand-alone basis. Items are
considered to have stand-alone value when they are sold
separately by any vendor or when the customer could resell the
item on a stand-alone basis.
For transactions entered into in 2009, consideration is
allocated at the inception of the contract to all deliverables
based on their relative selling price. The relative selling
price for each deliverable is determined using vendor specific
objective evidence (VSOE) of selling price or third-party
evidence of selling price if VSOE does not exist. If neither
VSOE nor third-party evidence exists, we use best estimate of
the selling price for the deliverable. See Recent Accounting
Pronouncements in Note 1 of Notes to Consolidated
Financial Statements for further information related to our
change in authoritative accounting guidance for revenue
recognition.
For transactions entered into prior to 2009, consideration was
generally allocated to each unit of accounting based upon its
relative fair value when objective and reliable evidence of fair
value existed for all units of accounting in an arrangement. The
fair value of an item was generally the price charged for the
product, if the item was regularly sold on a stand-alone basis.
In those instances when objective and reliable evidence of fair
value existed for the undelivered items but not for the
delivered items, the residual method was used to allocate the
arrangement consideration. Under the residual method, the amount
of arrangement consideration allocated to the delivered items
equaled the total arrangement consideration less the aggregate
fair value of the undelivered items. When we were unable to
establish stand-alone value for delivered items or when fair
value of undelivered items had not been established, revenue was
deferred until all elements were delivered and services had been
performed, or until fair value could objectively be determined
for any remaining undelivered elements.
In order to establish VSOE of selling price, we must regularly
sell the product
and/or
service on a standalone basis with a substantial majority priced
within a relatively narrow range. VSOE of selling price is
usually the midpoint of that range. If there is not a sufficient
number of standalone sales and VSOE of selling price cannot be
determined, then we consider whether third party evidence can be
used to establish selling price. Due to the lack of similar
products and services sold by other companies within the
industry, we have rarely established selling price using
third-party evidence. If neither VSOE nor third party evidence
of selling price exists, we determine its best estimate of
selling price using average selling prices over a rolling
12 month period as well as market conditions. If the
product or service has no history of sales, we rely upon prices
set by our pricing committee adjusted for applicable discounts.
We recognize revenue for delivered elements only when we
determine there are no uncertainties regarding customer
acceptance.
Investments
We determine the fair value of our assets and liabilities based
on the exchange price that would be received for an asset or
paid to transfer a liability (an exit price) in the principal or
most advantageous market for the asset or liability in an
orderly transaction between market participants on the
measurement date. Valuation techniques used to measure fair
value maximize the use of observable inputs and minimize the use
42
of unobservable inputs. We use a fair value hierarchy with three
levels of inputs, of which the first two are considered
observable and the last unobservable, to measure fair value:
|
|
|
|
|
Level 1 Quoted prices in active markets for
identical assets or liabilities.
|
|
|
|
Level 2 Inputs other than Level 1 that are
observable, either directly or indirectly, such as quoted prices
for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be
corroborated by observable market data for substantially the
full term of the assets or liabilities.
|
|
|
|
Level 3 Unobservable inputs that are supported
by little or no market activity and that are significant to the
fair value of the assets or liabilities.
|
In using this fair value hierarchy, management may be required
to make assumptions of pricing by market participants and
assumptions about risk, specifically when using unobservable
inputs to determine fair value. These assumptions are judgmental
in nature and may significantly affect our results of operations.
Allowance
for Doubtful Accounts
We maintain an allowance for doubtful accounts for estimated
losses resulting from the inability of our customers to make
required payments. We evaluate the collectibility of our
accounts receivable based on a combination of factors. We
regularly analyze customer accounts, review the length of time
receivables are outstanding, review historical loss rates and
assess current economic trends that may impact the level of
credit losses in the future. Our allowance for doubtful accounts
has generally been adequate to cover our actual credit losses.
However, since we cannot reliably predict future changes in the
financial stability of our customers, we cannot guarantee that
our reserves will continue to be adequate.
Inventory
Valuation
We record adjustments to inventory for potentially excess,
obsolete or impaired goods in order to state inventory at net
realizable value. We must make assumptions about future demand,
market conditions and the release of new products that will
supersede old ones. We regularly review inventory for excess and
obsolete products and components, taking into account product
life cycle and development plans, product expiration and quality
issues, historical experience and our current inventory levels.
If actual market conditions are less favorable than anticipated,
additional inventory adjustments could be required.
Contingencies
We are subject to legal proceedings primarily related to
intellectual property matters. We routinely assess the
likelihood of adverse judgments or outcomes to these matters, as
well as ranges of probable losses, to the extent losses are
reasonably estimable. If losses are probable and reasonably
estimable, we will record a liability and an expense for the
estimated loss. Disclosure for specific legal contingencies is
provided if the likelihood of occurrence is probable and the
exposure is considered material to the consolidated financial
statements. In making determinations of likely outcomes of
litigation matters, management considers many factors. These
factors include, but are not limited to, past history,
scientific and other evidence, and the specifics and status of
each matter. We may change our estimates if our assessment of
the various factors changes, which may result in the recording
of an accrual or a change in a previously recorded accrual.
Predicting the outcome of claims and litigation, and estimating
related costs and exposure involves substantial uncertainties
that could cause actual costs to vary materially from estimates
and accruals.
Business
Combinations and Intangible Asset Valuation
Under the purchase method of accounting, we allocate the
purchase price of acquired companies to the tangible and
identifiable intangible assets acquired and liabilities assumed
based on their estimated fair values. We record the excess of
purchase price over the aggregate fair values as goodwill. We
engage third-party appraisal firms to assist us in determining
the fair values of assets acquired and liabilities assumed.
These
43
valuations require us to make significant estimates and
assumptions, especially with respect to intangible assets.
The Companys intangible assets are comprised primarily of
licensed technology from the Affymetrix settlement entered into
on January 9, 2008 and acquired core technology and
customer relationships from the Solexa acquisition. Management
uses a discounted cash flow method to value our intangible
assets. This method requires significant management judgment to
forecast future operating results and establish residual growth
rates and discount factors. The estimates we use to value and
amortize intangible assets are consistent with the plans and
estimates that we use to manage our business and are based on
available historical information and industry estimates and
averages. If the subsequent actual results and updated
projections of the underlying business activity change compared
with the assumptions and projections used to develop these
values, we could experience impairment charges. In addition, we
have estimated the economic lives of certain acquired assets and
these lives are used to calculate depreciation and amortization
expense. If our estimates of the economic lives change,
depreciation or amortization expenses could be accelerated or
slowed.
Goodwill,
Intangible Assets and Other Long-Lived Assets
Impairment Assessments
We estimate the fair value of intangible assets and other
long-lived assets that have finite useful lives whenever an
event or change in circumstances indicates that the carrying
value of the asset may not be recovered through undiscounted
future operating cash flows. We test for potential impairment of
goodwill annually in our second fiscal quarter or whenever
indicators of impairment arise.
In order to estimate the fair value of purchased intangible
assets and other long-lived assets that have finite useful
lives, we estimate the present value of future cash flows from
those assets. The key assumptions that we use in our discounted
cash flow model are the amount and timing of estimated future
cash flows to be generated by the asset over an extended period
of time and a rate of return that considers the relative risk of
achieving the cash flows and the time value of money.
Significant judgment is required to estimate the amount and
timing of future cash flows and the relative risk of achieving
those cash flows. We had a total of $213.4 million in
goodwill, $117.2 million in net property and equipment and
$43.8 million in net intangible assets on our balance sheet
at January 3, 2010.
In order to estimate the fair value of goodwill, we use a
weighted combination of a discounted cash flow model (known as
the income approach) and comparisons to publicly traded
companies engaged in similar businesses (known as the market
approach). The income approach requires us to use a number of
assumptions, including market factors specific to the business,
the amount and timing of estimated future cash flows to be
generated by the business over an extended period of time,
long-term growth rates for the business, and a rate of return
that considers the relative risk of achieving the cash flows and
the time value of money. Although the assumptions we use in our
discounted cash flow model are consistent with the assumptions
we use to generate our internal strategic plans and forecasts,
significant judgment is required to estimate the amount and
timing of future cash flows and the relative risk of achieving
those cash flows. When using the market approach, we make
judgments about the comparability of publicly traded companies
engaged in similar businesses. We base our judgments on factors
such as size, growth rates, profitability, risk, and return on
investment. We also make judgments when adjusting market
multiples of revenue, operating income, and earnings for these
companies to reflect their relative similarity to our own
businesses.
Assumptions and estimates about future values and remaining
useful lives are complex and often subjective. They can be
affected by a variety of factors, including external factors
such as industry and economic trends, and internal factors such
as changes in our business strategy and our internal forecasts.
For example, if our future operating results do not meet current
forecasts or if we experience a sustained decline in our market
capitalization that is determined to be indicative of a
reduction in fair value of one or more of our reporting units,
we may be required to record future impairment charges for
purchased intangible assets and goodwill. Impairment charges
could materially decrease our future net income and result in
lower asset values on our balance sheet.
44
Convertible
Senior Notes
During the first quarter of 2009, we adopted new authoritative
guidance that significantly impacts the accounting for our
convertible senior notes by requiring us to account separately
for the liability and equity components of the notes. The
liability component is measured so the effective interest
expense associated with the notes reflects the issuers
borrowing rate at the date of issuance for similar debt
instruments without the conversion feature. The difference
between the cash proceeds associated with the notes and this
estimated fair value is recorded as a debt discount and
amortized to interest expense over the life of the notes.
Determining the fair value of the liability component requires
the use of accounting estimates and assumptions. These estimates
and assumptions are judgmental in nature and could have a
significant impact on the determination of the liability
component and, in effect, the associated interest expense.
According to the guidance, the carrying amount of the liability
component is determined by measuring the fair value of a similar
liability that does not have an associated equity component. If
no similar liabilities exist, estimates of fair value are
primarily determined using assumptions that market participants
would use in pricing the liability component, including market
interest rates, credit standing, yield curves and volatilities.
Stock-Based
Compensation
We are required to measure and recognize compensation expense
for all stock-based payment awards made to employees and
directors based on estimated fair value. We estimate the fair
value of stock options granted and stock purchases under our
employee stock purchase plan using the Black-Scholes-Merton
(BSM) option-pricing model. The fair value of our restricted
stock units is based on the market price of our common stock on
the date of grant.
The determination of fair value of stock-based awards using the
BSM model requires the use of certain estimates and highly
judgmental assumptions that affect the amount of stock-based
compensation expense recognized in our Consolidated Statements
of Operations. These include estimates of the expected
volatility of our stock price, expected option life, expected
dividends and the risk-free interest rate. We determine the
volatility of our stock price by equally weighing the historical
and implied volatility of our common stock. The historical
volatility of our common stock over the most recent period is
generally commensurate with the estimated expected life of our
stock options, adjusted for the impact of unusual fluctuations
not reasonably expected to recur and other relevant factors.
Implied volatility is calculated from the implied market
volatility of exchange-traded call options on our common stock.
The expected option life of an award is based on historical
forfeiture experience, exercise activity and on the terms and
conditions of the stock awards granted to employees. We
determined expected dividend yield to be 0% given we have never
declared or paid any cash dividends on our common stock and we
currently do not anticipate paying such cash dividends. The
risk-free interest rate is based upon U.S. Treasury
securities with remaining terms similar to the expected term of
the share-based awards. If any of the assumptions used in the
BSM model change significantly, stock-based compensation expense
may differ materially from what we have recorded in the current
period.
Income
Taxes
Our provision for income taxes, deferred tax assets and
liabilities, and reserves for unrecognized tax benefits reflect
our best assessment of estimated future taxes to be paid.
Significant judgments and estimates based on interpretations of
existing tax laws or regulations in the U.S. and the
numerous foreign jurisdictions where we are subject to income
tax are required in determining our provision for income taxes.
Changes in tax laws, statutory tax rates and estimates of the
companys future taxable income could impact the deferred
tax assets and liabilities provided for in the consolidated
financial statements and would require an adjustment to the
provision for income taxes.
Deferred tax assets are regularly assessed to determine the
likelihood they will be recovered from future taxable income. A
valuation allowance is established when we believe it is more
likely than not the future realization of all or some of a
deferred tax asset will not be achieved. In evaluating our
ability to recover deferred tax assets within the jurisdiction
which they arise we consider all available positive and negative
evidence. Factors reviewed include the cumulative pre-tax book
income for the past three years, scheduled
45
reversals of deferred tax liabilities, our history of earnings
and reliable forecasting, projections of pre-tax book income
over the foreseeable future, and the impact of any feasible and
prudent tax planning strategies. Based on the available evidence
as of January 3, 2010, we were not able to conclude it is
more likely than not certain U.S. and foreign deferred tax
assets will be realized. Therefore, we recorded a valuation
allowance of $2.8 million and $12.1 million against
certain U.S. and foreign deferred tax assets, respectively.
We recognize the impact of a tax position in our financial
statements only if that position is more likely than not of
being sustained upon examination by taxing authorities, based on
the technical merits of the position. Tax authorities regularly
examine our returns in the jurisdictions in which we do business
and we regularly assess the tax risk of the companys
return filing positions. Due to the complexity of some of the
uncertainties, the ultimate resolution may result in payments
that are materially different from our current estimate of the
tax liability. These differences, as well as any interest and
penalties, will be reflected in the provision for income taxes
in the period in which they are determined.
Recent
Accounting Pronouncements
Information with respect to recent accounting pronouncements is
included in Note 1 of Notes to Consolidated Financial
Statements.
|
|
Item 7A.
|
Quantitative
and Qualitative Disclosures about Market Risk.
|
Interest
Rate Sensitivity
Our exposure to market risk for changes in interest rates
relates primarily to our investment portfolio. The fair market
value of fixed rate securities may be adversely impacted by
fluctuations in interest rates while income earned on floating
rate securities may decline as a result of decreases in interest
rates. Under our current policies, we do not use interest rate
derivative instruments to manage exposure to interest rate
changes. We attempt to ensure the safety and preservation of our
invested principal funds by limiting default risk, market risk
and reinvestment risk. We mitigate default risk by investing in
investment grade securities. We have historically maintained a
relatively short average maturity for our investment portfolio,
and we believe a hypothetical 100 basis point adverse move
in interest rates along the entire interest rate yield curve
would not materially affect the fair value of our interest
sensitive financial instruments. For example, if a
100 basis point change in overall interest rates were to
occur in 2010, our interest income would change by approximately
$6.9 million in relation to amounts we would expect to
earn, based on our cash, cash equivalents, and short-term
investments as of January 3, 2010.
Market
Price Sensitive Instruments
In order to reduce potential equity dilution, in connection with
the issuance (and potential conversion) of our convertible
notes, we entered into convertible note hedge transactions,
entitling us to purchase up to 18,322,320 shares of our
common stock at a strike price of $21.83 per share, subject to
adjustment. In addition, we sold to the hedge transaction
counterparties warrants exercisable on a net-share basis, for up
to 18,322,320 shares of our common stock at a strike price
of $31.435 per share, subject to adjustment. The anti-dilutive
effect of the note hedge transactions, if any, could be
partially or fully offset to the extent the trading price of our
common stock exceeds the strike price of the warrants on the
exercise dates of the warrants, which occur during 2014,
assuming the warrants are exercised.
Foreign
Currency Exchange Risk
Many of our reporting entities conduct a portion of their
business in currencies other than the entitys
U.S. dollar functional currency. These transactions give
rise to monetary assets and liabilities that are denominated in
currencies other than the entitys functional currency. The
value of these monetary assets and liabilities are subject to
changes in currency exchange rates from the time the
transactions are originated until settlement in cash. Our
foreign currency exposures are primarily concentrated in the
Euro, Yen, British pound sterling, Australian dollar and
Singapore dollar. Both realized and unrealized gains or losses
on the value of these monetary assets and liabilities are
included in the determination of net income (loss). We
recognized a
46
net currency exchange gain on business transactions, net of
hedging transactions, of $0.4 million and $1.9 million
for the years ended January 3, 2010 and December 28,
2008, respectively, which are included in other income
(expense), net, in the consolidated statements of operations.
During 2009, we began using forward exchange contracts to manage
a portion of the foreign currency exposure risk for foreign
subsidiaries with monetary assets and liabilities denominated in
currencies other than the entitys functional currency. We
only use derivative financial instruments to reduce foreign
currency exchange rate risks; we do not hold any derivative
financial instruments for trading or speculative purposes. We
primarily use forward exchange contracts to hedge foreign
currency exposures, and they generally have terms of one month
or less. Realized and unrealized gains or losses on the value of
financial contracts entered into to hedge the exchange rate
exposure of these monetary assets and liabilities are also
included in the determination of net income (loss), as they have
not been designated for hedge accounting. These contracts, which
settle monthly, effectively fix the exchange rate at which these
specific monetary assets and liabilities will be settled, so
that gains or losses on the forward contracts offset the losses
or gains from changes in the value of the underlying monetary
assets and liabilities. At January 3, 2010, we had an
immaterial amount of foreign currency forward contracts
outstanding to hedge foreign currency risk.
|
|
Item 8.
|
Financial
Statements and Supplementary Data.
|
The Report of Independent Registered Public Accounting Firm,
Financial Statements and Notes to Financial Statements begin on
page F-1
immediately following the signature page and are incorporated
herein by reference.
|
|
Item 9.
|
Changes
In and Disagreements with Accountants on Accounting and
Financial Disclosure.
|
None.
|
|
Item 9A.
|
Controls
and Procedures.
|
We design our internal controls to provide reasonable assurance
that (1) our transactions are properly authorized;
(2) our assets are safeguarded against unauthorized or
improper use; and (3) our transactions are properly
recorded and reported in conformity with U.S. generally
accepted accounting principles. We also maintain internal
controls and procedures to ensure that we comply with applicable
laws and our established financial policies.
We have carried out an evaluation, under the supervision and
with the participation of our management, including our
principal executive officer and principal financial officer, of
the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in
Rules 13a-15(e)
and
15d-15(e)
under the Securities Exchange Act of 1934, as amended, or the
Securities Exchange Act), as of January 3, 2010. Based upon
that evaluation, our principal executive officer and principal
financial officer concluded that, as of January 3, 2010,
our disclosure controls and procedures were effective to ensure
that (a) the information required to be disclosed by us in
the reports that we file or submit under the Securities Exchange
Act is recorded, processed, summarized and reported within the
time periods specified in the SECs rules and forms, and
(b) such information is accumulated and communicated to our
management, including our principal executive officer and
principal financial officers, or persons performing similar
functions, as appropriate to allow timely decisions regarding
required disclosure. In designing and evaluating our disclosure
controls and procedures, our management recognized that any
controls and procedures, no matter how well designed and
operated, can provide only reasonable assurance of achieving the
desired control objectives, and our management have concluded
that the disclosure controls and procedures are effective at the
reasonable assurance level. Because of inherent limitations in
all control systems, no evaluation of controls can provide
absolute assurance that all control issues, if any, within a
company have been detected.
An evaluation was also performed under the supervision and with
the participation of our management, including our chief
executive officer and chief financial officer, of any change in
our internal control over financial reporting that occurred
during the fourth quarter of 2009 and that has materially
affected, or is
47
reasonably likely to materially affect, our internal control
over financial reporting. The evaluation did not identify any
such change.
MANAGEMENTS
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Our management is responsible for establishing and maintaining
adequate internal control over financial reporting, as such term
is defined in Exchange Act
Rules 13a-15(f).
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect all misstatements.
Therefore, even those systems determined to be effective can
provide only reasonable assurance with respect to financial
statement preparation and presentation.
We conducted an evaluation of the effectiveness of our internal
control over financial reporting based on the framework in
Internal Control Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway
Commission. Based on our evaluation under the framework in
Internal Control Integrated Framework, our
management concluded that our internal control over financial
reporting was effective as of January 3, 2010. The
effectiveness of our internal control over financial reporting
as of January 3, 2010 has been audited by Ernst &
Young LLP, an independent registered accounting firm, as stated
in their report which is included herein.
48
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of
Illumina, Inc.
We have audited Illumina, Inc.s internal control over
financial reporting as of January 3, 2010, based on
criteria established in Internal Control Integrated
Framework issued by the Committee of Sponsoring Organizations of
the Treadway Commission (the COSO criteria). Illumina,
Inc.s management is responsible for maintaining effective
internal control over financial reporting, and for its
assessment of the effectiveness of internal control over
financial reporting included in the accompanying
Managements Report on Internal Control over Financial
Reporting. Our responsibility is to express an opinion on the
companys internal control over financial reporting based
on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control
over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk
that a material weakness exists, testing and evaluating the
design and operating effectiveness of internal control based on
the assessed risk, and performing such other procedures as we
considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.
A companys internal control over financial reporting is a
process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
In our opinion, Illumina, Inc. maintained, in all material
respects, effective internal control over financial reporting as
of January 3, 2010, based on the COSO criteria.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
accompanying consolidated balance sheets of Illumina, Inc. as of
January 3, 2010 and December 28, 2008, and the related
consolidated statements of operations, stockholders
equity, and cash flows for each of the three years in the period
ended January 3, 2010 of Illumina, Inc. and our report
dated February 26, 2010 expressed an unqualified opinion
thereon.
San Diego, California
February 26, 2010
49
|
|
Item 9B.
|
Other
Information.
|
None.
PART III
|
|
Item 10.
|
Directors,
Executive Officers and Corporate Governance.
|
(a) Identification of Directors. Information concerning our
directors is incorporated by reference from the section entitled
Proposal One: Election of Directors,
Information About Directors, Director
Compensation and Board of Directors and Corporate
Governance to be contained in our definitive Proxy
Statement with respect to our 2010 Annual Meeting of
Stockholders to be filed with the SEC no later than
April 7, 2010.
(b) Identification of Executive Officers. Information
concerning our executive officers is incorporated by reference
from the section entitled Executive Officers to be
contained in our definitive Proxy Statement with respect to our
2010 Annual Meeting of Stockholders to be filed with the SEC no
later than April 7, 2010.
(c) Compliance with Section 16(a) of the Exchange Act.
Information concerning compliance with Section 16(a) of the
Securities Exchange Act of 1934 is incorporated by reference
from the section entitled Compliance with
Section 16(a) of the Securities Exchange Act to be
contained in our definitive Proxy Statement with respect to our
2010 Annual Meeting of Stockholders to be filed with the SEC no
later than April 7, 2010.
(d) Information concerning the audit committee financial
expert as defined by the SEC rules adopted pursuant to the
Sarbanes-Oxley Act of 2002 is incorporated by reference from the
section entitled Board of Directors and Corporate
Governance to be contained in our definitive Proxy
Statement with respect to our 2010 Annual Meeting of
Stockholders to be filed with the SEC no later than
April 7, 2010.
Code of
Ethics
We have adopted a code of ethics for our directors, officers and
employees, which is available on our website at www.illumina.com
in the Corporate Governance portal of the Investor Relations
section under Company. A copy of the Code of Ethics
is available in print free of charge to any stockholder who
requests a copy. Interested parties may address a written
request for a printed copy of the Code of Ethics to: Corporate
Secretary, Illumina, Inc., 9885 Towne Centre Dr.,
San Diego, California 92121. We intend to satisfy the
disclosure requirement regarding any amendment to, or a waiver
from, a provision of the Code of Ethics for our principal
executive officer, principal financial officer, principal
accounting officer or controller, or persons performing similar
functions, by posting such information on our website. The
information on, or that can be accessed from, our website is not
incorporated by reference into this report.
|
|
Item 11.
|
Executive
Compensation.
|
Information concerning executive compensation is incorporated by
reference from the sections entitled Compensation
Discussion and Analysis, Director Compensation
and Executive Compensation to be contained in our
definitive Proxy Statement with respect to our 2010 Annual
Meeting of Stockholders to be filed with the SEC no later than
April 7, 2010.
|
|
Item 12.
|
Security
Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters.
|
Information concerning the security ownership of certain
beneficial owners and management and information covering
securities authorized for issuance under equity compensation
plans is incorporated by reference from the sections entitled
Stock Ownership of Principal Stockholders and
Management, Executive Compensation and
Equity Compensation Plan Information to be contained
in our definitive Proxy
50
Statement with respect to our 2010 Annual Meeting of
Stockholders to be filed with the SEC no later than
April 7, 2010.
|
|
Item 13.
|
Certain
Relationships and Related Transactions, and Director
Independence.
|
Information concerning certain relationships and related
transactions, and director independence is incorporated by
reference from the sections entitled Proposal One:
Election of Directors, Information About
Directors, Director Compensation,
Executive Compensation and Certain
Relationships and Related Party Transactions to be
contained in our definitive Proxy Statement with respect to our
2010 Annual Meeting of Stockholders to be filed with the SEC no
later than April 7, 2010.
|
|
Item 14.
|
Principal
Accountant Fees and Services.
|
Information concerning principal accountant fees and services is
incorporated by reference from the sections entitled
Proposal Two: Ratification of Independent Registered
Public Accounting Firm and Independent Registered
Public Accountants to be contained in our definitive Proxy
Statement with respect to our 2010 Annual Meeting of
Stockholders to be filed with the SEC no later than
April 7, 2010.
PART IV
|
|
Item 15.
|
Exhibits,
Financial Statement Schedules.
|
(a) The following documents are filed as a part of this
report:
(1) Consolidated Financial Statements:
|
|
|
|
|
|
|
Page
|
|
Index to Consolidated Financial Statements
|
|
|
F-1
|
|
|
|
|
F-2
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
(2) Financial Statement Schedule:
|
|
|
|
|
|
|
|
F-39
|
|
(3) Exhibits:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
|
Exhibit
|
|
|
|
|
|
|
|
|
|
Filing
|
|
Filed
|
Number
|
|
Exhibit Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Date
|
|
Herewith
|
|
|
3
|
.1
|
|
Amended and Restated Certificate of Incorporation
|
|
8-K
|
|
000-30361
|
|
|
3
|
.1
|
|
09/23/08
|
|
|
|
3
|
.2
|
|
Amended and Restated Bylaws
|
|
8-K
|
|
000-30361
|
|
|
3
|
.2
|
|
04/29/09
|
|
|
|
3
|
.3
|
|
Certificate of Designation for Series A Junior
Participating Preferred Stock (included as Exhibit A to
exhibit 4.3)
|
|
8-A
|
|
000-30361
|
|
|
4
|
.3
|
|
05/14/01
|
|
|
|
4
|
.1
|
|
Specimen Common Stock Certificate
|
|
S-1/A
|
|
333-33922
|
|
|
4
|
.1
|
|
07/03/00
|
|
|
|
4
|
.2
|
|
Rights Agreement, dated as of May 3, 2001, between Illumina
and Equiserve Trust Company, N.A.
|
|
8-A
|
|
000-30361
|
|
|
4
|
.3
|
|
05/14/01
|
|
|
51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
|
Exhibit
|
|
|
|
|
|
|
|
|
|
Filing
|
|
Filed
|
Number
|
|
Exhibit Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Date
|
|
Herewith
|
|
|
4
|
.3
|
|
Indenture related to the 0.625% Convertible Senior Notes
due 2014, dated as of February 16, 2007, between Illumina
and The Bank of New York, as trustee
|
|
8-K
|
|
000-30361
|
|
|
4
|
.1
|
|
02/16/07
|
|
|
|
+10
|
.1
|
|
Form of Indemnification Agreement between Illumina and each of
its directors and officers
|
|
S-1/A
|
|
333-33922
|
|
|
10
|
.1
|
|
07/03/00
|
|
|
|
+10
|
.2
|
|
1998 Incentive Stock Plan
|
|
S-1/A
|
|
333-33922
|
|
|
10
|
.2
|
|
07/03/00
|
|
|
|
+10
|
.3
|
|
2000 Employee Stock Purchase Plan, as amended and restated
through October 28, 2009
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
+10
|
.4
|
|
2000 Stock Plan, as amended and restated through March 21,
2002
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.22
|
|
05/13/02
|
|
|
|
+10
|
.5
|
|
2005 Stock and Incentive Plan, as amended and restated through
October 28, 2009
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
+10
|
.6
|
|
Form of Restricted Stock Unit Agreement for Non-Employee
Directors under 2005 Stock and Incentive Plan
|
|
10-K
|
|
000-30361
|
|
|
10
|
.35
|
|
02/26/09
|
|
|
|
+10
|
.7
|
|
New Hire Stock and Incentive Plan, as amended and restated
through October 28, 2009
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
10
|
.8
|
|
License Agreement, effective as of May 6, 1998, between
Tufts University and Illumina
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.5
|
|
05/03/07
|
|
|
|
+10
|
.9
|
|
The Solexa Unapproved Company Share Option Plan
|
|
8-K
|
|
000-30361
|
|
|
99
|
.3
|
|
11/26/07
|
|
|
|
+10
|
.10
|
|
The Solexa Share Option Plan for Consultants
|
|
8-K
|
|
000-30361
|
|
|
99
|
.4
|
|
11/26/07
|
|
|
|
+10
|
.11
|
|
Solexa Limited Enterprise Management Incentive Plan
|
|
8-K
|
|
000-30361
|
|
|
99
|
.5
|
|
11/26/07
|
|
|
|
+10
|
.12
|
|
Amended and Restated Solexa 2005 Equity Incentive Plan
|
|
10-K
|
|
000-30361
|
|
|
10
|
.25
|
|
02/26/09
|
|
|
|
+10
|
.13
|
|
Amended and Restated Solexa 1992 Stock Option Plan
|
|
10-K
|
|
000-30361
|
|
|
10
|
.26
|
|
02/26/09
|
|
|
|
10
|
.14
|
|
License Agreement, dated June 24, 2002, between Dade
Behring Marburg GmbH and Illumina (with certain confidential
portions omitted)
|
|
S-3/A
|
|
333-111496
|
|
|
10
|
.23
|
|
03/02/04
|
|
|
|
10
|
.15
|
|
Non-exclusive License Agreement, dated January 24, 2002,
between Amersham Biosciences Corp. and Illumina (with certain
confidential portions omitted)
|
|
S-3/A
|
|
333-111496
|
|
|
10
|
.24
|
|
03/02/04
|
|
|
|
10
|
.16
|
|
Amended and Restated Lease between BMR-9885 Towne Centre Drive
LLC and Illumina for the 9885 Towne Centre Drive property, dated
January 26, 2007
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.41
|
|
05/03/07
|
|
|
|
10
|
.17
|
|
Settlement and Cross License Agreement dated August 18,
2004 between Applera Corporation and Illumina (with certain
confidential portions omitted)
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.27
|
|
11/12/04
|
|
|
|
10
|
.18
|
|
Collaboration Agreement, dated December 17, 2004, between
Invitrogen Corporation and Illumina (with certain confidential
portions omitted)
|
|
10-K
|
|
000-30361
|
|
|
10
|
.28
|
|
03/08/05
|
|
|
52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
|
Exhibit
|
|
|
|
|
|
|
|
|
|
Filing
|
|
Filed
|
Number
|
|
Exhibit Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Date
|
|
Herewith
|
|
|
+10
|
.19
|
|
Offer letter for Christian O. Henry dated April 26, 2005
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.33
|
|
08/08/05
|
|
|
|
10
|
.20
|
|
Joint Development and Licensing Agreement, dated May 15,
2006, between deCODE genetics, ehf. and Illumina (with certain
confidential portions omitted)
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.32
|
|
08/02/06
|
|
|
|
+10
|
.21
|
|
Amended and Restated Change in Control Severance Agreement
between Illumina and Jay T Flatley, dated October 22, 2008
|
|
10-K
|
|
000-30361
|
|
|
10
|
.33
|
|
02/26/09
|
|
|
|
+10
|
.22
|
|
Form of Amended and Restated Change in Control Severance
Agreement between Illumina and its executive officers
|
|
10-K
|
|
000-30361
|
|
|
10
|
.34
|
|
02/26/09
|
|
|
|
+10
|
.23
|
|
Form of Restricted Stock Unit Agreement for Non-Employee
Directors under Illuminas 2005 Stock and Incentive Plan
|
|
10-K
|
|
000-30361
|
|
|
10
|
.35
|
|
02/26/09
|
|
|
|
10
|
.24
|
|
Lease between BMR-9885 Towne Centre Drive LLC and Illumina for
the 9865 Towne Centre Drive property, dated January 26, 2007
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.42
|
|
05/03/07
|
|
|
|
10
|
.25
|
|
Settlement and Release Agreement between Affymetrix, Inc. and
Illumina, dated January 9, 2008
|
|
10-K
|
|
000-30361
|
|
|
10
|
.44
|
|
02/26/08
|
|
|
|
10
|
.26
|
|
Confirmation of Convertible Bond Hedge Transaction, dated
February 12, 2007, by and between Illumina and Goldman,
Sachs & Co.
|
|
8-K
|
|
000-30361
|
|
|
10
|
.1
|
|
02/16/07
|
|
|
|
10
|
.27
|
|
Confirmation of Convertible Bond Hedge Transaction, dated
February 12, 2007, by and between Illumina and Deutsche
Bank AG London
|
|
8-K
|
|
000-30361
|
|
|
10
|
.2
|
|
02/16/07
|
|
|
|
10
|
.28
|
|
Confirmation Issuer Warrant Transaction, dated February 12,
2007, by and between Illumina and Goldman, Sachs & Co.
|
|
8-K
|
|
000-30361
|
|
|
10
|
.3
|
|
02/16/07
|
|
|
|
10
|
.29
|
|
Confirmation Issuer Warrant Transaction, dated February 12,
2007, by and between Illumina and Deutsche Bank AG London
|
|
8-K
|
|
000-30361
|
|
|
10
|
.4
|
|
02/16/07
|
|
|
|
10
|
.30
|
|
Amendment to the Confirmation of Issuer Warrant Transaction,
dated February 13, 2007, by and between Illumina and
Goldman, Sachs & Co.
|
|
8-K
|
|
000-30361
|
|
|
10
|
.5
|
|
02/16/07
|
|
|
|
10
|
.31
|
|
Amendment to the Confirmation of Issuer Warrant Transaction,
dated February 13, 2007, by and between Illumina and
Deutsche Bank AG London
|
|
8-K
|
|
000-30361
|
|
|
10
|
.6
|
|
02/16/07
|
|
|
|
+10
|
.32
|
|
Indemnification Agreement between Illumina and Gregory F. Heath
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.55
|
|
07/25/08
|
|
|
|
+10
|
.33
|
|
Indemnification Agreement between Illumina and Joel McComb
|
|
10-Q
|
|
000-30361
|
|
|
10
|
.56
|
|
07/25/08
|
|
|
|
+10
|
.34
|
|
Severance and Release Agreement, dated February 22, 2010,
between Joel McComb and Illumina
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
21
|
.1
|
|
Subsidiaries of Illumina
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23
|
.1
|
|
Consent of Independent Registered Public Accounting Firm
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
24
|
.1
|
|
Power of Attorney (included on the signature page)
|
|
|
|
|
|
|
|
|
|
|
|
X
|
53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
|
Exhibit
|
|
|
|
|
|
|
|
|
|
Filing
|
|
Filed
|
Number
|
|
Exhibit Description
|
|
Form
|
|
File Number
|
|
Exhibit
|
|
Date
|
|
Herewith
|
|
|
31
|
.1
|
|
Certification of Jay T. Flatley pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
31
|
.2
|
|
Certification of Christian O. Henry pursuant to Section 302
of the Sarbanes-Oxley Act of 2002
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
32
|
.1
|
|
Certification of Jay T. Flatley pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
32
|
.2
|
|
Certification of Christian O. Henry pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002
|
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
+ |
|
Management contract or corporate plan or arrangement |
Supplemental
Information
No Annual Report to stockholders or proxy materials has been
sent to stockholders as of the date of this report. The Annual
Report to stockholders and proxy material will be furnished to
our stockholders subsequent to the filing of this Annual Report
on
Form 10-K
and we will furnish such material to the SEC at that time.
54
SIGNATURES
Pursuant to the requirements of the Section 13 or 15(d) of
the Securities Exchange Act of 1934, the Registrant has duly
caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized, on February 26,
2010.
Illumina, Inc.
Jay T. Flatley
President and Chief Executive Officer
February 26, 2010
POWER OF
ATTORNEY
KNOW ALL PERSONS BY THESE PRESENT, that each person whose
signature appears below constitutes and appoints Jay T. Flatley
and Christian O. Henry, and each or any one of them, his true
and lawful attorney-in-fact and agent, with full power of
substitution and resubstitution, for him and in his name, place
and stead, in any and all capacities, to sign any and all
amendments to this Annual Report on
Form 10-K,
and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and
agents, and each of them, full power and authority to do and
perform each and every act and thing requisite and necessary to
be done in connection therewith, as fully to all intents and
purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents, or any of
them, or their or his substitutes or substitute, may lawfully do
or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of
1934, this Annual Report on
Form 10-K
has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Jay
T. Flatley
Jay
T. Flatley
|
|
President, Chief Executive Officer and Director (Principal
Executive Officer)
|
|
February 26, 2010
|
|
|
|
|
|
/s/ Christian
O. Henry
Christian
O. Henry
|
|
Senior Vice President and Chief Financial Officer (Principal
Financial and Accounting Officer)
|
|
February 26, 2010
|
|
|
|
|
|
/s/ William
H. Rastetter
William
H. Rastetter
|
|
Chairman of the Board of Directors
|
|
February 26, 2010
|
|
|
|
|
|
/s/ A.
Blaine Bowman
A.
Blaine Bowman
|
|
Director
|
|
February 26, 2010
|
|
|
|
|
|
/s/ Daniel
M. Bradbury
Daniel
M. Bradbury
|
|
Director
|
|
February 26, 2010
|
|
|
|
|
|
/s/ Karin
Eastham
Karin
Eastham
|
|
Director
|
|
February 26, 2010
|
55
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Jack
Goldstein
Jack
Goldstein
|
|
Director
|
|
February 26, 2010
|
|
|
|
|
|
/s/ Paul
Grint
Paul
Grint
|
|
Director
|
|
February 26, 2010
|
|
|
|
|
|
/s/ David
R. Walt
David
R. Walt
|
|
Director
|
|
February 26, 2010
|
|
|
|
|
|
/s/ Roy
Whitfield
Roy
Whitfield
|
|
Director
|
|
February 26, 2010
|
56
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders of
Illumina, Inc.
We have audited the accompanying consolidated balance sheets of
Illumina, Inc. as of January 3, 2010 and December 28,
2008, and the related consolidated statements of operations,
stockholders equity, and cash flows for each of the three
years in the period ended January 3, 2010. Our audits also
included the financial statement schedule listed in the Index at
Item 15(a)(2). These financial statements and schedule are
the responsibility of the Companys management. Our
responsibility is to express an opinion on these financial
statements and schedule based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above
present fairly, in all material respects, the consolidated
financial position of Illumina, Inc., at January 3, 2010
and December 28, 2008, and the consolidated results of its
operations and its cash flows for each of the three years in the
period ended January 3, 2010, in conformity with
U.S. generally accepted accounting principles. Also, in our
opinion, the related financial statement schedule, when
considered in relation to the basic financial statements taken
as a whole, presents fairly, in all material respects, the
information set forth therein.
As discussed in Note 1 to the consolidated financial
statements, the Company adopted Financial Accounting Standards
Board Staff Position No. APB
14-1,
Accounting For Convertible Debt Instruments That May Be
Settled in Cash Upon Conversion (Including Partial Cash
Settlement) (Codified in FASB ASC Topic 470, Debt
Conversions and Other Options) effective as of
December 29, 2008 and retroactively adjusted all periods
presented in the consolidated financial statements for this
change. Also described in Note 1 is the Companys 2009
change in its method of accounting for revenue recognition with
the adoption of amendments to the Financial Accounting Standards
Board Accounting Standards Codification resulting from
Accounting Standards Update No.
2009-13,
Multiple-Deliverable Revenue Arrangements, and Accounting
Standards Update
No. 2009-14,
Certain Revenue Arrangements That Include Software
Elements, both adopted effective December 29, 2008.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States),
Illumina, Inc.s internal control over financial reporting
as of January 3, 2010, based on criteria established in
Internal Control-Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission and our
report dated February 26, 2010 expressed an unqualified
opinion thereon.
San Diego, California
February 26, 2010
F-2
ILLUMINA,
INC.
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008(1)
|
|
|
|
(In thousands)
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
144,633
|
|
|
$
|
327,024
|
|
Short-term investments
|
|
|
548,894
|
|
|
|
313,051
|
|
Accounts receivable, net
|
|
|
157,751
|
|
|
|
133,266
|
|
Inventory, net
|
|
|
92,776
|
|
|
|
73,431
|
|
Deferred tax assets, current portion
|
|
|
20,021
|
|
|
|
8,635
|
|
Prepaid expenses and other current assets
|
|
|
17,515
|
|
|
|
14,154
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
981,590
|
|
|
|
869,561
|
|
Property and equipment, net
|
|
|
117,188
|
|
|
|
89,436
|
|
Long-term investments
|
|
|
|
|
|
|
55,900
|
|
Goodwill
|
|
|
213,452
|
|
|
|
213,452
|
|
Intangible assets, net
|
|
|
43,788
|
|
|
|
47,755
|
|
Deferred tax assets, long-term portion
|
|
|
47,371
|
|
|
|
46,242
|
|
Other assets
|
|
|
26,548
|
|
|
|
4,825
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
1,429,937
|
|
|
$
|
1,327,171
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
52,781
|
|
|
$
|
29,204
|
|
Accrued liabilities
|
|
|
98,253
|
|
|
|
80,355
|
|
Long-term debt, current portion
|
|
|
290,202
|
|
|
|
276,889
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
441,236
|
|
|
|
386,448
|
|
Other long-term liabilities
|
|
|
24,656
|
|
|
|
18,946
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Conversion option subject to cash settlement
|
|
|
99,797
|
|
|
|
123,110
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 10,000,000 shares
authorized, no shares issued at January 3, 2010 and
December 28, 2008
|
|
|
|
|
|
|
|
|
Common stock, $0.01 par value, 320,000,000 shares
authorized, 143,544,265 shares issued at January 3,
2010,
138,936,582 shares issued at December 28, 2008
|
|
|
1,436
|
|
|
|
1,389
|
|
Additional paid-in capital
|
|
|
1,637,751
|
|
|
|
1,469,770
|
|
Accumulated other comprehensive income
|
|
|
2,830
|
|
|
|
2,422
|
|
Accumulated deficit
|
|
|
(280,226
|
)
|
|
|
(352,507
|
)
|
Treasury stock, at cost (24,068,450 shares at
January 3, 2010 and 17,927,983 shares at
December 28, 2008)
|
|
|
(497,543
|
)
|
|
|
(322,407
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
864,248
|
|
|
|
798,667
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
1,429,937
|
|
|
$
|
1,327,171
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Adjusted for required retroactive adoption of authoritative
accounting guidance for convertible debt instruments that may be
settled in cash upon conversion effective December 29, 2008. |
See accompanying notes to consolidated financial statements
F-3
ILLUMINA,
INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended_
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008(1)
|
|
|
2007(1)
|
|
|
|
(In thousands, except per share amounts)
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue
|
|
$
|
627,240
|
|
|
$
|
532,390
|
|
|
$
|
326,699
|
|
Service and other revenue
|
|
|
39,084
|
|
|
|
40,835
|
|
|
|
40,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
666,324
|
|
|
|
573,225
|
|
|
|
366,799
|
|
Costs and expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue (excluding impairment of manufacturing
equipment and amortization of intangible assets)
|
|
|
190,714
|
|
|
|
192,868
|
|
|
|
119,991
|
|
Cost of service and other revenue
|
|
|
15,055
|
|
|
|
12,756
|
|
|
|
12,445
|
|
Research and development
|
|
|
140,616
|
|
|
|
99,963
|
|
|
|
73,943
|
|
Selling, general and administrative
|
|
|
176,337
|
|
|
|
148,014
|
|
|
|
101,256
|
|
Impairment of manufacturing equipment
|
|
|
|
|
|
|
4,069
|
|
|
|
|
|
Amortization of intangible assets
|
|
|
6,680
|
|
|
|
10,438
|
|
|
|
2,429
|
|
Acquired in-process research and development
|
|
|
11,325
|
|
|
|
24,660
|
|
|
|
303,400
|
|
Litigation settlements
|
|
|
|
|
|
|
|
|
|
|
54,536
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
540,727
|
|
|
|
492,768
|
|
|
|
668,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations
|
|
|
125,597
|
|
|
|
80,457
|
|
|
|
(301,201
|
)
|
Other income (expense), net:
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
11,029
|
|
|
|
12,519
|
|
|
|
16,025
|
|
Interest expense
|
|
|
(23,718
|
)
|
|
|
(22,210
|
)
|
|
|
(18,297
|
)
|
Other income (expense), net
|
|
|
1,217
|
|
|
|
1,921
|
|
|
|
(47
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other expense, net
|
|
|
(11,472
|
)
|
|
|
(7,770
|
)
|
|
|
(2,319
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
|
114,125
|
|
|
|
72,687
|
|
|
|
(303,520
|
)
|
Provision (benefit) for income taxes
|
|
|
41,844
|
|
|
|
33,271
|
|
|
|
(16,215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
72,281
|
|
|
$
|
39,416
|
|
|
$
|
(287,305
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per basic share
|
|
$
|
0.59
|
|
|
$
|
0.34
|
|
|
$
|
(2.65
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per diluted share
|
|
$
|
0.53
|
|
|
$
|
0.30
|
|
|
$
|
(2.65
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in calculating basic net income (loss) per share
|
|
|
123,154
|
|
|
|
116,855
|
|
|
|
108,308
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in calculating diluted net income (loss) per share
|
|
|
137,096
|
|
|
|
133,607
|
|
|
|
108,308
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Adjusted for required retroactive adoption of authoritative
accounting guidance for convertible debt instruments that may be
settled in cash upon conversion effective December 29, 2008. |
See accompanying notes to consolidated financial statements
F-4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
Common Stock
|
|
|
Paid-In
|
|
|
Comprehensive
|
|
|
Accumulated
|
|
|
Treasury Stock
|
|
|
Stockholders
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income
|
|
|
Deficit
|
|
|
Shares
|
|
|
Amount
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2007
|
|
|
93,714
|
|
|
$
|
938
|
|
|
$
|
339,728
|
|
|
$
|
11,294
|
|
|
$
|
(104,618
|
)
|
|
|
|
|
|
$
|
|
|
|
$
|
247,342
|
|
Components of comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(287,305
|
)
|
|
|
|
|
|
|
|
|
|
|
(287,305
|
)
|
Unrealized loss on
available-for-sale
securities, net of deferred tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,529
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,529
|
)
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
582
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
582
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(297,252
|
)
|
Issuance of common stock
|
|
|
4,654
|
|
|
|
46
|
|
|
|
30,044
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,090
|
|
Issuance of common stock for the acquisition of Solexa,
Inc.
|
|
|
26,442
|
|
|
|
264
|
|
|
|
530,460
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
530,724
|
|
Fair value of options assumed from Solexa, Inc.
|
|
|
|
|
|
|
|
|
|
|
75,334
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
75,334
|
|
Convertible note hedge
|
|
|
|
|
|
|
|
|
|
|
(139,040
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(139,040
|
)
|
Warrants issued in connection with the convertible debt issuance
|
|
|
|
|
|
|
|
|
|
|
92,440
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
92,440
|
|
Warrants exercised
|
|
|
798
|
|
|
|
8
|
|
|
|
6,067
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,075
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
33,926
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
33,926
|
|
Incremental tax benefit related to stock options exercised
|
|
|
|
|
|
|
|
|
|
|
20,086
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,086
|
|
Incremental tax benefit related to convertible debt issuance
|
|
|
|
|
|
|
|
|
|
|
54,629
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
54,629
|
|
Repurchases of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(14,819
|
)
|
|
|
(251,622
|
)
|
|
|
(251,622
|
)
|
Impact of convertible debt(1)
|
|
|
|
|
|
|
|
|
|
|
(48,805
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(48,805
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 30, 2007(1)
|
|
|
125,608
|
|
|
|
1,256
|
|
|
|
994,869
|
|
|
|
1,347
|
|
|
|
(391,923
|
)
|
|
|
(14,819
|
)
|
|
|
(251,622
|
)
|
|
|
353,927
|
|
Components of comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39,416
|
|
|
|
|
|
|
|
|
|
|
|
39,416
|
|
Unrealized gain on
available-for-sale
securities, net of deferred tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
920
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
920
|
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
(16
|
)
|
|
|
155
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,475
|
|
Issuance of common stock in conjunction with secondary offering,
net of issuance costs
|
|
|
8,050
|
|
|
|
80
|
|
|
|
342,570
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
342,650
|
|
Issuance of common stock under employee stock plans
|
|
|
4,923
|
|
|
|
49
|
|
|
|
44,281
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
44,330
|
|
Warrants exercised
|
|
|
356
|
|
|
|
4
|
|
|
|
2,987
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,991
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
47,695
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
47,695
|
|
Incremental tax benefit related to stock options exercised
|
|
|
|
|
|
|
|
|
|
|
18,501
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,501
|
|
Repurchases of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,109
|
)
|
|
|
(70,785
|
)
|
|
|
(70,785
|
)
|
Impact of convertible debt(1)
|
|
|
|
|
|
|
|
|
|
|
18,883
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,883
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 28, 2008(1)
|
|
|
138,937
|
|
|
|
1,389
|
|
|
|
1,469,770
|
|
|
|
2,422
|
|
|
|
(352,507
|
)
|
|
|
(17,928
|
)
|
|
|
(322,407
|
)
|
|
|
798,667
|
|
Components of comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72,281
|
|
|
|
|
|
|
|
|
|
|
|
72,281
|
|
Unrealized gain on
available-for-sale
securities, net of deferred tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
408
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
408
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72,689
|
|
Issuance of common stock
|
|
|
3,569
|
|
|
|
36
|
|
|
|
39,343
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39,379
|
|
Warrants exercised
|
|
|
954
|
|
|
|
10
|
|
|
|
7,566
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,576
|
|
Stock-based compensation
|
|
|
|
|
|
|
|
|
|
|
60,813
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,813
|
|
Incremental tax benefit related to stock options exercised
|
|
|
|
|
|
|
|
|
|
|
39,319
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39,319
|
|
Repurchases of common stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,140
|
)
|
|
|
(175,136
|
)
|
|
|
(175,136
|
)
|
Impact of convertible debt
|
|
|
84
|
|
|
|
1
|
|
|
|
20,940
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,941
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 3, 2010
|
|
|
143,544
|
|
|
$
|
1,436
|
|
|
$
|
1,637,751
|
|
|
$
|
2,830
|
|
|
$
|
(280,226
|
)
|
|
|
(24,068
|
)
|
|
$
|
(497,543
|
)
|
|
$
|
864,248
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Adjusted for required retroactive adoption of authoritative
accounting guidance for convertible debt instruments that may be
settled in cash upon conversion effective December 29, 2008. |
See accompanying notes to consolidated financial statements
F-5
ILLUMINA,
INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008(1)
|
|
|
2007(1)
|
|
|
|
|
|
|
(In thousands)
|
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
72,281
|
|
|
$
|
39,416
|
|
|
$
|
(287,305
|
)
|
Adjustments to reconcile net income (loss) to net cash provided
by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired in-process research and development
|
|
|
11,325
|
|
|
|
24,660
|
|
|
|
303,400
|
|
Amortization of intangible assets
|
|
|
6,680
|
|
|
|
10,438
|
|
|
|
2,429
|
|
Amortization of debt discount
|
|
|
20,286
|
|
|
|
18,883
|
|
|
|
15,335
|
|
Depreciation expense
|
|
|
24,504
|
|
|
|
17,285
|
|
|
|
11,464
|
|
Impairment of manufacturing equipment
|
|
|
|
|
|
|
4,069
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
60,811
|
|
|
|
47,688
|
|
|
|
33,746
|
|
Incremental tax benefit related to stock options exercised
|
|
|
(39,319
|
)
|
|
|
(18,501
|
)
|
|
|
(20,086
|
)
|
Deferred income taxes
|
|
|
29,704
|
|
|
|
31,533
|
|
|
|
(17,197
|
)
|
Other non-cash adjustments
|
|
|
(487
|
)
|
|
|
803
|
|
|
|
1,347
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(18,578
|
)
|
|
|
(57,672
|
)
|
|
|
(37,060
|
)
|
Inventory
|
|
|
(19,201
|
)
|
|
|
(19,560
|
)
|
|
|
(27,130
|
)
|
Prepaid expenses and other current assets
|
|
|
(3,429
|
)
|
|
|
2,322
|
|
|
|
(6,128
|
)
|
Other assets
|
|
|
(2,670
|
)
|
|
|
(1,815
|
)
|
|
|
2,612
|
|
Accounts payable
|
|
|
11,778
|
|
|
|
4,840
|
|
|
|
12,262
|
|
Litigation settlements payable
|
|
|
|
|
|
|
(54,536
|
)
|
|
|
54,536
|
|
Accrued income taxes
|
|
|
2,378
|
|
|
|
2,377
|
|
|
|
1,586
|
|
Accrued liabilities
|
|
|
17,619
|
|
|
|
29,339
|
|
|
|
15,901
|
|
Other long-term liabilities
|
|
|
814
|
|
|
|
6,313
|
|
|
|
(3,418
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
174,496
|
|
|
|
87,882
|
|
|
|
56,294
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash (paid for) obtained in acquisition, including cash paid for
transaction costs
|
|
|
(1,325
|
)
|
|
|
(24,666
|
)
|
|
|
72,075
|
|
Sale of secured convertible debentures
|
|
|
|
|
|
|
|
|
|
|
3,593
|
|
Purchases of
available-for-sale
securities
|
|
|
(694,487
|
)
|
|
|
(568,707
|
)
|
|
|
(598,383
|
)
|
Sales and maturities of
available-for-sale
securities
|
|
|
515,216
|
|
|
|
411,817
|
|
|
|
479,415
|
|
Purchase of property and equipment
|
|
|
(51,822
|
)
|
|
|
(59,693
|
)
|
|
|
(24,301
|
)
|
Investments in other entities
|
|
|
(19,900
|
)
|
|
|
|
|
|
|
|
|
Cash paid for intangible assets
|
|
|
(3,400
|
)
|
|
|
(36,000
|
)
|
|
|
(85
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(255,718
|
)
|
|
|
(277,249
|
)
|
|
|
(67,686
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments on current portion of long-term debt
|
|
|
(10,000
|
)
|
|
|
(15
|
)
|
|
|
(95
|
)
|
Proceeds from issuance of convertible debt, net of issuance costs
|
|
|
|
|
|
|
|
|
|
|
390,269
|
|
Purchase of convertible note hedges
|
|
|
|
|
|
|
|
|
|
|
(139,040
|
)
|
Proceeds from the exercise of warrants
|
|
|
7,576
|
|
|
|
2,991
|
|
|
|
98,515
|
|
Common stock repurchases
|
|
|
(175,136
|
)
|
|
|
(70,785
|
)
|
|
|
(251,622
|
)
|
Proceeds from secondary offering, net of issuance cost
|
|
|
|
|
|
|
342,650
|
|
|
|
|
|
Proceeds from issuance of common stock
|
|
|
39,379
|
|
|
|
44,330
|
|
|
|
30,179
|
|
Incremental tax benefit related to stock options exercised
|
|
|
39,319
|
|
|
|
18,501
|
|
|
|
20,086
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by financing activities
|
|
|
(98,862
|
)
|
|
|
337,672
|
|
|
|
148,292
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of foreign currency translation on cash and cash
equivalents
|
|
|
(2,307
|
)
|
|
|
3,778
|
|
|
|
(345
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(182,391
|
)
|
|
|
152,083
|
|
|
|
136,555
|
|
Cash and cash equivalents at beginning of period
|
|
|
327,024
|
|
|
|
174,941
|
|
|
|
38,386
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
144,633
|
|
|
$
|
327,024
|
|
|
$
|
174,941
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
2,437
|
|
|
$
|
2,553
|
|
|
$
|
1,378
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid (refunded) for income taxes
|
|
$
|
10,361
|
|
|
$
|
(1,653
|
)
|
|
$
|
2,581
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Adjusted for required retroactive adoption of authoritative
accounting guidance for convertible debt instruments that may be
settled in cash upon conversion effective December 29, 2008. |
See accompanying notes to consolidated financial statements
F-6
ILLUMINA,
INC.
Unless the context requires otherwise, references in this
report to Illumina, we, us,
the Company, and our refer to Illumina,
Inc. and its consolidated subsidiaries.
|
|
1.
|
Organization
and Summary of Significant Accounting Policies
|
Organization
and Business
Illumina, Inc. (the Company) is a leading developer,
manufacturer and marketer of integrated systems for the analysis
of genetic variation and biological function. Using the
Companys proprietary technologies, Illumina provides a
comprehensive line of products and services that currently serve
the sequencing, genotyping and gene expression markets and the
Company expects to enter the market for molecular diagnostics.
The Companys customers include leading genomic research
centers, pharmaceutical companies, academic institutions,
clinical research organizations and biotechnology companies.
Acquisitions
On August 1, 2008, the Company completed its acquisition of
Avantome, Inc., a development-stage company creating a low cost,
long-read sequencing technology. At the time of the acquisition,
the Company paid $25.8 million in cash, including
transaction costs, and recorded a charge of $24.7 million
for purchased in-process research and development (IPR&D).
As part of the acquisition agreement, Illumina agreed to pay
Avantomes former shareholders up to an additional
$35.0 million in contingent cash consideration based on the
achievement of certain milestones. For the year ended
January 3, 2010, the Company recorded IPR&D of
$11.3 million and compensation expense of $3.7 million
associated with these milestones. For the year ended
December 28, 2008, compensation expense of
$1.5 million was recorded associated with these milestones.
Compensation expense associated with the Avantome acquisition is
included in research and development in the consolidated
statements of operations.
On January 26, 2007, the Company completed its acquisition
of Solexa, Inc., in a
stock-for-stock
merger transaction. The Company issued 26.2 million shares
of its common stock as consideration for this merger. Based on
the estimated fair values at the acquisition date, the Company
allocated $303.4 million to IPR&D, $62.2 million
to tangible assets acquired and liabilities assumed and
$24.4 million to intangible assets. The remaining excess of
the purchase price over the fair value of net assets acquired of
$213.4 million was allocated to goodwill.
Basis
of Presentation
The consolidated financial statements of the Company have been
prepared in conformity with U.S. generally accepted
accounting principles (GAAP) and include the accounts of the
Company and its wholly-owned subsidiaries. All intercompany
transactions and balances have been eliminated in consolidation.
Fiscal
Year
The Companys fiscal year is 52 or 53 weeks ending the
Sunday closest to December 31, with quarters of 13 or
14 weeks ending the Sunday closest to March 31,
June 30, and September 30. The year ended
January 3, 2010 was 53 weeks; the years ended
December 28, 2008 and December 30, 2007 were
52 weeks.
Reclassifications
Certain prior year amounts have been reclassified to conform to
current year presentation. During the fourth quarter of 2009,
the Company determined that pre-acquisition net operating loss
carryforwards of Solexa that were included in goodwill could be
utilized by the Company. Therefore, the Company has updated the
Consolidated Financial Statements and related disclosures to
reclassify $15.3 million from goodwill to
F-7
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
long-term deferred tax assets to correctly reflect the tax
effect of Solexas pre-acquisition net operating losses
that can be utilized by the Company.
Use of
Estimates
The preparation of financial statements requires that management
make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenue and expenses and related
disclosure of contingent assets and liabilities. Actual results
could differ from those estimates.
Segment
Information
During the first quarter of 2008, the Company reorganized its
operating structure into a newly created Life Sciences Business
Unit, which includes all products and services that are
primarily related to the research market, namely the sequencing,
BeadArray, and VeraCode product lines. The Company also created
a Diagnostics Business Unit to focus on the emerging opportunity
in molecular diagnostics. For the year ended January 3,
2010, the Company had limited activity related to the
Diagnostics Business Unit and operating results were reported on
an aggregate basis to the chief operating decision maker of the
Company, the chief executive officer. Accordingly, the Company
operated in one segment for the year ended January 3, 2010.
The Company will begin reporting in two segments once revenues,
operating profit or loss, or assets of the Diagnostics Business
Unit exceed 10% of the consolidated amounts.
Cash
Equivalents and Investments
Cash equivalents are comprised of short-term, highly liquid
investments with maturities of 90 days or less from the
date of purchase.
Short-term investments consist of U.S. Treasury and
U.S. government agency securities, municipal notes,
corporate notes and bonds and commercial paper. Management
classifies short-term investments as
available-for-sale
or trading at the time of purchase and reevaluates such
classification as of each balance sheet date. All short-term
investments are recorded at estimated fair value. Unrealized
gains and losses for
available-for-sale
and trading securities are included in accumulated other
comprehensive income, a component of stockholders equity,
and other income, net, respectively. The Company evaluates its
investments to assess whether those with unrealized loss
positions are other than temporarily impaired. Impairments are
considered to be other than temporary if it is likely that the
Company will have to sell the securities before the recovery of
their cost basis and it is the Companys intent to do so.
Realized gains and losses and declines in value judged to be
other than temporary are determined based on the specific
identification method and are reported in other income
(expense), net in the consolidated statements of operations.
Included in short-term investments are the Companys
auction rate securities and a put option related to the
Companys settlement agreement with UBS that gives the
Company the right to sell its auction rate securities to
UBS AG (UBS) at par value during the period of
June 30, 2010 through July 2, 2012 (the Settlement).
These securities had previously been classified as long-term
investments; however, they were reclassified to short-term
investments in fiscal 2009 as the Company intends to exercise
its right to sell the securities back to UBS during the
Settlement period. The auction rate securities are classified as
trading securities and both the put option and the auction rate
securities are recorded at estimated fair value, with unrealized
gains and losses, if any, recognized in other income (expense),
net on the consolidated statements of operations. See
Note 3 for further detailed discussion.
F-8
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Fair
Value of Financial Instruments
The carrying amounts of financial instruments such as cash
equivalents, foreign cash accounts, accounts receivable, prepaid
expenses and other current assets, accounts payable, accrued
expenses and other current liabilities approximate the related
fair values due to the short-term maturities of these
instruments. The estimated fair value of the convertible senior
notes is determined by using available market information as of
the latest trading date prior to the Companys fiscal
year-end provided by a third party financial institution. The
par value and fair value of the Companys convertible notes
was $390.0 million and $553.2 million, respectively,
at January 3, 2010 and $400.0 million and
$473.0 million, respectively, at December 28, 2008.
Accounts
Receivable
Trade accounts receivable are recorded at the net invoice value
and are not interest bearing. The Company considers receivables
past due based on the contractual payment terms. The Company
reviews its exposure to amounts receivable and reserves specific
amounts if collectibility is no longer reasonably assured. The
Company also reserves a percentage of its trade receivable
balance based on collection history and current economic trends
that might impact the level of future credit losses. The Company
re-evaluates such reserves on a regular basis and adjusts its
reserves as needed.
Concentrations
of Risk
The Company operates in markets that are highly competitive and
rapidly changing. Significant technological changes, shifting
customer needs, the emergence of competitive products or
services with new capabilities and other factors could
negatively impact the Companys operating results.
The Company is also subject to risks related to its financial
instruments including its cash and cash equivalents, investments
and accounts receivable. Most of the Companys cash and
cash equivalents as of January 3, 2010 were deposited with
financial institutions in the United States. The Companys
investment policy restricts the amount of credit exposure to any
one issuer to 5% of the portfolio at the time of purchase and to
any one industry sector, as defined by Bloomberg
classifications, to 25% of the portfolio at the time of
purchase. There is no limit to the percentage of the portfolio
that may be maintained in securities issued by the U.S
government and money market funds. The Company has historically
not experienced significant credit losses from investments and
accounts receivable. The Company performs a regular review of
customer activity and associated credit risks.
The Companys products require customized components that
currently are available from a limited number of sources. The
Company obtains certain key components included in its products
from single vendors.
Shipments to customers outside the United States comprised 48%,
51% and 43% of the Companys revenue for the years ended
January 3, 2010, December 28, 2008 and
December 30, 2007, respectively. Customers outside the
United States represented 46% and 61% of the Companys net
accounts receivable balance as of January 3, 2010 and
December 28, 2008, respectively. Sales to territories
outside of the United States are generally denominated in
U.S. dollars. International sales entail a variety of
risks, including currency exchange fluctuations, longer payment
cycles and greater difficulty in accounts receivable collection.
The Company is also subject to general geopolitical risks, such
as political, social and economic instability and changes in
diplomatic and trade relations. The risks of international sales
are mitigated in part by the extent to which sales are
geographically distributed.
Aggregated accounts receivable from one customer comprised more
than 10% of gross customer receivable at January 3, 2010.
F-9
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Inventories
Inventories are stated at the lower of cost (on a first in,
first out basis) or market. Inventory includes raw materials and
finished goods that may be used in the research and development
process and such items are expensed as consumed or expired.
Provisions for slow moving, excess and obsolete inventories are
provided based on product life cycle and development plans,
product expiration and quality issues, historical experience and
inventory levels.
Property
and Equipment
Property and equipment are stated at cost, subject to review of
impairment, and depreciated over the estimated useful lives of
the assets (generally three to seven years) using the
straight-line method. Amortization of leasehold improvements is
computed over the shorter of the lease term or the estimated
useful life of the related assets. Maintenance and repairs are
charged to operations as incurred. When assets are sold, or
otherwise disposed of, the cost and related accumulated
depreciation are removed from the accounts and any gain or loss
is included in operating expense.
Goodwill,
Intangible Assets and Other Long-Lived Assets
Goodwill represents the excess of cost over fair value of net
assets acquired. Intangible assets include acquired technology,
customer relationships, other license agreements and licensed
technology (capitalized as part of the Affymetrix litigation).
The cost of identified intangible assets is amortized on a
straight-line basis over periods ranging from three to ten years
unless the expected benefit pattern is declining, in which case
an accelerated method is used.
The Company regularly performs reviews to determine if the
carrying values of the long-lived assets are impaired. Goodwill
and other intangible assets that have indefinite useful lives
are reviewed for impairment at least annually during the second
fiscal quarter, or more frequently if an event occurs indicating
the potential for impairment. The Company performed its annual
impairment test of goodwill in May of 2009, utilizing a test
that begins with an estimate of the fair value of the reporting
unit or intangible asset, noting no impairment and has
determined there have been no impairment indicators for goodwill
through January 3, 2010. A review of intangible assets that
have finite useful lives and other long-lived assets is
performed when an event occurs indicating the potential for
impairment. If indicators of impairment exist, the Company
assesses the recoverability of the affected long-lived assets by
determining whether the carrying amount of such assets exceeds
its estimated fair value. If impairment is indicated, the
Company compares the carrying amount to the estimated fair value
of the asset and adjusts the value of the asset accordingly.
Factors that would necessitate an impairment assessment include
a significant decline in the Companys stock price and
market capitalization compared to its net book value,
significant changes in the ability of a particular asset to
generate positive cash flows and significant changes in the
Companys strategic business objectives and utilization of
the asset.
Reserve
for Product Warranties
The Company generally provides a one-year warranty on
genotyping, gene expression and sequencing systems.
Additionally, the Company provides a warranty on its consumable
sales through the expiry date, which generally ranges from six
to twelve months after the manufacture date. At the time revenue
is recognized, the Company establishes an accrual for estimated
warranty expenses based on historical experience as well as
anticipated product performance. This expense is recorded as a
component of cost of product revenue. Estimated warranty
expenses associated with extended maintenance contracts for
systems are recorded as a cost of service and other revenue
ratably over the term of the maintenance contract. See
Note 6 for further detailed discussion.
F-10
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Revenue
Recognition
The Companys revenue is generated primarily from the sale
of products and services. Product revenue primarily consists of
sales of arrays, reagents, flow cells and instrumentation.
Service and other revenue consists of revenue received for
performing genotyping and sequencing services, extended warranty
sales and amounts earned under research agreements with
government grants, which are recognized in the period during
which the related costs are incurred.
The Company recognizes revenue when persuasive evidence of an
arrangement exists, delivery has occurred or services have been
rendered, the sellers price to the buyer is fixed or
determinable and collectibility is reasonably assured. In
instances where final acceptance of the product or system is
required, revenue is deferred until all the acceptance criteria
have been met. All revenue is recorded net of any discounts.
Revenue for product sales is recognized generally upon shipment
and transfer of title to the customer, provided no significant
obligations remain and collection of the receivable is
reasonably assured. Revenue for genotyping and sequencing
services is recognized when earned, which is generally at the
time the genotyping or sequencing analysis data is made
available to the customer or agreed upon milestones are reached.
In order to assess whether the price is fixed or determinable,
the Company ensures there are no refund rights. If payment terms
are based on future performance, the Company defers revenue
recognition until the price becomes fixed or determinable. The
Company assesses collectibility based on a number of factors,
including past transaction history with the customer and the
creditworthiness of the customer. If the Company determines that
collection of a payment is not reasonably assured, revenue
recognition is deferred until the time collection becomes
reasonably assured, which is generally upon receipt of payment.
Sales of instrumentation generally include a standard one-year
warranty. The Company also sells separately priced maintenance
(extended warranty) contracts, which are generally for one year,
upon the expiration of the initial warranty. Revenue for
extended warranty sales is recognized ratably over the term of
the extended warranty period. Reserves are provided for
estimated product warranty expenses at the time the associated
revenue is recognized. If the Company were to experience an
increase in warranty claims or if costs of servicing its
products under warranty were greater than its estimates, gross
margins could be adversely affected.
The Company regularly enters into contracts where revenue is
derived from multiple deliverables including any mix of products
and/or
services. These products
and/or
services are generally delivered within a short time frame,
approximately three to six months, of the contract execution
date. Revenue recognition for contracts with multiple
deliverables is based on the individual units of accounting
determined to exist in the contract. A delivered item is
considered a separate unit of accounting when the delivered item
has value to the customer on a stand-alone basis. Items are
considered to have stand-alone value when they are sold
separately by any vendor or when the customer could resell the
item on a stand-alone basis.
For transactions entered into during 2009, consideration is
allocated at the inception of the contract to all deliverables
based on their relative selling price. The relative selling
price for each deliverable is determined using vendor specific
objective evidence (VSOE) of selling price or third-party
evidence of selling price if VSOE does not exist. If neither
VSOE nor third-party evidence exists, the Company uses its best
estimate of the selling price for the deliverable. See Recent
Accounting Pronouncements in Note 1 for further
information related to the Companys change in
authoritative accounting guidance for revenue recognition.
For transactions entered into prior to 2009, consideration was
generally allocated to each unit of accounting based upon its
relative fair value when objective and reliable evidence of fair
value existed for all units of accounting in an arrangement. The
fair value of an item was generally the price charged for the
product, if the item was regularly sold on a stand-alone basis.
In those instances when objective and reliable
F-11
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
evidence of fair value existed for the undelivered items but not
for the delivered items, the residual method was used to
allocate the arrangement consideration. Under the residual
method, the amount of arrangement consideration allocated to the
delivered items equaled the total arrangement consideration less
the aggregate fair value of the undelivered items. When the
Company was unable to establish stand-alone value for delivered
items or when fair value of undelivered items had not been
established, revenue was deferred until all elements were
delivered and services had been performed, or until fair value
could objectively be determined for any remaining undelivered
elements.
In order to establish VSOE of selling price, the Company must
regularly sell the product
and/or
service on a standalone basis with a substantial majority priced
within a relatively narrow range. VSOE of selling price is
usually the midpoint of that range. If there is not a sufficient
number of standalone sales and VSOE of selling price cannot be
determined, then the Company considers whether third party
evidence can be used to establish selling price. Due to the lack
of similar products and services sold by other companies within
the industry, the Company has rarely established selling price
using third-party evidence. If neither VSOE nor third party
evidence of selling price exists, the Company determines its
best estimate of selling price using average selling prices over
a rolling 12 month period as well as market conditions. If
the product or service has no history of sales, the Company
relies upon prices set by the Companys pricing committee
adjusted for applicable discounts.
The Company recognizes revenue for delivered elements only when
it determines there are no uncertainties regarding customer
acceptance. Changes in the allocation of the sales price between
delivered and undelivered elements can impact the timing of
revenue recognition but do not change the total revenue
recognized on any arrangement.
Fair
Value Measurements
The Company determines the fair value of its assets and
liabilities based on the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure
fair value maximize the use of observable inputs and minimize
the use of unobservable inputs. The Company uses a fair value
hierarchy with three levels of inputs, of which the first two
are considered observable and the last unobservable, to measure
fair value:
|
|
|
|
|
Level 1 Quoted prices in active markets
for identical assets or liabilities.
|
|
|
|
Level 2 Inputs, other than Level 1,
that are observable, either directly or indirectly, such as
quoted prices for similar assets or liabilities; quoted prices
in markets that are not active; or other inputs that are
observable or can be corroborated by observable market data for
substantially the full term of the assets or liabilities.
|
|
|
|
Level 3 Unobservable inputs that are
supported by little or no market activity and that are
significant to the fair value of the assets or liabilities.
|
The following table presents the Companys fair value
hierarchy for assets measured at fair value on a recurring basis
as of January 3, 2010 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
Debt securities in government sponsored entities
|
|
$
|
289,701
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
289,701
|
|
Corporate debt securities
|
|
|
192,821
|
|
|
|
|
|
|
|
|
|
|
|
192,821
|
|
Auction rate securities
|
|
|
|
|
|
|
|
|
|
|
54,900
|
|
|
|
54,900
|
|
U.S. Treasury securities
|
|
|
11,472
|
|
|
|
|
|
|
|
|
|
|
|
11,472
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets measured at fair value
|
|
$
|
493,994
|
|
|
$
|
|
|
|
$
|
54,900
|
|
|
$
|
548,894
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-12
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Shipping
and Handling Expenses
Shipping and handling expenses are included in cost of product
revenue and totaled $4.8 million, $3.7 million and
$2.2 million for the years ended January 3, 2010,
December 28, 2008 and December 30, 2007, respectively.
Research
and Development
Research and development expenses consist of costs incurred for
internal and grant-sponsored research and development. Research
and development expenses include salaries, contractor fees,
facilities costs, utilities and allocations of benefits.
Expenditures relating to research and development are expensed
in the period incurred.
Advertising
Costs
The Company expenses advertising costs as
incurred. Advertising costs were
$4.2 million, $3.4 million and $2.8 million for
the years ended January 3, 2010, December 28, 2008 and
December 30, 2007, respectively.
Leases
Leases are reviewed and classified as capital or operating at
their inception. For leases that contain rent escalations, the
Company records the total rent payable on a straight-line basis
over the term of the lease, which includes the construction
build-out period but excludes lease extension periods. The
difference between rent payments and straight-line rent expense
is recorded in other long-term liabilities. Landlord allowances
are also recorded in other long-term liabilities, which are
amortized on a straight-line basis over the lease term as a
reduction to rent expense.
Income
Taxes
The provision for income taxes is computed using the asset and
liability method, under which deferred tax assets and
liabilities are recognized for the expected future tax
consequences of temporary differences between the financial
reporting and tax bases of assets and liabilities, and for the
expected future tax benefit to be derived from tax loss and
credit carryforwards. Deferred tax assets and liabilities are
determined using the enacted tax rates in effect for the years
in which those tax assets are expected to be realized. The
effect of a change in tax rates on deferred tax assets and
liabilities is recognized in the provision for income taxes in
the period that includes the enactment date.
Deferred tax assets are regularly assessed to determine the
likelihood they will be recovered from future taxable income. A
valuation allowance is established when the Company believes it
is more likely than not the future realization of all or some of
a deferred tax asset will not be achieved. In evaluating the
ability to recover deferred tax assets within the jurisdiction
which they arise the Company considers all available positive
and negative evidence. Factors reviewed include the cumulative
pre-tax book income for the past three years, scheduled
reversals of deferred tax liabilities, history of earnings and
reliable forecasting, projections of pre-tax book income over
the foreseeable future, and the impact of any feasible and
prudent tax planning strategies.
The Company recognizes excess tax benefits associated with
share-based compensation to stockholders equity only when
realized. When assessing whether excess tax benefits relating to
share-based compensation have been realized, the Company follows
the
with-and-without
approach excluding any indirect effects of the excess tax
deductions. Under this approach, excess tax benefits related to
share-based compensation are not deemed to be realized until
after the utilization of all other tax benefits available to the
Company.
F-13
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company recognizes the impact of a tax position in the
financial statements only if that position is more likely than
not of being sustained upon examination by taxing authorities,
based on the technical merits of the position. Any interest and
penalties related to uncertain tax positions will be reflected
in income tax expense.
Functional
Currency
Prior to the third quarter of 2008, the Company identified the
local currency as the functional currency in each of its foreign
subsidiaries, with all translation adjustments recorded as part
of other comprehensive income. Beginning in the third quarter of
2008, the Company reorganized its international structure to
execute a more efficient relationship between product
development, product manufacturing and sales. This
reorganization increased the foreign subsidiaries
dependence on the U.S. entity for management decisions,
financial support, production assets and inventory, thereby
making the foreign subsidiaries a direct and integral component
of the U.S. entitys operations. As a result, the
Company reassessed the primary economic environment of its
foreign subsidiaries, resulting in a U.S. dollar functional
currency determination. Beginning in the third quarter of 2008,
the Company remeasures its foreign subsidiaries assets and
liabilities and revenue and expense accounts related to monetary
assets and liabilities to the U.S. dollar and records the
net gains or losses resulting from remeasurement in other income
(expense), net in the consolidated statements of operations.
Gains resulting from remeasurement were $0.4 million and
$1.9 million for the years ended January 3, 2010 and
December 28, 2008, respectively. There were no gains or
losses resulting from remeasurement in the year ended
December 30, 2007.
Derivatives
The Company is exposed to foreign exchange rate risks in the
normal course of business. To manage a portion of the accounting
exposure resulting from changes in foreign currency exchange
rates, the Company enters into foreign exchange contracts to
hedge monetary assets and liabilities that are denominated in
currencies other than the functional currency of its
subsidiaries. These foreign exchange contracts are carried at
fair value and do not qualify for hedge accounting treatment and
are not designated as hedging instruments. Changes in the value
of the derivative are recognized in other income (expense), net,
in the consolidated statements of operations for the current
period, along with an offsetting gain or loss on the underlying
assets or liabilities.
Stock-Based
Compensation
The Company uses the Black-Scholes-Merton option-pricing model
to estimate the fair value of stock options granted and stock
purchases under the Employee Stock Purchase Plan (ESPP). This
model incorporates various assumptions including expected
volatility, expected option life, expected dividends, and the
risk-free interest rates. The Company determines volatility by
equally weighing the historical and implied volatility of the
Companys common stock. The historical volatility of the
Companys common stock over the most recent period is
generally commensurate with the estimated expected life of the
Companys stock options, adjusted for the impact of unusual
fluctuations not reasonably expected to recur and other relevant
factors. The implied volatility is calculated from the implied
market volatility of exchange-traded call options on the
Companys common stock. The expected life of an award is
based on historical forfeiture experience, exercise activity,
and on the terms and conditions of the stock awards granted to
employees.
F-14
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The assumptions used for the specified reporting periods and the
resulting estimates of weighted-average fair value per share of
options granted and for stock purchases under the ESPP during
those periods are as follows:
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
January 3,
|
|
December 28,
|
|
December 30,
|
|
|
2010
|
|
2008
|
|
2007
|
|
Interest rate stock options
|
|
1.69 - 1.97%
|
|
2.31 - 3.52%
|
|
3.68 - 4.90%
|
Interest rate stock purchases
|
|
0.28 - 2.90%
|
|
1.88 - 4.71%
|
|
4.71 -4.86%
|
Volatility stock options
|
|
55 - 58%
|
|
51 - 65%
|
|
55-70%
|
Volatility stock purchases
|
|
48 - 58%
|
|
53 - 69%
|
|
69 - 76%
|
Expected life stock options
|
|
5 years
|
|
5 - 6 years
|
|
6 years
|
Expected life stock purchases
|
|
6 - 12 months
|
|
6 - 12 months
|
|
6 - 12 months
|
Expected dividend yield
|
|
0%
|
|
0%
|
|
0%
|
Weighted average fair value per share of options granted
|
|
$14.79
|
|
$18.31
|
|
$12.86
|
Weighted average fair value per share of employee stock purchases
|
|
$9.24
|
|
$11.45
|
|
$7.33
|
The fair value of restricted stock units granted during the
years ended January 3, 2010 and December 28, 2008 was
based on the market price of our common stock on the date of
grant.
As of January 3, 2010, $153.1 million of total
unrecognized compensation cost related to stock options,
restricted stock and ESPP shares issued to date is expected to
be recognized over a weighted-average period of approximately
1.67 years.
Total share-based compensation expense for employee stock
options and stock purchases consists of the following (in
thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
Cost of product revenue
|
|
$
|
4,776
|
|
|
$
|
4,710
|
|
|
$
|
4,045
|
|
Cost of service and other revenue
|
|
|
514
|
|
|
|
400
|
|
|
|
279
|
|
Research and development
|
|
|
19,960
|
|
|
|
14,086
|
|
|
|
10,016
|
|
Selling, general and administrative
|
|
|
35,561
|
|
|
|
28,492
|
|
|
|
19,406
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation expense before taxes
|
|
|
60,811
|
|
|
|
47,688
|
|
|
|
33,746
|
|
Related income tax benefits
|
|
|
(20,121
|
)
|
|
|
(15,844
|
)
|
|
|
(11,005
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation expense, net of taxes
|
|
$
|
40,690
|
|
|
$
|
31,844
|
|
|
$
|
22,741
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net share-based compensation expense per share of common stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.33
|
|
|
$
|
0.27
|
|
|
$
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
$
|
0.30
|
|
|
$
|
0.24
|
|
|
$
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
Income (Loss) per Share
On July 22, 2008, the Company announced a
two-for-one
stock split in the form of a 100% stock dividend with a record
date of September 10, 2008 and a distribution date of
September 22, 2008. Share and per share amounts have been
restated to reflect the stock split for all periods presented.
F-15
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Basic net income or loss per share is computed by dividing net
income or loss by the weighted-average number of common shares
outstanding during the reporting period. Diluted net income per
share is computed by dividing net income by the weighted average
number of common shares outstanding during the reporting period
increased to include dilutive potential common shares using the
treasury stock method. Dilutive potential common shares consist
of stock options with combined exercise prices and unrecognized
compensation expense that are less than the average market price
of the Companys common stock, restricted stock units with
unrecognized compensation expense, convertible debt when the
average market price of the Companys common stock is above
the conversion price of $21.83 and warrants with exercise prices
that are less than the average market price of the
Companys common stock. Under the treasury stock method,
the amount that must be paid to exercise stock options and
warrants, the amount of compensation expense for future services
that the Company has not yet recognized for stock options and
restricted stock units and the amount of tax benefits that will
be recorded in additional paid-in capital when the awards become
deductible are assumed to be used to repurchase shares. In loss
periods, basic net loss per share and diluted net loss per share
are identical since the effect of dilutive potential common
shares is anti-dilutive and therefore excluded.
The following table presents the calculation of weighted-average
shares used to calculate basic and diluted net income (loss) per
share (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
Weighted-average shares outstanding
|
|
|
123,154
|
|
|
|
116,855
|
|
|
|
108,328
|
|
Less: Weighted-average shares of common stock subject to
repurchase
|
|
|
|
|
|
|
|
|
|
|
(20
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used in calculating basic net income
(loss) per share
|
|
|
123,154
|
|
|
|
116,855
|
|
|
|
108,308
|
|
Plus: Effect of dilutive Convertible Senior Notes
|
|
|
6,497
|
|
|
|
6,653
|
|
|
|
|
|
Plus: Effect of dilutive equity awards
|
|
|
4,335
|
|
|
|
5,373
|
|
|
|
|
|
Plus: Effect of dilutive warrants sold in connection with the
Convertible Senior Notes
|
|
|
1,566
|
|
|
|
2,487
|
|
|
|
|
|
Plus: Effect of dilutive warrants assumed in the acquisition of
Solexa
|
|
|
1,544
|
|
|
|
2,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used in calculating diluted net income
(loss) per share
|
|
|
137,096
|
|
|
|
133,607
|
|
|
|
108,308
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares excluded from calculation due to
anti-dilutive effect
|
|
|
924
|
|
|
|
370
|
|
|
|
42,882
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive
Income
Comprehensive income (loss) is comprised of net income (loss)
and other comprehensive income (loss). Other comprehensive
income (loss) includes unrealized gains and losses on the
Companys
available-for-sale
securities and foreign currency translation adjustments. The
Company has disclosed comprehensive income as a component of
stockholders equity.
F-16
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The components of accumulated other comprehensive income are as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008
|
|
|
Foreign currency translation adjustments
|
|
$
|
1,338
|
|
|
$
|
1,338
|
|
Unrealized gain on
available-for-sale
securities, net of deferred tax
|
|
|
1,492
|
|
|
|
1,084
|
|
|
|
|
|
|
|
|
|
|
Total other comprehensive income
|
|
$
|
2,830
|
|
|
$
|
2,422
|
|
|
|
|
|
|
|
|
|
|
Recent
Accounting Pronouncements
Adopted
Accounting Pronouncements
Convertible
Debt Instruments
In May 2008, the Financial Accounting Standards Board (FASB)
issued authoritative guidance for convertible debt instruments
that may be settled in cash upon conversion. The Company adopted
the guidance effective December 29, 2008, impacting the
accounting for the Companys convertible senior notes by
requiring the Company to account separately for the liability
and equity components of the convertible debt. The liability
component is measured at its estimated fair value such that the
effective interest expense associated with the convertible debt
reflects the issuers borrowing rate at the date of
issuance for similar debt instruments without the conversion
feature. The difference between the cash proceeds associated
with the convertible debt and this estimated fair value is
recorded as a debt discount and amortized to interest expense
over the life of the convertible debt using the effective
interest rate method. Upon application of this guidance, the
only change to diluted earnings per share resulted from the
effects of increased interest expense and the associated tax
effects. The guidance requires retrospective application to the
terms of instruments as they existed for all periods presented.
See Note 7 for information on the impact of our adoption of
the guidance and the assumptions we used to estimate the fair
value of the liability component.
Derivatives
In June 2008, the FASB ratified authoritative guidance
addressing the accounting for certain instruments (or embedded
features) determined to be indexed to an entitys own
stock. This guidance provides that an entity should use a
two-step approach to evaluate whether an equity-linked financial
instrument (or embedded feature) is indexed to its own stock,
including evaluating the instruments contingent exercise
and settlement provisions. The Company adopted this guidance
effective December 29, 2008, requiring the Company to
perform additional analyses on both its freestanding equity
derivatives and embedded equity derivative features. However,
the adoption of this guidance did not have a material effect on
the Companys consolidated financial statements.
Fair
Value of Financial Instruments
In April 2009, the FASB issued additional authoritative guidance
on the fair value of financial instruments, which provides:
|
|
|
|
|
further provisions on estimating fair value when the markets
become inactive and quoted prices reflect distressed
transactions;
|
|
|
|
extended disclosure requirements for interim financial
statements regarding the fair value of financial
instruments; and
|
|
|
|
new criteria for recording impairment charges on investments in
debt instruments.
|
F-17
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company adopted the guidance on a prospective basis in the
interim period ended June 28, 2009 without material impact
on the Companys consolidated financial statements. Refer
to Note 3 for further detailed discussion on the fair value
of financial instruments.
Accounting
for Subsequent Events
In May 2009, the FASB issued authoritative guidance related to
general standards of accounting for and disclosure of events
that occur after the balance sheet date but before financial
statements are issued or are available to be issued. The Company
adopted this guidance in the interim period ended June 28,
2009 without material impact on the Companys consolidated
financial statements.
FASB
Codification
In June 2009, the FASB issued authoritative guidance for the
FASB Codification to become the source of authoritative,
nongovernmental GAAP. The Codification did not change GAAP but
reorganizes the literature. The Company adopted this guidance in
the interim period ended September 27, 2009 without
material impact on the Companys consolidated financial
statements.
Revenue
Recognition
In September 2009, the FASB ratified authoritative accounting
guidance regarding revenue recognition for arrangements with
multiple deliverables. The guidance affects the determination of
separate units of accounting in arrangements with multiple
deliverables and the allocation of transaction consideration to
each of the identified units of accounting. Previously, a
delivered item was considered a separate unit of accounting when
it had value to the customer on a stand-alone basis and there
was objective and reliable evidence of the fair value of the
undelivered items. The new guidance eliminates the requirement
for objective and reliable evidence of fair value to exist for
the undelivered items in order for a delivered item to be
treated as a separate unit of accounting. The guidance also
requires arrangement consideration to be allocated at the
inception of the arrangement to all deliverables using the
relative-selling-price method and eliminates the use of the
residual method of allocation. Under the relative-selling-price
method, the selling price for each deliverable is determined
using VSOE of selling price or third-party evidence of selling
price if VSOE does not exist. If neither VSOE nor third-party
evidence of selling price exists for a deliverable, the guidance
requires an entity to determine the best estimate of the selling
price.
The Company adopted the guidance on a prospective basis in the
interim period ended September 27, 2009. Prospective
application required the Company to apply the guidance to all
revenue arrangements entered into or materially modified since
the beginning of fiscal 2009. This prospective application had
no impact on the Companys consolidated financial
statements for the interim periods ended March 29, 2009 and
June 28, 2009. During the third and fourth quarter of 2009,
the Company recorded additional revenue of $2.3 million and
$5.7 million respectively, which would have been deferred
under previous accounting guidance. In future interim and fiscal
year periods, the adoption of this guidance may have a material
impact on the Companys financial results to the extent the
Company enters into arrangements with multiple deliverables and
does not have VSOE or third party evidence of selling price for
material undelivered elements. Refer to the Summary of
Significant Accounting Principles in Note 1 for further
information on the Companys revenue recognition policies.
In September 2009, the FASB also ratified authoritative
accounting guidance requiring the sales of all tangible products
containing both software and non-software components that
function together to deliver the products essential
functionality to be excluded from the scope of the software
revenue guidance. The Company adopted the guidance on a
prospective basis during the three months ended
September 27, 2009 effective for all periods in 2009. Prior
to the adoption of this guidance, the Company assessed all
software items included in the Companys product offerings
to be incidental to the product itself and, therefore,
F-18
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
excluded all sales from the scope of the related software
revenue guidance. As a result, the adoption of this guidance had
no impact on the Companys consolidated financial
statements.
Definition
of a Business
During 2009, the FASB revised guidance related to business
combinations, which changed the definition of a business.
Previously, a business was defined as having three elements:
(i) inputs, (ii) processes applied to those inputs,
and (iii) outputs. The new guidance broadens the definition
and no longer requires the third element to be present for a set
of activities and assets to be considered a business. The
Company has adopted this guidance for the interim period ending
January 3, 2010. The adoption of this guidance did not have
a material impact on the Companys consolidated financial
statements.
Fair
Value of Liabilities
In August 2009, the FASB issued authoritative guidance related
to measuring liabilities at fair value when a quoted price in an
active market is not available. This guidance is effective for
reporting periods beginning after August 28, 2009. The
Company has adopted this guidance in the interim period ending
January 3, 2010. The adoption of this guidance did not have
a material impact on the Companys consolidated financial
statements.
New
Accounting Pronouncements
Variable
Interest Entities
In June 2009, the FASB issued authoritative guidance that amends
the evaluation criteria to identify the primary beneficiary of a
variable interest entity and requires a quarterly reassessment
of the treatment of such entities. The guidance also requires
additional disclosures about an enterprises involvement in
a variable interest entity. The Company will adopt this guidance
in the first interim period of fiscal 2010 and is currently
evaluating the impact of the pending adoption on the
consolidated financial statements.
|
|
2.
|
Balance
Sheet Account Details
|
Accounts receivable consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008
|
|
|
Accounts receivable from product and service sales
|
|
$
|
157,536
|
|
|
$
|
132,564
|
|
Other receivables
|
|
|
1,613
|
|
|
|
1,840
|
|
|
|
|
|
|
|
|
|
|
|
|
|
159,149
|
|
|
|
134,404
|
|
Allowance for doubtful accounts
|
|
|
(1,398
|
)
|
|
|
(1,138
|
)
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
157,751
|
|
|
$
|
133,266
|
|
|
|
|
|
|
|
|
|
|
Inventory, net, consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008
|
|
|
Raw materials
|
|
$
|
39,144
|
|
|
$
|
32,501
|
|
Work in process
|
|
|
51,670
|
|
|
|
34,063
|
|
Finished goods
|
|
|
1,962
|
|
|
|
6,867
|
|
|
|
|
|
|
|
|
|
|
Total inventory, net
|
|
$
|
92,776
|
|
|
$
|
73,431
|
|
|
|
|
|
|
|
|
|
|
F-19
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Property and equipment consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008
|
|
|
Leasehold improvements
|
|
$
|
55,322
|
|
|
$
|
26,637
|
|
Manufacturing and laboratory equipment
|
|
|
92,956
|
|
|
|
83,317
|
|
Computer equipment and software
|
|
|
37,071
|
|
|
|
27,490
|
|
Furniture and fixtures
|
|
|
5,993
|
|
|
|
4,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
191,342
|
|
|
|
141,611
|
|
Accumulated depreciation and amortization
|
|
|
(74,154
|
)
|
|
|
(52,175
|
)
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
117,188
|
|
|
$
|
89,436
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense was $24.5 million, $17.3 million
and $11.5 million for the years ended January 3, 2010,
December 28, 2008 and December 30, 2007, respectively.
Accrued liabilities consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008
|
|
|
Compensation
|
|
$
|
32,487
|
|
|
$
|
30,330
|
|
Short-term deferred revenue
|
|
|
27,445
|
|
|
|
15,862
|
|
Taxes
|
|
|
12,109
|
|
|
|
9,456
|
|
Reserve for product warranties
|
|
|
10,215
|
|
|
|
8,203
|
|
Customer deposits
|
|
|
6,121
|
|
|
|
6,583
|
|
Accrued royalties
|
|
|
2,552
|
|
|
|
2,695
|
|
Legal and other professional fees
|
|
|
1,818
|
|
|
|
1,708
|
|
Other
|
|
|
5,506
|
|
|
|
5,518
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
98,253
|
|
|
$
|
80,355
|
|
|
|
|
|
|
|
|
|
|
F-20
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
3.
|
Short-term
investments
|
The following is a summary of short-term investments (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 3, 2010
|
|
|
|
|
|
|
Gross
|
|
|
Gross
|
|
|
|
|
|
|
Amortized
|
|
|
Unrealized
|
|
|
Unrealized
|
|
|
Estimated
|
|
|
|
Cost
|
|
|
Gains
|
|
|
Losses
|
|
|
Fair Value
|
|
|
Available-for-sale
securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities in government sponsored entities
|
|
$
|
289,101
|
|
|
$
|
702
|
|
|
$
|
(102
|
)
|
|
$
|
289,701
|
|
Corporate debt securities
|
|
|
190,949
|
|
|
|
2,039
|
|
|
|
(166
|
)
|
|
|
192,822
|
|
U.S. treasury securities
|
|
|
11,487
|
|
|
|
12
|
|
|
|
(28
|
)
|
|
|
11,471
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
available-for-sale
securities
|
|
|
491,537
|
|
|
|
2,753
|
|
|
|
(296
|
)
|
|
|
493,994
|
|
Trading securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Auction rate securities
|
|
|
54,900
|
|
|
|
|
|
|
|
(6,129
|
)
|
|
|
48,771
|
|
Put option
|
|
|
|
|
|
|
6,129
|
|
|
|
|
|
|
|
6,129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total trading securities
|
|
|
54,900
|
|
|
|
6,129
|
|
|
|
(6,129
|
)
|
|
|
54,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total short-term investments
|
|
$
|
546,437
|
|
|
$
|
8,882
|
|
|
$
|
(6,425
|
)
|
|
$
|
548,894
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 28, 2008
|
|
|
|
|
|
|
Gross
|
|
|
Gross
|
|
|
|
|
|
|
Amortized
|
|
|
Unrealized
|
|
|
Unrealized
|
|
|
Estimated
|
|
|
|
Cost
|
|
|
Gains
|
|
|
Losses
|
|
|
Fair Value
|
|
|
Available-for-sale
securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities in government sponsored entities
|
|
$
|
218,964
|
|
|
$
|
1,544
|
|
|
$
|
|
|
|
$
|
220,508
|
|
Corporate debt securities
|
|
|
92,301
|
|
|
|
547
|
|
|
|
(305
|
)
|
|
|
92,543
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
311,265
|
|
|
$
|
2,091
|
|
|
$
|
(305
|
)
|
|
$
|
313,051
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Available-For-Sale
Securities
As of January 3, 2010, the Company had 38
available-for-sale
securities in a gross unrealized loss position, all of which had
been in such position for less than twelve months. All
impairments are not considered other than temporary as it is
likely the Company will not have to sell any securities before
the recovery of their cost basis and it is not the
Companys intent to do so. The following table shows the
fair values and the gross unrealized losses of the
Companys
available-for-sale
securities that were in an unrealized loss position at
January 3, 2010 and December 28, 2008 aggregated by
investment category (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 3, 2010
|
|
|
December 28, 2008
|
|
|
|
|
|
|
Gross
|
|
|
|
|
|
Gross
|
|
|
|
|
|
|
Unrealized
|
|
|
|
|
|
Unrealized
|
|
|
|
Fair Value
|
|
|
Losses
|
|
|
Fair Value
|
|
|
Losses
|
|
|
Government sponsored entities
|
|
$
|
73,783
|
|
|
$
|
(102
|
)
|
|
$
|
|
|
|
$
|
|
|
Corporate debt securities
|
|
|
26,488
|
|
|
|
(166
|
)
|
|
|
19,240
|
|
|
|
(305
|
)
|
U.S. treasury securities
|
|
|
4,471
|
|
|
|
(28
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
104,742
|
|
|
$
|
(296
|
)
|
|
$
|
19,240
|
|
|
$
|
(305
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-21
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Realized gains and losses are determined based on the specific
identification method and are reported in other income
(expense), net in the consolidated statements of operations.
Gross realized losses on sales of
available-for-sale
securities were immaterial for the years ended January 3,
2010, December 28, 2008 and December 30, 2007. Gross
realized gains on sales of
available-for-sale
securities totaled $1.0 million and $0.6 million for
the years ended January 3, 2010 and December 28, 2008
respectively, and were immaterial for the year ended
December 30, 2007.
Contractual maturities of
available-for-sale
securities at January 3, 2010 were as follows (in
thousands):
|
|
|
|
|
|
|
Estimated
|
|
|
|
Fair Value
|
|
|
Due within one year
|
|
$
|
169,671
|
|
After one but within five years
|
|
|
324,323
|
|
|
|
|
|
|
Total
|
|
$
|
493,994
|
|
|
|
|
|
|
Trading
Securities
At January 3, 2010, the Companys trading securities
consisted of $54.9 million (at cost) in auction rate
securities issued primarily by municipalities and universities.
The auction rate securities are held in a brokerage account with
UBS Financial Services, Inc., a subsidiary of UBS. These
securities are debt instruments with a long-term maturity and
with an interest rate that is reset in short intervals through
auctions.
The markets for auction rate securities effectively ceased when
the vast majority of auctions failed in February 2008,
preventing investors from selling these securities. As of
January 3, 2010, the securities continued to fail auction
and remained illiquid. Changes in the fair value of the
Companys auction rate securities from December 28,
2008 through January 3, 2010 are as follows (in thousands):
|
|
|
|
|
Fair value as of December 28, 2008
|
|
$
|
47,235
|
|
Redeemed by issuer
|
|
|
(1,000
|
)
|
Unrealized Gain(1)
|
|
|
2,536
|
|
|
|
|
|
|
Fair value as of January 3, 2010
|
|
$
|
48,771
|
|
|
|
|
|
|
|
|
|
(1) |
|
Unrealized gains and losses associated with the Companys
auction rate securities are classified as other income
(expense), net in the consolidated statements of operations for
the year ended January 3, 2010. |
In determining the fair value of the Companys auction rate
securities, the Company considered trades in the secondary
market. However, due to the auction failures of the auction rate
securities in the marketplace and the lack of trading in the
secondary market of these instruments, there was insufficient
observable auction rate security market information available to
directly determine the fair value of the Companys
investments. As a result, the value of these securities and
resulting unrealized gain was determined using Level 3
hierarchical inputs. These inputs include managements
assumptions of pricing by market participants, including
assumptions about risk. The Company used the concepts of fair
value based on estimated discounted future cash flows of
interest income over a projected 17 year period, which is
reflective of the weighted average life of the student loans in
the underlying trust. In preparing this model, the Company used
historical data of the rates upon which a majority of the
auction rate securities contractual rates were based, such
as the LIBOR and average trailing twelve-month
90-day
treasury interest rate spreads, to estimate future interest
rates. The Company also considered the discount factors, taking
into account the credit ratings of the auction rate securities,
using a range of discount rates from 5.9% to 7.2%. The Company
obtained information from multiple sources, including UBS, to
determine a reasonable range of assumptions to use in valuing
the auction rate securities. The Companys model was
corroborated by a separate comparable cash flow analysis
prepared by UBS. To understand the sensitivity of the
Companys valuation, the liquidity factor and estimated
F-22
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
remaining life was varied. Variations in those results were
evaluated and it was determined the factors and valuation method
chosen were reasonable and representative of the Companys
auction rate security portfolio.
As a result of the auction rate failures, various regulatory
agencies initiated investigations into the sales and marketing
practices of several banks and broker-dealers, including UBS,
which sold auction rate securities, alleging violations of
federal and state laws. Along with several other broker-dealers,
UBS subsequently reached a settlement with the federal and state
regulators that required them to repurchase auction rate
securities from certain investors at par at some future date. In
November 2008, the Company signed a settlement agreement
granting the Company an option to sell its auction rate
securities at par value to UBS during the period of
June 30, 2010 through July 2, 2012 (the Settlement).
In accepting the Settlement, the Company released UBS from any
claims relating to the marketing and sale of auction rate
securities. Although the Company expects to sell its auction
rate securities under the Settlement, if the Settlement is not
exercised before July 2, 2012, it will expire and UBS will
have no further rights or obligation to buy the Companys
auction rate securities. In lieu of the acceptance of the
Settlement, the auction rate securities will continue to accrue
interest as determined by the auction process or the terms
outlined in the prospectus of the auction rate securities if the
auction process fails. In addition to offering to repurchase the
Companys auction rate securities, as part of the
Settlement, UBS has agreed to provide the Company with a
no net cost loan up to 75% of the par value of the
auction rate securities until June 30, 2010. According to
the terms of the Settlement, the interest rate on the loan will
approximate the weighted average interest or dividend rate
payable to the Company by the issuer of any auction rate
securities pledged as collateral.
UBSs obligations under the Settlement are not secured by
its assets and do not require UBS to obtain any financing to
support its performance obligations under the Settlement. UBS
has disclaimed any assurance that it will have sufficient
financial resources to satisfy its obligations under the
Settlement.
To account for the Settlement, the Company recorded a separate
freestanding asset (put option) of $8.7 million and
recognized a corresponding gain in earnings during the fourth
quarter of 2008. Changes in the fair value of the Companys
put option from December 28, 2008 through January 3,
2010 are as follows (in thousands):
|
|
|
|
|
Fair value as of December 28, 2008
|
|
$
|
8,665
|
|
Unrealized loss(1)
|
|
|
(2,536
|
)
|
|
|
|
|
|
Fair value as of January 3, 2010
|
|
$
|
6,129
|
|
|
|
|
|
|
|
|
|
(1) |
|
Unrealized gains and losses associated with the Companys
put option are classified as other income (expense), net in the
consolidated statements of operations for the year ended
January 3, 2010. |
Since the put option does not meet the definition of a
derivative instrument, the Company elected to measure it at fair
value in accordance with authoritative guidance related to the
fair value option for financial assets and financial
liabilities. The Company valued the put option using a
discounted cash flow approach including estimates of interest
rates, timing and amount of cash flow, with consideration given
to UBSs financial ability to repurchase the auction rate
securities beginning June 30, 2010. These assumptions are
volatile and subject to change as the underlying sources of
these assumptions and market conditions change.
The Company will continue to recognize gains and losses in
earnings approximating the changes in the fair value of the
auction rate securities at each balance sheet date. These gains
and losses are expected to be approximately offset by changes in
the fair value of the put option.
The fair value of the auction rate securities and the put option
total $54.9 million and $55.9 million at
January 3, 2010 and December 28, 2008, respectively.
At January 3, 2010, the auction rate securities were
classified as short-term investments as the Company intends to
exercise the right to sell the securities back to UBS within the
next year. At December 28, 2008, the Company classified
these securities as long-term assets
F-23
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
since the Company believed it would not able to liquidate its
investments without significant loss during the year ended
January 3, 2010.
The Companys intangible assets are comprised primarily of
licensed technology from the Affymetrix settlement entered into
on January 9, 2008 and acquired core technology and
customer relationships from the acquisition of Solexa. As a
result of the Affymetrix settlement, the Company agreed, without
admitting liability, to make a one-time payment to Affymetrix of
$90.0 million. In return, Affymetrix agreed to dismiss with
prejudice all lawsuits it had brought against the Company, and
the Company agreed to dismiss with prejudice its counterclaims
in the relevant lawsuits. Affymetrix also agreed not to sue the
Company or its affiliates or customers for making, using or
selling any of the Companys current products, evolutions
of those products or services related to those products. In
addition, Affymetrix agreed that, for four years, it will not
sue the Company for making, using or selling the Companys
products or services that are based on future technology
developments. The covenant not to sue covers all fields other
than photolithography, the process by which Affymetrix
manufactures its arrays and a field in which the Company does
not operate.
Of the total $90.0 million payment made on January 25,
2008, $36.0 million was recorded as licensed technology and
classified as an intangible asset. The remaining
$54.0 million was charged to expense during the fourth
quarter of 2007. This allocation was determined based on the
fair value of past and estimated future revenue streams related
to the products covered by the patents previously under dispute.
The value of the licensed technology is the benefit derived,
calculated using estimated discounted cash flows and future
revenue projections, from the perpetual covenant not to sue for
damages related to the sale of the Companys current
products. The effective life of the licensed technology extends
through 2015, the final expiry date of all patents considered in
valuing the intangible asset. The related amortization is based
on the higher of the percentage of usage or the straight-line
method. The percentage of usage was determined using actual and
projected revenues generated from products covered by the
patents previously under dispute.
Acquired core technology and customer relationships are being
amortized on a straight-line basis over their effective useful
lives of ten and three years, respectively. The amortization of
the Companys intangible assets is excluded from cost of
product revenue and is separately classified as amortization of
intangible assets on the Companys consolidated statements
of operations.
The following is a summary of the Companys amortizable
intangible assets as of the respective balance sheet dates (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 3, 2010
|
|
|
December 28, 2008
|
|
|
|
Gross Carrying
|
|
|
Accumulated
|
|
|
Intangibles,
|
|
|
Gross Carrying
|
|
|
Accumulated
|
|
|
Intangibles,
|
|
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
|
Amount
|
|
|
Amortization
|
|
|
Net
|
|
|
Licensed technology
|
|
$
|
36,000
|
|
|
$
|
(11,820
|
)
|
|
$
|
24,180
|
|
|
$
|
36,000
|
|
|
$
|
(7,788
|
)
|
|
$
|
28,212
|
|
Core technology
|
|
|
23,500
|
|
|
|
(6,854
|
)
|
|
|
16,646
|
|
|
|
23,500
|
|
|
|
(4,504
|
)
|
|
|
18,996
|
|
Customer relationships
|
|
|
900
|
|
|
|
(875
|
)
|
|
|
25
|
|
|
|
900
|
|
|
|
(575
|
)
|
|
|
325
|
|
License agreements
|
|
|
4,456
|
|
|
|
(1,519
|
)
|
|
|
2,937
|
|
|
|
1,154
|
|
|
|
(932
|
)
|
|
|
222
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total intangible assets, net
|
|
$
|
64,856
|
|
|
$
|
(21,068
|
)
|
|
$
|
43,788
|
|
|
$
|
61,554
|
|
|
$
|
(13,799
|
)
|
|
$
|
47,755
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense associated with the intangible assets was
$6.7 million and $10.4 million for the years ended
January 3, 2010 and December 28, 2008, respectively.
F-24
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The estimated annual amortization of intangible assets for the
next five years is shown in the following table (in thousands).
Actual amortization expense to be reported in future periods
could differ from these estimates as a result of acquisitions,
divestitures, asset impairments and other factors.
|
|
|
|
|
2010
|
|
$
|
6,816
|
|
2011
|
|
|
6,781
|
|
2012
|
|
|
6,770
|
|
2013
|
|
|
6,755
|
|
2014
|
|
|
6,736
|
|
Thereafter
|
|
|
9,930
|
|
|
|
|
|
|
Total
|
|
$
|
43,788
|
|
|
|
|
|
|
|
|
5.
|
Impairment
of Manufacturing Equipment
|
During fiscal 2008, the Company implemented next-generation
imaging and decoding systems to be used in manufacturing. These
systems were developed to increase existing capacity and allow
the Company to transition to the Infinium High-Density (HD)
product line. As a result of this transition, the demand for
products manufactured on the previous infrastructure was reduced
and certain systems were no longer being utilized. A non-cash
impairment charge of $4.1 million was recorded in the
second quarter of fiscal 2008 for the excess machinery. This
charge is included as a separate line item in the Companys
consolidated statement of operations. There was no change to
useful lives and related depreciation expense of the remaining
assets as the Company believes these estimates are currently
reflective of the period the assets will be used in operations.
The Company generally provides a one-year warranty on
genotyping, gene expression and sequencing systems.
Additionally, the Company provides a warranty on its consumable
sales through the expiry date, which generally ranges from six
to twelve months after the manufacture date. At the time revenue
is recognized, the Company establishes an accrual for estimated
warranty expenses based on historical experience as well as
anticipated product performance. This expense is recorded as a
component of cost of product revenue. Estimated warranty
expenses associated with extended maintenance contracts for
systems are recorded as a cost of service and other revenue
ratably over the term of the maintenance contract.
Changes in the Companys reserve for product warranties
from January 1, 2007 through January 3, 2010 are as
follows (in thousands):
|
|
|
|
|
Balance as of January 1, 2007
|
|
$
|
996
|
|
Additions charged to cost of revenue
|
|
|
4,939
|
|
Repairs and replacements
|
|
|
(2,219
|
)
|
|
|
|
|
|
Balance as of December 30, 2007
|
|
|
3,716
|
|
Additions charged to cost of revenue
|
|
|
13,044
|
|
Repairs and replacements
|
|
|
(8,557
|
)
|
|
|
|
|
|
Balance as of December 28, 2008
|
|
|
8,203
|
|
Additions charged to cost of revenue
|
|
|
14,613
|
|
Repairs and replacements
|
|
|
(12,601
|
)
|
|
|
|
|
|
Balance as of January 3, 2010
|
|
$
|
10,215
|
|
|
|
|
|
|
F-25
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
7.
|
Convertible
Senior Notes
|
On February 16, 2007, the Company issued
$400.0 million principal amount of 0.625% convertible
senior notes due 2014. The net proceeds from the offering, after
deducting the initial purchasers discount and offering
expenses, were approximately $390.3 million. The Company
will pay 0.625% interest per annum on the principal amount of
the notes, payable semi-annually in arrears in cash on February
15 and August 15 of each year. The Company made interest
payments of $1.2 million on February 15, 2009 and
August 15, 2009. The notes mature on February 15, 2014.
The notes will be convertible into cash and, if applicable,
shares of the Companys common stock, $0.01 par value
per share, based on a conversion rate, subject to adjustment, of
45.8058 shares per $1,000 principal amount of notes (which
represents a conversion price of approximately $21.83 per
share), only in the following circumstances and to the following
extent: (1) during the five
business-day
period after any five consecutive
trading-day
period (the measurement period) in which the trading price per
note for each day of such measurement period was less than 97%
of the product of the last reported sale price of the
Companys common stock and the conversion rate on each such
day; (2) during any calendar quarter, if the last reported
sale price of the Companys common stock for 20 or more
trading days in a period of 30 consecutive trading days ending
on the last trading day of the immediately preceding calendar
quarter exceeds 130% of the applicable conversion price in
effect on the last trading day of the immediately preceding
calendar quarter; (3) upon the occurrence of specified
events; and (4) at any time on or after November 15,
2013 through the third scheduled trading day immediately
preceding the maturity date. The requirements of the second
condition above were satisfied during the first, second and
third quarters of 2009. Accordingly, the notes were convertible
during the period from, and including, April 1, 2009
through, and including, December 31, 2009. Additionally,
these same requirements were satisfied during the third quarter
of 2008, and, as a result, the notes were convertible during the
period from, and including, October 1, 2008 through, and
including, December 31, 2008. On December 29, 2008, a
noteholder converted notes in an aggregate principal amount of
$10.0 million. On February 4, 2009, the settlement
date, we paid the noteholder the conversion value of the notes
in cash, up to the principal amount of the notes. The excess of
the conversion value over the principal amount, totaling
$2.9 million, was paid in shares of common stock. This
equity dilution upon conversion of the notes was offset by the
reacquisition of the shares under the convertible note hedge
transactions entered into in connection with the offering of the
notes.
The hedge transaction entered with the initial purchasers
and/or their
affiliates (the hedge counterparties) entitles the Company to
purchase up to 18,322,320 shares of the Companys
common stock at a strike price of approximately $21.83 per
share, subject to adjustment. In addition, the Company sold to
these hedge counterparties warrants exercisable, on a cashless
basis, for up to 18,322,320 shares of the Companys
common stock at a strike price of $31.435 per share, subject to
adjustment. The cost of the hedge transaction that was not
covered by the proceeds from the sale of the warrants was
approximately $46.6 million and was reflected as a
reduction of additional paid-in capital. The hedge transaction
is expected to reduce the potential equity dilution upon
conversion of the notes to the extent the Company exercises the
hedge to purchase shares from the hedge counterparties to
deliver to converting noteholders. However, the warrants could
have a dilutive effect on the Companys earnings per share
to the extent that the price of the Companys common stock
exceeds the strike price of the warrants.
Impact
of the Adoption of Authoritative Guidance Related to Accounting
for Convertible Debt Instruments That May Be Settled in Cash
upon Conversion
See Note 1 for a description of the Companys adoption
of authoritative guidance related to accounting for convertible
debt instruments that may be settled in cash upon conversion.
The following table summarizes
F-26
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the effects of this new guidance on the Companys
consolidated balance sheets as of January 3, 2010 and its
consolidated statements of operations for the year ended
January 3, 2010 (in thousands except per share data).
|
|
|
|
|
|
|
January 3, 2010
|
|
|
|
Adjustments
|
|
|
Assets:
|
|
|
|
|
Prepaid expenses and other current assets
|
|
$
|
(2,051
|
)
|
Deferred tax assets, long-term portion
|
|
|
(38,135
|
)
|
Total assets
|
|
|
(40,186
|
)
|
Liabilities and Stockholders Equity:
|
|
|
|
|
Current portion of long-term debt
|
|
|
(99,797
|
)
|
Conversion option subject to cash settlement
|
|
|
99,797
|
|
Stockholders equity
|
|
|
(40,186
|
)
|
Total liabilities and stockholders equity
|
|
|
(40,186
|
)
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3, 2010
|
|
|
|
Adjustments
|
|
|
Income from operations
|
|
$
|
|
|
Interest expense
|
|
|
(19,656
|
)*
|
Other income (expense), net
|
|
|
767
|
|
Provision for income taxes
|
|
|
(7,691
|
)
|
Net income
|
|
|
(11,198
|
)
|
Net income per basic share
|
|
|
(0.09
|
)
|
Net income per diluted share
|
|
|
(0.08
|
)
|
|
|
|
* |
|
These adjustments include only non-cash interest expense. Cash
interest expense for the year ended January 3, 2010 totaled
$2.4 million. |
In addition, we have included below reconciliations (in
thousands, except per share data) between amounts reported in
previous filings as of December 28, 2008 to the amounts
reported in the current filing for the same period to reflect
retroactive adjustments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 28, 2008
|
|
|
|
Pre adoption
|
|
|
Adjustments
|
|
|
Post adoption
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets
|
|
$
|
9,530
|
|
|
$
|
4,624
|
|
|
$
|
14,154
|
|
Deferred tax assets, long-term portion
|
|
|
93,603
|
|
|
|
(47,361
|
)
|
|
|
46,242
|
|
Other assets
|
|
|
12,017
|
|
|
|
(7,192
|
)
|
|
|
4,825
|
|
Total assets
|
|
|
1,377,100
|
|
|
|
(49,929
|
)
|
|
|
1,327,171
|
|
Liabilities and Stockholders Equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
Current portion of long-term debt
|
|
|
399,999
|
|
|
|
(123,110
|
)
|
|
|
276,889
|
|
Conversion option subject to cash settlement
|
|
|
|
|
|
|
123,110
|
|
|
|
123,110
|
|
Stockholders equity
|
|
|
848,596
|
|
|
|
(49,929
|
)
|
|
|
798,667
|
|
Total liabilities and stockholders equity
|
|
|
1,377,100
|
|
|
|
(49,929
|
)
|
|
|
1,327,171
|
|
F-27
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
December 28, 2008
|
|
|
December 30, 2007
|
|
|
|
Pre adoption
|
|
|
Adjustments
|
|
|
Post adoption
|
|
|
Pre adoption
|
|
|
Adjustments
|
|
|
Post adoption
|
|
|
Income (loss) from operations
|
|
$
|
80,457
|
|
|
$
|
|
|
|
$
|
80,457
|
|
|
$
|
(301,201
|
)
|
|
$
|
|
|
|
$
|
(301,201
|
)
|
Interest expense
|
|
|
(3,991
|
)
|
|
|
(18,219
|
)*
|
|
|
(22,210
|
)
|
|
|
(3,562
|
)
|
|
|
(14,735
|
)*
|
|
|
(18,297
|
)
|
Provision (benefit) for income taxes
|
|
|
40,429
|
|
|
|
(7,158
|
)
|
|
|
33,271
|
|
|
|
(10,426
|
)
|
|
|
(5,789
|
)
|
|
|
(16,215
|
)
|
Net income (loss)
|
|
|
50,477
|
|
|
|
(11,061
|
)
|
|
|
39,416
|
|
|
|
(278,359
|
)
|
|
|
(8,946
|
)
|
|
|
(287,305
|
)
|
Net income (loss) per basic share
|
|
|
0.43
|
|
|
|
(0.09
|
)
|
|
|
0.34
|
|
|
|
(2.57
|
)
|
|
|
(0.08
|
)
|
|
|
(2.65
|
)
|
Net income (loss) per diluted share
|
|
|
0.38
|
|
|
|
(0.08
|
)
|
|
|
0.30
|
|
|
|
(2.57
|
)
|
|
|
(0.08
|
)
|
|
|
(2.65
|
)
|
|
|
|
* |
|
These adjustments include only non-cash interest expense. Cash
interest expense for the year ended December 28, 2008 and
December 30, 2007 totaled $2.6 million and
$1.4 million, respectively. |
The new guidance requires the carrying amount of the liability
component to be estimated by measuring the fair value of a
similar liability that does not have an associated conversion
feature. As the Company was unable to find any other comparable
companies in industry and size with outstanding non-convertible
public debt, the Company determined that senior, unsecured
corporate bonds represent a similar liability to the convertible
senior notes without the conversion option. To measure the fair
value of the similar liability at February 16, 2007, the
Company estimated an interest rate using assumptions that market
participants would use in pricing the liability component,
including market interest rates, credit standing, yield curves
and volatilities, all of which are defined as Level 2
Observable Inputs. The estimated interest rate of 8.27% was
applied to the convertible senior notes and coupon interest
using a present value technique to arrive at the fair value of
the liability component. The difference between the cash
proceeds associated with the convertible debt and this estimated
fair value of the liability component is recorded as an equity
component. We classified a portion of the equity component as
temporary equity measured as the excess of a) the amount of
cash that would be required to be paid upon conversion over
b) the current carrying amount of the liability-classified
component. This amount is reflected within conversion option
subject to cash settlement in the consolidated balance sheets.
As of December 28, 2008, the principal amount of the
convertible senior notes was $400.0 million and the
unamortized discount was $123.1 million resulting in a net
carrying amount of the liability component of
$276.9 million. As of January 3, 2010, the principal
amount of the liability component was $390.0 million due to
the conversion of $10.0 million of the notes during the
first quarter of 2009. Upon conversion, the Company recorded a
gain of $0.8 million in the first quarter of 2009,
calculated as the difference between the carrying amount of the
converted notes and their estimated fair value as of the
settlement date. To measure the fair value of the converted
notes as of the settlement date, the Company calculated an
interest rate of 11.3% using Level 2 Observable Inputs.
This rate was applied to the converted notes and coupon interest
rate using the same present value technique used in the issuance
date valuation. The unamortized discount on the remaining
convertible senior notes as of January 3, 2010 was
$99.8 million, resulting in a net carrying amount of
$290.2 million. The remaining period over which the
discount on the liability component will be amortized is
4.12 years.
F-28
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Operating
Leases
The Company leases office and manufacturing facilities under
various noncancellable operating lease agreements. Facilities
leases generally provide for periodic rent increases, and many
contain escalation clauses and renewal options. Certain leases
require the Company to pay property taxes and routine
maintenance. The Company is headquartered in San Diego,
California and leases facilities in Hayward, California, the
United Kingdom, The Netherlands, Japan, Singapore, Australia and
China.
Annual future minimum payments under these operating leases as
of January 3, 2010 were as follows (in thousands):
|
|
|
|
|
2010
|
|
$
|
11,668
|
|
2011
|
|
|
12,393
|
|
2012
|
|
|
12,477
|
|
2013
|
|
|
11,907
|
|
2014
|
|
|
10,403
|
|
Thereafter
|
|
|
89,567
|
|
|
|
|
|
|
Total
|
|
$
|
148,415
|
|
|
|
|
|
|
Rent expense, net of amortization of the deferred gain on sale
of property, was $13.6 million, $10.7 million and
$7.7 million for the years ended January 3, 2010,
December 28, 2008 and December 30, 2007, respectively.
Common
Stock
On July 22, 2008, the Company announced a
two-for-one
stock split in the form of a 100% stock dividend with a record
date of September 10, 2008 and a distribution date of
September 22, 2008. Share and per share amounts have been
restated to reflect the stock split for all periods presented.
On August 12, 2008, a total of 8,050,000 shares were
sold to the public at a public offering price of $43.75 per
share, raising net proceeds to the Company of
$342.7 million, after deducting underwriting discounts and
commissions and offering expenses.
On January 3, 2010, the Company had 119,475,815 shares
of common stock outstanding.
Stock
Options
On January 3, 2010, the Company had three active stock
plans: the 2005 Stock and Incentive Plan (the 2005 Stock Plan),
the 2005 Solexa Equity Incentive Plan (the 2005 Solexa Equity
Plan) and the New Hire Stock and Incentive Plan. As of
January 3, 2010, options to purchase 7,280,267 shares
remained available for future grant under the 2005 Stock Plan
and 2005 Solexa Equity Plan. There is no set number of shares
reserved for issuance under the New Hire Stock and Incentive
Plan.
Stock options granted at the time of hire primarily vest over a
four or five-year period, with 20% or 25% of options vesting on
the first anniversary of the grant date and the remaining
options vesting monthly over the remaining vesting period. Stock
options granted subsequent to hiring primarily vest monthly over
a four or five-year period. Each grant of options has a maximum
term of ten years, measured from the applicable grant date,
subject to earlier termination if the optionees service
with us ceases. Vesting in all cases is subject to
F-29
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the individuals continued service to us through the
vesting date. The Company satisfies option exercises through the
issuance of new shares.
The Companys stock option activity under all stock option
plans from January 1, 2007 through January 3, 2010 is
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-
|
|
|
|
|
|
|
Average
|
|
|
|
Options
|
|
|
Exercise Price
|
|
|
Outstanding at January 1, 2007
|
|
|
16,718,240
|
|
|
$
|
6.97
|
|
Options assumed through business combination
|
|
|
2,848,664
|
|
|
$
|
10.69
|
|
Granted
|
|
|
7,569,016
|
|
|
$
|
20.32
|
|
Exercised
|
|
|
(4,358,572
|
)
|
|
$
|
6.03
|
|
Cancelled
|
|
|
(1,929,480
|
)
|
|
$
|
11.19
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 30, 2007
|
|
|
20,847,868
|
|
|
$
|
12.13
|
|
Granted
|
|
|
3,091,108
|
|
|
$
|
34.23
|
|
Exercised
|
|
|
(4,571,855
|
)
|
|
$
|
8.52
|
|
Cancelled
|
|
|
(1,232,917
|
)
|
|
$
|
19.93
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 28, 2008
|
|
|
18,134,204
|
|
|
$
|
16.26
|
|
Granted
|
|
|
1,560,024
|
|
|
$
|
28.86
|
|
Exercised
|
|
|
(2,965,606
|
)
|
|
$
|
10.56
|
|
Cancelled
|
|
|
(639,184
|
)
|
|
$
|
14.88
|
|
|
|
|
|
|
|
|
|
|
Outstanding at January 3, 2010
|
|
|
16,089,438
|
|
|
$
|
18.59
|
|
|
|
|
|
|
|
|
|
|
The following is a further breakdown of the options outstanding
as of January 3, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Average
|
|
|
Weighted
|
|
|
|
|
|
Exercise Price
|
|
Range of
|
|
Options
|
|
|
Remaining Life
|
|
|
Average
|
|
|
Options
|
|
|
of Options
|
|
Exercise Prices
|
|
Outstanding
|
|
|
in Years
|
|
|
Exercise Price
|
|
|
Exercisable
|
|
|
Exercisable
|
|
|
$0.20-4.26
|
|
|
1,969,183
|
|
|
|
3.25
|
|
|
$
|
3.36
|
|
|
|
1,602,420
|
|
|
$
|
3.15
|
|
$4.30-6.85
|
|
|
1,676,898
|
|
|
|
4.99
|
|
|
$
|
5.41
|
|
|
|
1,449,009
|
|
|
$
|
5.31
|
|
$6.87-13.30
|
|
|
1,803,330
|
|
|
|
5.66
|
|
|
$
|
10.75
|
|
|
|
1,312,461
|
|
|
$
|
10.71
|
|
$13.43-17.58
|
|
|
1,624,453
|
|
|
|
6.90
|
|
|
$
|
15.62
|
|
|
|
869,862
|
|
|
$
|
15.58
|
|
$17.60-19.61
|
|
|
1,371,403
|
|
|
|
6.87
|
|
|
$
|
18.74
|
|
|
|
718,826
|
|
|
$
|
18.74
|
|
$19.71-20.04
|
|
|
1,888,561
|
|
|
|
6.96
|
|
|
$
|
20.03
|
|
|
|
934,462
|
|
|
$
|
20.04
|
|
$20.12-27.97
|
|
|
1,673,797
|
|
|
|
8.09
|
|
|
$
|
24.38
|
|
|
|
496,340
|
|
|
$
|
23.76
|
|
$28.03-32.49
|
|
|
2,197,532
|
|
|
|
8.20
|
|
|
$
|
29.97
|
|
|
|
727,353
|
|
|
$
|
30.49
|
|
$32.58-41.37
|
|
|
1,624,281
|
|
|
|
8.29
|
|
|
$
|
35.05
|
|
|
|
650,680
|
|
|
$
|
35.46
|
|
$42.02-44.38
|
|
|
260,000
|
|
|
|
8.58
|
|
|
$
|
44.11
|
|
|
|
87,291
|
|
|
$
|
44.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.20-44.38
|
|
|
16,089,438
|
|
|
|
6.59
|
|
|
$
|
18.59
|
|
|
|
8,848,704
|
|
|
$
|
15.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average remaining life in years of options
exercisable is 6.14 years as of January 3, 2010.
The aggregate intrinsic value of options outstanding and options
exercisable as of January 3, 2010 was $194.5 million
and $107.0 million, respectively. Aggregate intrinsic value
represents the difference between the Companys closing
stock price per share on the last trading day of the fiscal
period, which was $30.68 as
F-30
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
of December 31, 2009, and the exercise price multiplied by
the number of options outstanding. Total intrinsic value of
options exercised was $73.4 million, $136.6 million
and $72.1 million for the years ended January 3, 2010,
December 28, 2008 and December 30, 2007, respectively.
Employee
Stock Purchase Plan
In February 2000, the board of directors and stockholders
adopted the 2000 ESPP. A total of 15,467,426 shares of the
Companys common stock have been reserved for issuance
under the ESPP. The ESPP permits eligible employees to purchase
common stock at a discount, but only through payroll deductions,
during defined offering periods.
The price at which stock is purchased under the ESPP is equal to
85% of the fair market value of the common stock on the first or
last day of the offering period, whichever is lower. The initial
offering period commenced in July 2000. In addition, beginning
with fiscal 2001, the ESPP provides for annual increases of
shares available for issuance by the lesser of 3% of the number
of outstanding shares of the Companys common stock on the
last day of the immediately preceding fiscal year,
3,000,000 shares or such lesser amount as determined by the
Companys board of directors. Shares totaling 359,713,
276,198 and 266,962 were issued under the ESPP during fiscal
2009, 2008 and 2007, respectively. As of January 3, 2010,
there were 13,434,449 shares available for issuance under
the ESPP.
Restricted
Stock Units
In 2007 the Company began granting restricted stock units
pursuant to its 2005 Stock and Incentive Plan as part of its
periodic employee equity compensation review program. Restricted
stock units are share awards that, upon vesting, will deliver to
the holder shares of the Companys common stock. Restricted
stock units granted during 2007 vest over four years as follows:
15% vest on the first and second anniversaries of the grant
date, 30% vest on the third anniversary of the grant date and
40% vest on the fourth anniversary of the grant date. Effective
January 2008, the Company changed the vesting schedule for
grants of new restricted stock units. Currently, restricted
stock units vest 15% on the first anniversary of the grant date,
20% on the second anniversary of the grant date, 30% on the
third anniversary of the grant date and 35% on the fourth
anniversary of the grant date. The Company satisfies restricted
stock units vesting through the issuance of new shares.
A summary of the Companys restricted stock unit activity
and related information from January 1, 2007 through
January 3, 2010 is as follows:
|
|
|
|
|
|
|
Restricted Stock Units(1)
|
|
|
Outstanding at December 30, 2007
|
|
|
394,500
|
|
Awarded
|
|
|
1,287,504
|
|
Vested
|
|
|
(55,638
|
)
|
Cancelled
|
|
|
(47,090
|
)
|
|
|
|
|
|
Outstanding at December 28, 2008
|
|
|
1,579,276
|
|
Awarded
|
|
|
1,292,473
|
|
Vested
|
|
|
(246,055
|
)
|
Cancelled
|
|
|
(116,986
|
)
|
|
|
|
|
|
Outstanding at January 3, 2010
|
|
|
2,508,708
|
|
|
|
|
|
|
|
|
|
(1) |
|
Each stock unit represents the fair market value of one share of
common stock. |
F-31
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The weighted average grant-date fair value per share for the
restricted stock units was $32.32 and $34.53 for the years ended
January 3, 2010 and December 28, 2008, respectively.
No restricted stock units were outstanding as of
December 30, 2007.
Based on the closing price per share of the Companys
common stock of $30.68 on December 31, 2009, the total
pretax intrinsic value of all outstanding restricted stock units
on that date was $81.1 million.
Warrants
In conjunction with its acquisition of Solexa, Inc. on
January 26, 2007, the Company assumed 4,489,686 warrants
issued by Solexa prior to the acquisition. During the year ended
January 3, 2010, there were 954,376 warrants exercised,
resulting in cash proceeds to the Company of approximately
$7.6 million. As of January 3, 2010, 252,164 of the
assumed warrants had expired.
A summary of all warrants outstanding as of January 3, 2010
is as follows:
|
|
|
|
|
|
|
|
|
Number of Shares
|
|
Exercise Price
|
|
|
Expiration Date
|
|
|
16,380
|
|
$
|
7.27
|
|
|
|
4/25/2010
|
|
307,132
|
|
$
|
7.27
|
|
|
|
7/12/2010
|
|
732,230
|
|
$
|
10.91
|
|
|
|
11/23/2010
|
|
1,027,412
|
|
$
|
10.91
|
|
|
|
1/19/2011
|
|
18,322,320(1)
|
|
$
|
31.44
|
|
|
|
2/15/2014
|
|
|
|
|
|
|
|
|
|
|
20,405,474
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Represents warrants sold in connection with the offering of the
Companys convertible senior notes (See Note 7). |
Treasury
Stock
In October 2008, the board of directors authorized a
$120.0 million stock repurchase program. In fiscal 2008,
the Company repurchased 3.1 million shares for
$70.8 million under the program.
In July 2009, the board of directors authorized a
$75.0 million stock repurchase program and concurrently
terminated the $120.0 million stock repurchase program
authorized in October 2008. In November 2009, upon the
completion of the repurchase program authorized in
July 2009, our board of directors authorized an additional
$100.0 million stock repurchase program. In fiscal 2009,
the Company repurchased a total of 6.1 million shares for
$175.1 million under both programs in open-market
transactions or through privately negotiated transactions in
compliance with
Rule 10b-18
under the Securities Exchange Act of 1934.
Stockholder
Rights Plan
On May 3, 2001, the board of directors of the Company
declared a dividend of one preferred share purchase right (a
Right) for each outstanding share of common stock of the
Company. The dividend was payable on May 14, 2001 (the
Record Date) to the stockholders of record on that date. Each
Right entitles the registered holder to purchase from the
Company one unit consisting of one-thousandth of a share of its
Series A Junior Participating Preferred Stock at a price of
$100 per unit. The Rights will be exercisable if a person or
group hereafter acquires beneficial ownership of 15% or more of
the outstanding common stock of the Company or announces an
offer for 15% or more of the outstanding common stock. If a
person or group acquires 15% or more of the outstanding common
stock of the Company, each Right will entitle its holder to
purchase, at the exercise price of the Right, a number of shares
of common stock having a market value of
F-32
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
two times the exercise price of the Right. If the Company is
acquired in a merger or other business combination transaction
after a person acquires 15% or more of the Companys common
stock, each Right will entitle its holder to purchase, at the
Rights then-current exercise price, a number of common
shares of the acquiring company which at the time of such
transaction have a market value of two times the exercise price
of the Right. The board of directors will be entitled to redeem
the Rights at a price of $0.01 per Right at any time before any
such person acquires beneficial ownership of 15% or more of the
outstanding common stock. The Rights expire on May 14, 2011
unless such date is extended or the Rights are earlier redeemed
or exchanged by the Company.
From time to time, we are party to litigation and other legal
proceedings in the ordinary course, and incidental to the
conduct, of our business. While the results of any litigation or
other legal proceedings are uncertain, management does not
believe the ultimate resolution of any pending legal matters is
likely to have a material adverse effect on our financial
position or results of operations.
The income (loss) before income taxes summarized by region is as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
United States
|
|
$
|
65,081
|
|
|
$
|
46,205
|
|
|
$
|
43,710
|
|
Foreign
|
|
|
49,044
|
|
|
|
26,482
|
|
|
|
(347,230
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income (loss) before income taxes
|
|
$
|
114,125
|
|
|
$
|
72,687
|
|
|
$
|
(303,520
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The provision (benefit) for income taxes consists of the
following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
Current:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
43,565
|
|
|
$
|
13,868
|
|
|
$
|
18,564
|
|
State
|
|
|
2,511
|
|
|
|
2,134
|
|
|
|
4,801
|
|
Foreign
|
|
|
6,204
|
|
|
|
5,042
|
|
|
|
(2,172
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current provision
|
|
|
52,280
|
|
|
|
21,044
|
|
|
|
21,193
|
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
(14,607
|
)
|
|
|
11,700
|
|
|
|
(25,071
|
)
|
State
|
|
|
5,184
|
|
|
|
901
|
|
|
|
(12,594
|
)
|
Foreign
|
|
|
(1,013
|
)
|
|
|
(374
|
)
|
|
|
257
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total deferred provision
|
|
|
(10,436
|
)
|
|
|
12,227
|
|
|
|
(37,408
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total tax provision (benefit)
|
|
$
|
41,844
|
|
|
$
|
33,271
|
|
|
$
|
(16,215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-33
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The provision (benefit) for income taxes reconciles to the
amount computed by applying the federal statutory rate to income
(loss) before taxes as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
Tax at federal statutory rate
|
|
$
|
39,944
|
|
|
$
|
25,440
|
|
|
$
|
(106,232
|
)
|
State, net of federal benefit
|
|
|
4,275
|
|
|
|
3,461
|
|
|
|
(10,304
|
)
|
Research and other credits
|
|
|
(4,050
|
)
|
|
|
(4,060
|
)
|
|
|
(3,118
|
)
|
Acquired in-process research & development
|
|
|
4,386
|
|
|
|
9,508
|
|
|
|
116,916
|
|
Change in valuation allowance
|
|
|
(1,967
|
)
|
|
|
(6,892
|
)
|
|
|
(17,125
|
)
|
Permanent differences
|
|
|
2,093
|
|
|
|
1,449
|
|
|
|
653
|
|
Foreign rate adjustments
|
|
|
(5,400
|
)
|
|
|
4,124
|
|
|
|
3,160
|
|
Other
|
|
|
2,563
|
|
|
|
241
|
|
|
|
(165
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total tax provision (benefit)
|
|
$
|
41,844
|
|
|
$
|
33,271
|
|
|
$
|
(16,215
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant components of the Companys deferred tax assets
and liabilities are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Net operating losses
|
|
$
|
15,869
|
|
|
$
|
33,839
|
|
Tax credits
|
|
|
18,681
|
|
|
|
19,139
|
|
Other accruals and reserves
|
|
|
17,813
|
|
|
|
11,341
|
|
Stock compensation
|
|
|
25,442
|
|
|
|
15,962
|
|
Inventory capitalization
|
|
|
4,172
|
|
|
|
3,555
|
|
Other amortization
|
|
|
4,216
|
|
|
|
3,101
|
|
Other
|
|
|
10,808
|
|
|
|
6,612
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
97,001
|
|
|
|
93,549
|
|
Valuation allowance on deferred tax assets
|
|
|
(14,852
|
)
|
|
|
(15,200
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
|
82,149
|
|
|
|
78,349
|
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Purchased intangible amortization
|
|
|
(5,043
|
)
|
|
|
(5,985
|
)
|
Accrued litigation settlements
|
|
|
(3,810
|
)
|
|
|
(11,084
|
)
|
Convertible debt
|
|
|
(3,901
|
)
|
|
|
(4,905
|
)
|
Other
|
|
|
(2,810
|
)
|
|
|
(1,498
|
)
|
|
|
|
|
|
|
|
|
|
Total deferred tax liabilities
|
|
|
(15,564
|
)
|
|
|
(23,472
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
66,585
|
|
|
$
|
54,877
|
|
|
|
|
|
|
|
|
|
|
A valuation allowance is established when it is more likely than
not the future realization of all or some of the deferred tax
assets will not be achieved. The evaluation of the need for a
valuation allowance is performed on a
jurisdiction-by-jurisdiction
basis, and includes a review of all available positive and
negative evidence. Based on the available evidence as of
January 3, 2010, the Company was not able to conclude it is
more likely than not certain U.S. and foreign deferred tax
assets will be realized. Therefore, the Company
F-34
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
recorded a valuation allowance of $2.8 million and
$12.1 million against certain U.S. and foreign net
deferred tax assets, respectively.
As of January 3, 2010, the Company had net operating loss
carryforwards for federal and state tax purposes of
$25.4 million and $132.1 million, respectively, which
begin to expire in 2012 and 2013, respectively, unless
previously utilized. In addition, the Company also had
U.S. federal and state research and development tax credit
carryforwards of $16.0 million and $16.2 million,
respectively, which begin to expire in 2018 and 2019,
respectively, unless previously utilized.
As of January 3, 2010, the valuation allowance includes
$12.3 million of pre-acquisition foreign deferred tax
assets of Solexa. In accordance with the adoption of Topic 805
to the extent any of these assets are recognized in the future
the adjustment will be recorded as a reduction to the provision
for income taxes.
Pursuant to Section 382 and 383 of the Internal Revenue
Code, utilization of the Companys net operating loss and
credits may be subject to annual limitations in the event of any
significant future changes in its ownership structure. These
annual limitations may result in the expiration of net operating
losses and credits prior to utilization. The deferred tax assets
as of January 3, 2010 are net of any previous limitations
due to Section 382 and 383.
Due to the adoption of SFAS No. 123R, the Company
recognizes excess tax benefits associated with share-based
compensation to stockholders equity only when realized.
When assessing whether excess tax benefits relating to
share-based compensation have been realized, the Company follows
the
with-and-without
approach excluding any indirect effects of the excess tax
deductions. Under this approach, excess tax benefits related to
share-based compensation are not deemed to be realized until
after the utilization of all other tax benefits available to the
Company. During 2009, the Company realized $39.3 million of
such excess tax benefits, and accordingly recorded a
corresponding credit to additional paid in capital. As of
January 3, 2010, the Company has $17.1 million of
unrealized excess tax benefits associated with share-based
compensation. These tax benefits will be accounted for as a
credit to additional paid-in capital, if and when realized,
rather than a reduction of the provision for income taxes.
The Companys manufacturing operations in Singapore operate
under various tax holidays and incentives that begin to expire
in 2018. For the year ended January 3, 2010, these tax
holidays and incentives resulted in an approximate
$2.3 million decrease to the provision for income taxes and
an increase to net income per diluted share of $0.02.
Residual U.S. income taxes have not been provided on
$38.6 million of undistributed earnings of foreign
subsidiaries as of January 3, 2010, since the earnings are
considered to be indefinitely invested in the operations of such
subsidiaries.
The following table summarizes the gross amount of the
Companys uncertain tax positions (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
Balance at beginning of year
|
|
$
|
9,402
|
|
|
$
|
7,000
|
|
|
$
|
5,381
|
|
Increases related to current year tax positions
|
|
|
2,358
|
|
|
|
2,402
|
|
|
|
1,619
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at end of year
|
|
$
|
11,760
|
|
|
$
|
9,402
|
|
|
$
|
7,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
During 2009 the Company determined that $14.4 million of
previously reported uncertain tax positions, which related to
pre-acquistion net operating loss carryforwards of Solexa, were
not uncertain as of the Solexa acquisition in January 2007.
Accordingly, the uncertain tax position balances that were
previously reported have been reduced by $14.4 million to
correctly present the uncertain tax position balances.
F-35
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
As of January 3, 2010, $9.6 million of the
Companys uncertain tax positions would reduce the
Companys annual effective tax rate, if recognized.
The Company does not expect its uncertain tax positions to
change significantly over the next 12 months. Any interest
and penalties related to uncertain tax positions will be
reflected in income tax expense. As of January 3, 2010, no
interest or penalties have been accrued related to the
Companys uncertain tax positions. Tax years 1995 to 2009
remain subject to future examination by the major tax
jurisdictions in which the Company is subject to tax.
|
|
12.
|
Employee
Benefit Plans
|
Retirement
Plan
The Company has a 401(k) savings plan covering substantially all
of its employees. Company contributions to the plan are
discretionary. During the years ended January 3, 2010,
December 28, 2008 and December 30, 2007, the Company
made matching contributions of $3.3 million,
$2.6 million and $1.4 million, respectively.
Executive
Deferred Compensation Plan
For the Companys executives and members of the board of
directors, the Company adopted the Illumina, Inc. Deferred
Compensation Plan (the Plan) that became effective
January 1, 2008. Eligible participants can contribute up to
80% of their base salary and 100% of all other forms of
compensation into the Plan, including bonus, commission and
director fees. The Company has agreed to credit the
participants contributions with earnings that reflect the
performance of certain independent investment funds. On a
discretionary basis, the Company may also make employer
contributions to participant accounts in any amount determined
by the Company. The vesting schedules of employer contributions
are at the sole discretion of the Compensation Committee.
However, all employer contributions shall become 100% vested
upon the occurrence of the participants disability, death
or retirement or a change in control of the Company. The
benefits under this plan are unsecured. Participants are
generally eligible to receive payment of their vested benefit at
the end of their elected deferral period or after termination of
their employment with the Company for any reason or at a later
date to comply with the restrictions of Section 409A. As of
January 3, 2010, no employer contributions were made to the
Plan.
In January 2008, the Company also established a rabbi trust for
the benefit of its directors and executives under the Plan. In
accordance with authoritative guidance related to consolidation
of variable interest entities and accounting for deferred
compensation arrangements where amounts earned are held in a
rabbi trust and invested, the Company has included the assets of
the rabbi trust in its consolidated balance sheet since the
trusts inception. As of January 3, 2010, the assets
of the trust and liabilities of the Company were
$4.0 million. The assets and liabilities are classified as
other assets and accrued liabilities, respectively, on the
Companys balance sheet as of January 3, 2010. Changes
in the values of the assets held by the rabbi trust accrue to
the Company.
|
|
13.
|
Segment
Information, Geographic Data and Significant Customers
|
During the first quarter of 2008, the Company reorganized its
operating structure into a newly created Life Sciences Business
Unit, which includes all products and services related to the
research market, namely the sequencing, BeadArray, and VeraCode
product lines. The Company also created a Diagnostics Business
Unit to focus on the emerging opportunity in molecular
diagnostics. For the year ended January 3, 2010, the
Company had limited activity related to the Diagnostics Business
Unit, and operating results were reported on an aggregate basis
to the chief operating decision maker of the Company, the chief
executive officer. In
F-36
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
accordance with authoritative guidance for disclosures about
segments of an enterprise and related information, the Company
operated in one reportable segment for the year ended
January 3, 2010.
The Company had revenue in the following regions for the years
ended January 3, 2010, December 28, 2008 and
December 30, 2007 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
December 30,
|
|
|
|
2010
|
|
|
2008
|
|
|
2007
|
|
|
United States
|
|
$
|
347,195
|
|
|
$
|
280,064
|
|
|
$
|
207,692
|
|
United Kingdom
|
|
|
55,854
|
|
|
|
67,973
|
|
|
|
34,196
|
|
Other European countries
|
|
|
140,931
|
|
|
|
127,397
|
|
|
|
75,360
|
|
Asia-Pacific
|
|
|
96,396
|
|
|
|
72,740
|
|
|
|
35,155
|
|
Other markets
|
|
|
25,948
|
|
|
|
25,051
|
|
|
|
14,396
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
666,324
|
|
|
$
|
573,225
|
|
|
$
|
366,799
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net revenues are attributable to geographic areas based on the
region of destination.
The majority of our product sales consist of consumables and
instruments. For the years ended January 3, 2010,
December 28, 2008 and December 30, 2007, consumable
sales represented 59%, 58% and 53%, respectively, of total
revenues and instrument sales comprised 34%, 32%, and 33%,
respectively, of total revenues. Our customers include leading
genomic research centers, pharmaceutical companies, academic
institutions, clinical research organizations and biotechnology
companies. The Company had no customers that provided more than
10% of total revenue in the years ended January 3, 2010,
December 28, 2008 and December 30, 2007.
Net long-lived assets exclude goodwill and other intangible
assets since they are not allocated on a geographic basis. The
Company had net long-lived assets consisting of property and
equipment in the following regions as of January 3, 2010
and December 28, 2008(in thousands):
|
|
|
|
|
|
|
|
|
|
|
January 3,
|
|
|
December 28,
|
|
|
|
2010
|
|
|
2008
|
|
|
United States
|
|
$
|
75,095
|
|
|
$
|
65,630
|
|
United Kingdom
|
|
|
27,862
|
|
|
|
9,849
|
|
Other European countries
|
|
|
864
|
|
|
|
1,055
|
|
Singapore
|
|
|
12,599
|
|
|
|
12,586
|
|
Other Asia-Pacific countries
|
|
|
768
|
|
|
|
316
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
117,188
|
|
|
$
|
89,436
|
|
|
|
|
|
|
|
|
|
|
F-37
ILLUMINA,
INC.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
14.
|
Quarterly
Financial Information (unaudited)
|
The following financial information reflects all normal
recurring adjustments, except as noted below, which are, in the
opinion of management, necessary for a fair statement of the
results and cash flows of interim periods. All quarters for 2008
and 2009 were 13 weeks except for the fourth quarter 2009,
which was 14 weeks. Summarized quarterly data for fiscal
2009 and 2008 are as follows (in thousands except per share
data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter
|
|
|
Second Quarter
|
|
|
Third Quarter
|
|
|
Fourth Quarter
|
|
|
2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
165,757
|
|
|
$
|
161,643
|
|
|
$
|
158,360
|
|
|
$
|
180,564
|
|
Total cost of revenue (excluding impairment of manufacturing
equipment and amortization of intangible assets)
|
|
|
54,022
|
|
|
|
48,815
|
|
|
|
49,564
|
|
|
|
53,368
|
|
Net income
|
|
|
18,811
|
|
|
|
24,688
|
|
|
|
17,077
|
|
|
|
11,705
|
|
Net income per share, basic
|
|
|
0.15
|
|
|
|
0.20
|
|
|
|
0.14
|
|
|
|
0.10
|
|
Net income per share, diluted
|
|
|
0.14
|
|
|
|
0.18
|
|
|
|
0.12
|
|
|
|
0.09
|
|
2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
121,861
|
|
|
$
|
140,177
|
|
|
$
|
150,260
|
|
|
$
|
160,927
|
|
Total cost of revenue (excluding amortization of intangible
assets)
|
|
|
46,081
|
|
|
|
50,459
|
|
|
|
54,430
|
|
|
|
54,654
|
|
Net income (loss)(1)
|
|
|
10,743
|
|
|
|
12,659
|
|
|
|
(10,078
|
)
|
|
|
26,092
|
|
Net income (loss) per share, basic(1)
|
|
|
0.10
|
|
|
|
0.11
|
|
|
|
(0.08
|
)
|
|
|
0.21
|
|
Net income (loss) per share, diluted(1)
|
|
|
0.08
|
|
|
|
0.09
|
|
|
|
(0.08
|
)
|
|
|
0.20
|
|
|
|
|
(1) |
|
Adjusted for required retroactive adoption of authoritative
accounting guidance for convertible debt instruments that may be
settled in cash upon conversion effective December 29, 2008. |
F-38
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Additions Charged
|
|
|
|
|
|
|
|
|
|
Beginning of
|
|
|
to Expense/
|
|
|
|
|
|
Balance at End of
|
|
|
|
Period
|
|
|
Revenue(1)
|
|
|
Deductions(2)
|
|
|
Period
|
|
|
|
(In thousands)
|
|
|
Year ended January 3, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts
|
|
$
|
1,138
|
|
|
|
828
|
|
|
|
(568
|
)
|
|
$
|
1,398
|
|
Reserve for inventory
|
|
|
6,431
|
|
|
|
8,403
|
|
|
|
(4,237
|
)
|
|
|
10,597
|
|
Year ended December 28, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts
|
|
$
|
540
|
|
|
|
893
|
|
|
|
(295
|
)
|
|
$
|
1,138
|
|
Reserve for inventory
|
|
|
2,089
|
|
|
|
7,154
|
|
|
|
(2,812
|
)
|
|
|
6,431
|
|
Year ended December 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts
|
|
$
|
338
|
|
|
|
237
|
|
|
|
(35
|
)
|
|
$
|
540
|
|
Reserve for inventory
|
|
|
850
|
|
|
|
2,302
|
|
|
|
(1,063
|
)
|
|
|
2,089
|
|
|
|
|
(1) |
|
Additions to the allowance for doubtful accounts and reserve for
inventory are charged to selling, general and administrative
expense and cost of product revenue respectively. |
|
(2) |
|
Deductions for allowance for doubtful accounts and reserve for
inventory are for accounts receivable written off and disposal
of obsolete inventory. |
F-39